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Developmental pathways, including Hedgehog (HH) and Hippo, are involved 
in cancer and tissue regeneration in various ways. HH signaling from the 
prostate epithelium was known to regulate mesenchyme expansion during 
development and regeneration. However, any role of HH signaling in stromal 
cells during prostate cancer (PCa) progression was poorly understood. I 
studied both mouse models and human PCa and observed paracrine HH 
signaling from epithelium to stroma. Genetic fate mapping suggested that the 
cancer-associated stroma derives from distinct cell types in different mouse 
models of PCa. Furthermore, I found that increasing HH signaling in the 
stroma results in decreased tumor progression and the presence of more 
smooth muscle, which correlated with lower grade PCa in human. Thus, we 
propose HH signaling restrains tumor progression by maintaining the smooth 
muscle and preventing invasion by tumor cells. 
 
The Hippo pathway has been implicated in the repair of several tissue types. 
However, any possible role of the Hippo pathway in development or postnatal 
regeneration of the mouse cerebellum was unknown. I used genetic mouse 
models involving deletion of the transcriptional co-activators YAP and/or TAZ, 
and found that YAP, but not TAZ, is an essential regulator of effective recovery 
of the cerebellum after irradiation-induced injury at birth. Specifically, genetic 
ablation of Yap in the Nestin-expressing progenitors (NEPs), a progenitor 
	  
	  
population central to cerebellar regeneration of granule cell precursors (GCPs) 
following injury, results in significantly impaired cerebellar growth and 
disruption in the cellular cytoarchitecture. The Yap mutant NEPs respond 
normally to the injury by migrating to the GCP niche, but then undergo 
increased cell death. Loss of YAP in NEPs or GCPs during normal 
development only mildly affects differentiation. Moreover, loss of TAZ does not 
alter development or regeneration of the cerebellum, or abrogate regeneration 
of GCPs by Yap mutant NEPs. Instead, Taz ablation seems to partially rescue 
the poor recovery of GCPs by Yap mutant NEPs, indicating that TAZ and YAP 
have distinct functions during cerebellar regeneration.  
 
In summary, my thesis research provides new insights into the molecular 
signaling underlying PCa progression and the development and regeneration 
of the neonatal cerebellum.  
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Chapter 1 Introduction 
 
Signaling pathways that are essential for organ growth during development 
are often also exploited by cancer and utilized during tissue regeneration in a 
variety of different ways. The Hedgehog and Hippo pathways have important 
and usually distinct functions in organ development. Hedgehog signaling is 
known for exerting both mitogenic and morphogenic effects on organ growth 
and patterning, including the prostate and cerebellum. Hippo signaling is 
known to control the size of many organs, albeit with a less-defined role in the 
brain. Here I review the contribution of Hedgehog and Hippo pathways in 
development and their exploitation in tissue regeneration and cancer, 
particularly in the prostate and brain, respectively.  
 
1.1 Hedgehog signaling 
1.1.1 Overview of the Hedgehog pathway 
Mammalian Hedgehog (HH) signaling has three secreted ligands that are 
homologs of the Drosophila HH polarity protein: Sonic Hedgehog (SHH), 
Indian Hedgehog (IHH), and Desert Hedgehog (DHH). HH signaling usually 
acts in a paracrine manner, in which HH ligands secreted from HH-producing 
cells act on neighboring or nearby HH-receiving cells of a different lineage. In 
HH-producing cells, the ligands undergo autoproteolytic cleavage and 
extensive post-translational modifications (Pepinsky et al., 1998; Perler, 1998; 
Taylor et al., 2001) before being exported by a membrane transporter protein 
named Dispatched (Briscoe and Therond, 2013). These modifications enable 
the ligands to travel and establish a protein gradient, and interact with the HH-
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receiving cells to exert their functions (Beachy et al., 2010; Chuang and 
McMahon, 1999).  
 
The HH-receiving cells carry out signal transduction through its receptor 
repertoire, including the twelve-pass transmembrane receptor Patched 1 
(PTCH1) (Briscoe and Therond, 2013), and three co-receptors in vertebrates, 
CDO, BOC and GAS1 (Allen et al., 2007; Okada et al., 2006; Tenzen et al., 
2006). Humans and mice have a second Ptch gene, Ptch2, with a different 
expression pattern and less defined function (Motoyama et al., 1998a; 
Motoyama et al., 1998b; Smyth et al., 1999). In the absence of HH ligand, 
PTCH1 uses its internal “tunnel” to export membrane cholesterol, which 
depletes cholesterol that is required for the activation of Smoothened (SMO), a 
seven-pass G-protein-coupled membrane protein (Sommer and Lemmon, 
2018). When a HH ligand is present, two PTCH1 molecules bind to distinct 
sites of HH ligand in a steroid-dependent manner, resulting in the blockade of 
“tunnels” within PTCH1 (Gong et al., 2018; Qi et al., 2018; Sommer and 
Lemmon, 2018) (Fig. 1.1). Thus, abundant membrane cholesterol is free to 
traverse and bind with SMO, which induces a conformational change in SMO 
(Huang et al., 2018; Sommer and Lemmon, 2018; Zhang et al., 2018). With a 
structure that resembles activated G-protein-coupled receptors (Huang et al., 
2018), SMO is able to activate Hedgehog signaling through the downstream 
GLI (glioma-associated oncogene family members) zinc-finger transcription 
factors. 
 
The mammalian GLI protein family has three members – GLI1, GLI2, and 
GLI3, each with both distinct and overlapping functions in the nervous system 
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(Bai et al., 2002; Bai and Joyner, 2001; Bai et al., 2004; Motoyama et al., 2003; 
Park et al., 2000; Persson et al., 2002; Petrova et al., 2013) and in other 
organs (Drakopoulou et al., 2010; Rowbotham et al., 2009; Sabol et al., 2018; 
Solanki et al., 2017; Solanki et al., 2018; Theil et al., 1999). Upon HH ligand 
binding, SMO activation protects GLI2/GLI3 from proteasomal degradation, 
promoting GLI2, and to a lesser extent GLI3, to act as transcriptional 
activators. This in turn stimulates the expression of HH target genes including 
Gli1 (Bai et al., 2004; Sasaki et al., 1999; Smelkinson et al., 2007), which 
forms a positive feedback on HH signaling (Bai et al., 2002; Park et al., 2000). 
Expression of another direct HH target gene Ptch1 positively correlates with 
HH activity, imposing a negative feedback on HH signaling (Vokes et al., 2007; 
Vokes et al., 2008). When HH signaling is inactive, GLI2/GLI3 are 
phosphorylated and proteolytically processed, rendering GLI3, and to a lesser 
extent GLI2, to become transcriptional repressors (Bhatia et al., 2006; Pan et 
al., 2006; Wang et al., 2000; Wang and Li, 2006) (Fig. 1.1).  
 
What is unique to mammalian HH signaling is the dependence on primary cilia. 
Primary cilia are slender microtubule-based cellular antennae that sense 
extracellular cues and convey intracellular signaling. They function as 
signaling hubs with concentration of several HH pathway components (Goetz 
and Anderson, 2010). The importance of primary cilia for proper mammalian 
HH signaling was first demonstrated by altered GLI protein activities in 
mutants of genes encoding ciliary proteins (Haycraft et al., 2005; Huangfu and 
Anderson, 2005; Liu et al., 2005). The dynamic translocation of PTCH and 
SMO into and out of the primary cilium is essential for proper modulation of 
mammalian HH signaling (Rohatgi et al., 2007). In the absence of HH, PTCH1 
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is enriched in the cilium and prevents SMO from entering the same location, 
thus downregulating SMO activity. When HH is present, SMO accumulates in 
the cilium and antagonizes SUFU (Suppressor of Fused), a negative regulator 
of HH signaling, which leads to the convertion of GLI2/3 into transcriptional 
activators to promote the expression of HH target genes (Cooper et al., 2005; 
Svard et al., 2006).  
 
Figure 1.1 Schematics of the Hedgehog signaling pathway in mammals. 
(Adpated from (Peng and Joyner, 2015)) 
 
(A) In the absence of HH, PTCH1 prevents SMO from translocating to the 
primary cilium. GLI2/3 are associated with SUFU and phosphorylated by PKA, 
CK1, and GSK3β. GLI2/3 undergo proteolysis, leading to the conversion of 
GLI3, and to a lesser extent GLI2, into transcriptional repressors.  
(B) In the presence of HH, the ligand binds with two PTCH1 molecules, 
alleviating the inhibition on SMO. SMO enters the cilium and promotes the 
dissociation of the SUFU-GLI2/3 complex. The proteolysis of GLI2/3 is 
inhibited, which promotes the formation of GLI2, and to a lesser extent GLI3, 
transcriptional activators, to induce expression of HH target genes including 
Gli1 and Ptch1.  
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1.1.2 Hedgehog signaling in development of the prostate 
HH signaling exerts crucial effects on the development of the prostate. The 
prostate is a male sex-accessory gland that originates from the endoderm-
derived urogenital sinus (UGS). The first morphological event in prostate 
development occurs at embryonic day 16.5 (E16.5) in the mouse, when the 
urogenital sinus epithelium (UGE) starts to form solid epithelial buds that 
invade the surrounding urogenital sinus mesenchyme (UGM). This so-called 
budding is initiated by androgen signaling from the mesenchyme that specifies 
the epithelium (Cunha et al., 1986; Cunha and Lung, 1978). During embryonic 
development, the epithelial buds elongate and form unbranched ducts. After 
birth, these nascent epithelial ducts further elongate, canalize, and undergo 
extensive branching, to form an elaborate ductal system (Sugimura et al., 
1986a). This branching morphogenesis starts by postnatal day 15 (P15) and is 
largely completed by P30 (Sugimura et al., 1986a). The mature mouse 
prostate consists of four pairs of lobes: anterior prostate (AP), dorsal prostate 
(DP), lateral prostate (LP), and ventral (VP) prostate, with each prostatic lobe 
having its distinct branching pattern (Sugimura et al., 1986a). In some studies, 
the DP and LP are collectively referred to as the dorsolateral prostate (DLP). 
Importantly, androgen signaling in the epithelium is essential for the production 
of prostate gland secretion (Cunha et al., 1987; Cunha and Lung, 1978).  
 
During prostate development, Shh expression is enriched in the epithelium of 
nascent buds and the growing tips of elongating ducts (Lamm et al., 2002; 
Podlasek et al., 1999), while the surrounding mesenchyme has expression of 
HH targets including Ptch1 and Gli1 (Lamm et al., 2002; Pu et al., 2004), 
among many growth-inducing molecules (Yu and Bushman, 2013; Yu et al., 
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2009). This points to a paracrine HH signaling from the epithelium to the 
mesenchyme. HH signaling was initially considered to be indispensible for 
prostate morphogenesis, since the use of a SHH neutralizing antibody 
abolished the growth and ductal morphogenesis of E15 UGS transplants that 
were grafted under the renal capsule of another adult male host mouse 
(Podlasek et al., 1999). Moreover, chemical inhibitor of SHH signaling using 
the SMO antagonist cyclopamine resulted in a severe inhibition of ductal 
budding in prostate organ cultures (Lamm et al., 2002). However, subsequent 
studies showed that UGS from Shh-null embryos had normal morphogenesis 
when it was grafted in male host mouse with normal androgen levels, or when 
UGS was treated with exogenous androgen (Berman et al., 2004; Freestone 
et al., 2003). This result seems to argue against the requirement of HH 
signaling for prostate development since the defects in Shh-null mutants could 
be rescued by androgens. But it is also possible that paracrine HH signaling in 
the mesenchyme induces androgen signaling in the epithelium in order for the 
prostate to grow. In the studies using chemical inhibition or SHH neutralizing 
antibody, paracrine HH signaling in the mesenchyme was inhibited, and thus 
prostate development was abrogated in the absence of exogenous androgens. 
In addition, elevated expression of Ihh was observed in Shh-null UGS, which 
potentially provided functional compensation for the loss of Shh (Doles et al., 
2006).  
 
Shh expression in the UGS epithelium is at its peak upon ductal budding and 
is maintained until ductal branching, then gradually decreases and eventually 
tapers off to a low but detectable level in the adult (Lamm et al., 2002; 
Podlasek et al., 1999) (Fig. 1.2). The effects of HH signaling on prostate ductal 
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morphogenesis are also stage-dependent (Yu and Bushman, 2013). 
Specifically, in vitro organ cultures showed that chemical inhibition of HH 
signaling reduced ductal tips in prenatal UGS explants but increased ductal 
tips in postnatal prostate explants. When explants were co-cultured with a 
SMO-overexpressing mesenchymal cell line, embryonic prostates had an 
increase in ductal growth while postnatal prostates had a decrease in ductal 
growth (Yu and Bushman, 2013). Furthermore, using transgenic mouse 
models with ectopic HH signaling in the mesenchyme from midgestation 
onwards, Yu and Bushman (2013) found that epithelial cell proliferation is 
enhanced in the embryonic prostate but reduced in postnatal prostates (Yu 
and Bushman, 2013). This elegant study reveals a growth-inducing effect of 
HH signaling during embryonic development of the prostate and a growth-
inhibiting effect postnatally. 	  
 
Figure 1.2	  Schematic of HH signaling in the prostate during development, 
tissue homeostasis, and cancer 
 
SHH signaling is at its peak during embryonic development of the prostate, 
and then gradually decreases and eventually tapers off to a low but detectable 
level in the adult. The signaling is increased in prostate cancer, and stromal 
HH signaling acts to inhibit tumor progression (this thesis).  
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1.1.3 Hedgehog signaling in regeneration of the prostate 
The adult mouse prostate normally stays quiescent with sparse cell 
proliferation in distal duct tips (Sugimura et al., 1986c). Both development and 
maintenance of the prostate require androgen signaling. Castration of adult 
males causes a major glandular involution of the prostate due to widespread 
epithelial apoptosis and reduction in ductal tips and branching points 
(Sugimura et al., 1986b). Additionally, concurrent apoptotic death in both 
epithelial and stromal cells was observed in rat prostate following castration 
(Banerjee et al., 1995). However, administration of exogenous testosterone 
induces robust cell proliferation and branching morphogenesis in involuted 
prostates, which completely reconstitutes the architecture and restores the 
function of the prostate after only 14 days (Sugimura et al., 1986b). Amazingly, 
such cycles of involution and regeneration can be repeated over 30 times 
(Isaacs, 1985). The extensive regenerative capacity of the adult prostate has 
stimulated a general postulation of the existence of a population of castration-
resistant stem or progenitor cells that are capable of self-renewal.  
 
A potential role of HH signaling in prostate regeneration was indicated from an 
experiment involving inhibition of HH signaling by SMO inhibitors or HH-
blocking antibodies that resulted in abrogation of the normal regeneration 
process (Karhadkar et al., 2004). This was interpreted to mean that HH 
signaling is important for stem cell-driven prostate regeneration, but the mode 
of action by HH signaling was not distinguished between aurocrine versus 
paracrine, and also the exact cell types that could respond to HH signaling 
were not identified. Contrary to the proposed positive role of HH signaling for 
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prostate regeneration, another study by the same group found that decreased 
HH activity in the epithelium enhanced ductal branching during prostate 
regeneration (Lim et al., 2014). Specifically, Ihh expression is enriched in 
epithelial cells between growing buds and focally decreased at ductal 
branching sites. Functional studies indicate that IHH downregulates the 
stromal expression of hepatocyte growth factor (HFG), which stimulates 
epithelial proliferation, and thus IHH negatively regulates epithelial bud 
formation during regeneration (Lim et al., 2014). Additional evidence is needed 
for a comprehensive understanding of the function of HH signaling, particularly 
in regard to its crosstalk with other regulators during prostate regeneration.  
 
1.1.4 Hedgehog signaling in human cancers 
Aberrant Hedgehog signaling is observed in a wide variety of human cancers. 
The mode of action for HH signaling can be categorized into two types. The 
first type involves cell autonomous HH signaling which results from somatic 
mutations in HH pathway genes including Ptch1, Smo, or SuFu. In this class, 
HH signaling is constitutively activated in cancer cells independent of HH 
ligands to drive tumor development. Reported human cancer types that fall 
into this class include basal cell carcinoma (BCC) (Hahn et al., 1996), 
medulloblastoma (Cavalli et al., 2017; Kool et al., 2014), rhabdomyosarcoma 
(Pressey et al., 2011; Tostar et al., 2006), and meningiomas (Aavikko et al., 
2012; Clark et al., 2013; Kijima et al., 2012). For example, loss-of-function 
mutation in PTCH1 directly associates with Gorlin syndrome, and patients with 
Gorlin syndrome develop medulloblastoma and BCC (Gorlin, 2004). Gain-of-
function mutations of SMO are observed in BCCs (Epstein, 2001; Hahn et al., 
1996; Johnson et al., 1996) and medulloblastomas (Kool et al., 2014). 
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Consistent with the human genetics, in mouse models where Ptch1 is deleted 
or SmoM2 (a constitutively active form of SMO) is expressed in the 
appropriate cell type, tumors form that are similar to Gorlin syndrome patients, 
BCCs and medulloblastomas (Mao et al., 2006; Xie et al., 1998). Vismodegib, 
a SMO inhibitor, has been approved by the FDA for the treatment of locally 
advanced and metastatic BCCs.  
 
The second mode of action of HH signaling in cancer is cell non-autonomous 
paracrine signaling due to ectopic expression of HH ligands and the 
surrounding tumor stroma respond to the signaling. It is generally found that 
the HH receiving tumor stroma also returns reciprocal paracrine signals by 
secreting factors that stimulate the growth of tumor epithelium. A number of 
studies in human and mouse prostate cancer supported paracrine HH 
signaling from epithelium to stroma (Fan et al., 2004; Ibuki et al., 2013; Shaw 
et al., 2009). Several other studies reported the co-expression of SHH ligands 
and HH target genes such as Gli1, Ptch1, and Hip in prostate cancer epithelial 
cells (Chen et al., 2009; Karhadkar et al., 2004; Sanchez et al., 2004), 
particularly in advanced and metastatic cancers (Chen et al., 2009; Sheng et 
al., 2004; Tzelepi et al., 2011). However, these results are not sufficient to 
indicate autocrine HH signaling in prostate cancer due to the questionable 
reliability of antibodies to HH pathway components, the high heterogeneity of 
prostate cancer, and the fact that epithelium and stroma were not effectively 
separated in these analyses. In Chapter 2, I describe a paracrine mode of HH 
signaling in multiple mouse models of prostate cancer.  
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In addition, HH signaling may be activated in a non-canonical way, in which 
ligand binding of PTCH1 and activation of SMO is bypassed and GLI 
transcription factors are directly targeted, transcriptionally or epigenetically, by 
other molecules or signaling (Kasper et al., 2006). HH signaling may also 
synergize with other signaling pathways to regulate certain target genes 
(Kasper et al., 2006). 
 
The functions of HH signaling for tumor progression are likely related to its 
mode of action. For example, in a mouse model of small cell lung cancer with 
cell autonomous HH signaling, ectopic expression of SmoM2 in tumor cells 
increased the tumor number and volume (Park et al., 2011). In other cancers 
dominated by paracrine HH signaling, HH activity was indicated to have 
negative effects on tumor progression. Recent studies in pancreas and 
bladder cancers showed that inhibition of HH signaling through genetic 
ablation of HH activating components in the stroma enhances tumor 
progression and decreases survival (Lee et al., 2014a; Rhim et al., 2014; Shin 
et al., 2014). Additionally, in mouse models of colon cancer, stroma-specific 
HH activation inhibits tumor progression, while decreased HH activity 
accelerates colon tumorigenesis (Gerling et al., 2016; Lee et al., 2016). 
Similarly in prostate cancer, SmoM2 expression in the epithelium was not 
sufficient to initiate tumorigenesis in mice (Mao et al., 2006). However, it was 
not tested in mouse models whether alteration of HH signaling in the stroma 
changes prostate tumor progression. In Chapter 2, I describe experiments in 
which we test whether HH signaling in the tumor stroma can alter prostate 
cancer progression in a mouse model, and found that excess HH signaling in 
prostate stromal cells has an inhibitory effect on cancer progression (Fig. 1.2). 
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Prostate cancer is the second leading cause of cancer-related death in men in 
the United States (Siegel et al., 2018) and the second most common 
malignancy in men worldwide (Torre et al., 2015). Currently, the dominant 
therapies for local prostate cancer are surgical removal and radiation. For 
advanced tumors, androgen deprivation is the primary treatment that 
effectively reduces tumor size. However, castration-resistant cancer eventually 
recurs and becomes refractory to any existing treatment (Ramamurthy et al., 
2017). A popular idea is that cancer-initiating cells remain dormant and survive 
through therapies, then may awake and become active in repopulating tumor 
cells. In this process, many signaling pathways, including HH, have been 
proposed to play significant roles. Given the current diagnostic system that 
mainly relies on tumor histology assessment, a thorough characterization of 
the molecular signature for prostate cancer will be instrumental for the 
development of more effective diagnosis and treatments.  
	  
1.2 Hippo signaling 
1.2.1 Overview of Hippo pathway 
The Hippo pathway, first discovered through mosaic genetic screens for tissue 
growth related genes in Drosophila melanogaster, is evolutionarily conserved 
between mammals and fruit flies. In Drosophila, the Hippo pathway comprises 
a core kinase cascade of Ste20-like kinase Hippo (Hpo) (Harvey et al., 2003; 
Jia et al., 2003; Pantalacci et al., 2003; Udan et al., 2003; Wu et al., 2003) and 
NDR family kinase Warts (Wts) (Justice et al., 1995; Xu et al., 1995). Hpo 
directly binds with a scaffold protein Salvador (Sav) to phosphorylate and 
activate Wts, which then complexes with its regulatory protein Mats (Mob as 
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tumor suppressor) (Kango-Singh et al., 2002; Lai et al., 2005; Tapon et al., 
2002). Downstream to the kinase cascade is a Wts-interacting protein Yorkie 
(Yki) that is directly subject to negative regulation by Wts (Dong et al., 2007; 
Huang et al., 2005). Yki is a Hippo pathway transcription co-activator with 
phosphorylation-dependent shuttling between the nucleus and cytoplasm. 
Specifically, when Hippo pathway is in the “on” state, Yki is phosphorylated by 
the Wts-Mats complex and binds with 14-3-3, which leads to its retention in the 
cytoplasm (Oh and Irvine, 2008; Ren et al., 2010). When the Hippo pathway is 
in the “off” state, unphosphorylated Yki translocates into the nucleus, and acts 
together with the transcription factor Scalloped (Sd) to initiate downstream 
target gene expression that promotes cell proliferation, survival, and growth 
(Mahoney et al., 2005; Vassilev et al., 2001).  
 
In mammals, the core kinase components and transcription effectors are 
highly conserved as their Drosophila counterparts (Fig. 1.3). The mammalian 
orthologs of Hippo pathway components include the serine/threonine kinases 
MST1/2 (Mammalian Sterile 20-like kinases 1 and 2, Hpo homologs) and 
LATS1/2 (large tumor suppressor 1 and 2, Wts homologs), the scaffold 
proteins SAV1 (Salvador homolog 1, Sav homolog) and MOB1A/B (MOB 
kinase activator 1A and 1B, Mats homolog), the Yki homologs YAP (Yes-
associated protein) and its paralog TAZ (transcriptional co-activator with PDZ-
binding motif; also called WWTR1, for WW-domain containing transcription 
regulator 1), and the TEA domain-containing sequence-specific transcription 
factors TEAD1-4 (also referred to as TEFs, for transcriptional enhancer factors, 
Sd homologs). The pathway is considered to be in the active state when the 
MST and LATS kinases are active. Upon activation of the Hippo pathway, the 
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complex of MST1/2 and SAV1 phosphorylates and activates LATS1/2 and 
MOB1 cofactors (Callus et al., 2006; Chan et al., 2005; Praskova et al., 2008; 
Wei et al., 2007; Wu et al., 2003), which in turn directs multi-site 
phosphorylation of YAP/TAZ and hinders their nuclear transport, thereby 
inhibiting transcriptional activation of growth-promoting genes (Hao et al., 2008; 
Huang et al., 2005; Lei et al., 2008; Oka et al., 2008; Zhao et al., 2010). 
Phosphorylated YAP/TAZ are retained in the cytoplasm by 14-3-3 and 
undergo ubiquitin-dependent protein degradation (Kanai et al., 2000; Liu et al., 
2010; Ren et al., 2010; Zhao et al., 2010). Conversely, when the Hippo 
pathway is inactive, dephosphorylated YAP/TAZ translocate into the nucleus, 
form complexes with the TEADs that can directly bind to DNA to drive 
transcriptional programs related to cell proliferation and organ growth 
(Vassilev et al., 2001; Zhao et al., 2008). In addition to the TEAD family 
transcription factors, YAP/TAZ can also interact with many other transcription 
factors including SMADs (Alarcon et al., 2009; Ferrigno et al., 2002; Varelas et 
al., 2008), RUNT-related transcription factors  (RUNXs) (Cui et al., 2003; Hong 
et al., 2005; Yagi et al., 1999; Zaidi et al., 2004), T-box transcription factor 5 
(TBX5) (Murakami et al., 2005; Rosenbluh et al., 2012) to regulate the 
transcription of a variety of downstream target genes.  
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Figure 1.3 Schematic of the core Hippo signaling pathway in mammals. 
(Adapted from (Johnson and Halder, 2014)) 
 
(A) When the Hippo pathway is active, MST1/MST2 phosphorylates SAV1, 
and together they phosphorylate and activate LATS1/LATS2 kinases and 
MOB1A/MOB1B, which then phosphorylate YAP/TAZ. Phosphorylated YAP 
and TAZ are sequestered in the cytoplasm by the 14-3-3 protein and undergo 
proteasomal degradation. As a result, there is no expression of their target 
genes.  
(B) When the Hippo pathway is inactive, the kinases MST1, MST2, LATS1 and 
LATS2 are inactive. Unphosphorylated YAP and TAZ enter the nucleus and 
form a complex with TEADs to promote the expression of target genes 
including Ctgf.  
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1.2.2 Hippo signaling in development of the brain and other organs 
The function of the Hippo pathway in development has been extensively 
studied using genetically engineered mouse models. Yap null mutant mice 
have an embryonic lethal phenotype (Morin-Kensicki et al., 2006), and Taz null 
mutant mice show partial embryonic lethality (Hossain et al., 2007; Makita et 
al., 2008; Tian et al., 2007), suggesting that YAP, and to a lesser extent TAZ, 
are indispensible in embryonic development. Meanwhile, normal Hippo 
signaling controls organ size by preventing overgrowth such as the heart and 
liver (Camargo et al., 2007; Dong et al., 2007; Heallen et al., 2011).  
 
Accumulating evidence shows that Hippo signaling controls organ growth 
through regulating the maintenance and differentiation of stem cells and 
progenitor cells. For example, YAP and TAZ have been reported to maintain 
ES cell self-renewal (Alarcon et al., 2009; Varelas et al., 2008). Consistently, 
Yap knockdown in mouse ES cells leads to loss of pluripotency, whereas 
overexpression of Yap inhibits ES cell differentiation (Lian et al., 2010). In the 
mouse fetal heart, genetic deletion of Sav1 or activation of YAP stimulates 
cardiomyocyte proliferation (Heallen et al., 2011; von Gise et al., 2012). In liver, 
LATS1/2 are required for hepatocyte differentiation through inhibition of 
YAP/TAZ activities, while YAP overexpression suppresses normal hepatocyte 
maturation (Yi et al., 2016). Similarly in the skin, YAP overexpression causes 
expansion of basal epidermal progenitors and failure in terminal differentiation 
(Beverdam et al., 2013; Zhang et al., 2011).  
 
The balance of progenitor expansion and terminal differentiation is presumably 
attributed to the subcellular localization-dependent transcriptional activities of 
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YAP/TAZ. For example, in the developing lungs, expression and subcellular 
localization of YAP controls progenitor cell behaviors through control of SOX2 
expression (Mahoney et al., 2014). In particular, in the transition zone between 
airway and distal lung, YAP mainly accumulates in the nucleus of progenitors 
cells, which promotes TGF-β-dependent induction of SOX2 expression. In 
contrast, YAP remains in the cytoplasm of airway epithelial progenitors, which 
promotes cell differentiation and ultimately generates the airway epithelium 
(Mahoney et al., 2014). It has also been shown that nuclear YAP is required 
for branching morphogenesis through control of cell proliferation and physical 
properties of the epithelium (Lin et al., 2017). Similarly during skin 
development, nuclear YAP expression is high in skin progenitor cells, which 
correlates with the proliferative capacity and declines with age (Schlegelmilch 
et al., 2011; Zhang et al., 2011). Cytoplasmic YAP becomes evident upon skin 
progenitor cell differentiation. In addition, recent work revealed a non-
canonical mechanism of YAP regulation on cardiomyocyte proliferation, where 
AMOTL1 (Angiomotin-like 1) directly binds with both YAP and FAT4 (FAT 
tumor suppressor homolog 4) to sequester YAP in the cytoplasm in a 
LATS1/2-independent manner, thereby inhibiting YAP-mediated cardiac 
growth (Ragni et al., 2017). In summary, nuclear YAP/TAZ promotes 
progenitor cell proliferation and proper organ growth through control of 
downstream transcriptional programs. In contrast, cytoplasmic YAP/TAZ 
drives progenitor differentiation during organ development. 
 
During development, the brain requires rigorous control over the expansion of 
neural progenitors and the production of post-mitotic neurons and glial cells. 
Therefore, any disruption of the balance may result in severe consequences 
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on brain size and structure and neural functions. Several studies have 
implicated the Hippo pathway in regulating cell proliferation and differentiation 
in the nervous system. For example, YAP over-activation in the embryonic 
chick neural tube leads to expansion of neural progenitor cells (Cao et al., 
2008), suggesting the importance of YAP in the maintenance of neural 
progenitor proliferation. A recent study in Drosophila showed that disruption of 
Hippo signaling through loss-of-function mutations of core kinases Hpo or Wts 
results in increased neuroblast proliferation and substantial brain overgrowth 
(Poon et al., 2016). In the postnatal mouse retina, shRNA against Yap was 
found to decrease proliferation and increase terminal differentiation of retinal 
progenitors, whereas ectopic expression of Yap promotes proliferation (Zhang 
et al., 2012). Conditional ablation of Yap alone from embryonic murine neural 
stem cells using a Nestin-Cre results in hydrocephalus with no reported major 
anatomical changes in the brain, and very subtle defects in the proliferation of 
radial glial progenitors (Park et al., 2016). Strikingly, genetic ablation of both 
Yap and Taz in radial glial progenitors of the dorsal telencephalon using an 
Emx1-Cre results in profound cortical defects, including significant thinning of 
cortical tissues and severe hydrocephalus, accompanied by a marked 
reduction of radial glial progenitors and intermediate progenitors (Kong, 2018). 
The phenotype is attributed to impaired proliferation and premature 
differentiation of neural progenitor cells (Kong, 2018). These two studies could 
indicate redundant functions of YAP and TAZ, but the same Cre transgene 
needs to be used to ablate Yap alone and Yap/Taz together to confirm this. 
Moreover, inactivation of LATS1/2 with Nestin-Cre in the neural progenitor 
population in the embryonic mouse brain leads to YAP/TAZ-driven global 
hypertranscription with upregulation of many target genes related to cell 
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growth and proliferation, as revealed by cell-number normalized transcriptome 
analysis, which in turn inhibits the differentiation of neural progenitors (Lavado 
et al., 2018). As for the cerebellum, one study using cultured granule cell 
precursors, which are the most abundant cell population in the brain and 
critical for the growth of cerebellum, showed that cell proliferation is increased 
by overexpression of Yap and decreased by shRNA knockdown of Yap 
(Fernandez et al., 2009). Given the lack of evidence for a function of the Hippo 
pathway in cerebellar development, in Chapter 3, I describe experiments in 
which we test the requirement for Yap and Taz in two critical cerebellar 
progenitor populations during development, and found that loss of YAP/TAZ 
did not affect the growth of the cerebellum but had mild effects on the 
differentiation of progenitor cells (Fig. 1.4).  
 
Figure 1.4 Schematic of Hippo signaling in the development and 
regeneration of the cerebellum.  
YAP in the Hippo signaling pathway has a minor role in CB development, with 
a negative effect on the differentiation of progenitor cells. YAP has a major 
role in the regeneration of neonatal CB (this thesis).  
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1.2.3 Hippo signaling in regeneration of the brain and other tissues 
There is very limited evidence for the function of Hippo signaling in the 
regeneration of the central nervous system (CNS), largely due to the fact that 
the CNS has a very limited capacity for self-renewal. One study using adult rat 
spinal cord showed elevated expression of YAP and TAZ after peripheral 
nerve injury (Li et al., 2013). Intriguingly, a recent study revealed a remarkable 
capacity of regeneration in the neonatal mouse cerebellum (Wojcinski et al., 
2017), consistent with previous work that had a similar finding in the rat 
cerebellum (Altman et al., 1969). In Chapter 3, I describe the essential role of 
YAP in a population of plastic neural progenitors during recovery of the 
neonatal mouse cerebellum from irradiation-induced cell death of granule cell 
precursors, and show evidence that TAZ may have a divergent role from YAP 
during cerebellar regeneration.  
 
The role of Hippo pathway in the regeneration of several other organs has 
been studied more extensively. For example, in the adult liver, Yap 
overexpression forces dedifferentiation of hepatocytes into progenitor-like cells, 
which is reversed by YAP inhibition (Yimlamai et al., 2014). Partial 
hepatectomy induces a higher level of nuclear localized YAP and increases 
YAP target gene expression, as well as a decrease in Mst1/2, Lats1/2, and 
Mob1 (Grijalva et al., 2014). Livers with dual depletion of YAP and TAZ failed 
to restore liver mass due to defects in cell cycle entry during regeneration, 
indicating overlapping functions of the proteins (Lu et al., 2018). In the skin, 
small interfering RNA (siRNA)-mediated knockdown of Yap and Taz markedly 
delayed wound healing (Lee et al., 2014b). Moreover, YAP inhibition severely 
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impairs intestinal regeneration following chemical damage (Cai et al., 2010; 
Camargo et al., 2007). In a mouse model of colon regeneration induced by 
chemical insult, YAP/TAZ was shown to be required for repair of the 
epithelium (Yui et al., 2018). Interestingly, in a mouse incisor model, YAP and 
TAZ were found to be required to promote proliferation of transient-amplifying 
cells and inhibit differentiation (Hu et al., 2017). Together, these findings point 
to a positive role of YAP/TAZ for the survival and expansion of stem/progenitor 
cells during tissue regeneration.  
	  
1.2.4 Hippo signaling in human cancers 
Extensive studies have established a prominent role of the Hippo pathway in 
human cancers. Considerable evidence indicates that loss of Hippo signaling 
is associated with tumor progression. For example, elevated YAP/TAZ protein 
levels and nuclear localization has been found in various human cancers, 
including liver, prostate, colon, lung, and breast cancers (Chan et al., 2008; 
Steinhardt et al., 2008; Zhao et al., 2007; Zhou et al., 2011). These results 
place YAP/TAZ as a potential prognostic parameter for certain human cancers 
(Xu et al., 2009). In mouse models, genetic ablation of LATS1 causes soft 
tissue sarcoma and ovarian tumors (St John et al., 1999). Deletion of Sav1 or 
Mst1/2 also leads to liver tumor formation (Lee et al., 2010; Song et al., 2010; 
Zhou et al., 2009). Brain tumors were also reported to be associated with 
decreased Hippo pathway activity. In a glioblastoma study, the overexpression 
of Taz or constitutive activation of nuclear TAZ was shown to increase tumor 
grade in a mouse model (Bhat et al., 2011). Amplification of the YAP gene 
locus has been reported in medulloblastomas, a pediatric brain tumor of the 
cerebellum (Fernandez et al., 2009).  
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Besides the genetic mutations of the Hippo pathway tumor suppressor genes, 
epigenetic silencing of Hippo components has been implicated in human 
cancers, including hypermethylation of Mst1/2 in soft tissue sarcoma (Seidel et 
al., 2007) and Lats1/2 in breast cancers (Takahashi et al., 2005). It is also 
worth noting that besides its role as a potential oncogene, YAP has been 
found to have tumor-suppressing functions in certain types of cancers. 
Specifically, loss of YAP is observed in human breast cancer and colon 
carcinomas (Barry et al., 2013; Yuan et al., 2008). In human head and neck 
cancers, cytoplasmic YAP is abundant while nuclear YAP overexpression 
results in cell death (Ehsanian et al., 2010). Together, the function of YAP in 
cancers appears dependent on the cell context. Thus it is crucial to determine 
the exact role of YAP as an oncoprotein versus a tumor suppressor in different 
cancers in order to conduct appropriate targeting of YAP as a cancer therapy. 
  
23 
	  
REFERENCES 
 
Aavikko, M., Li, S. P., Saarinen, S., Alhopuro, P., Kaasinen, E., 
Morgunova, E., Li, Y., Vesanen, K., Smith, M. J., Evans, D. G., et al. 
(2012). Loss of SUFU function in familial multiple meningioma. 
American journal of human genetics 91, 520-526. 
Alarcon, C., Zaromytidou, A. I., Xi, Q., Gao, S., Yu, J., Fujisawa, S., Barlas, 
A., Miller, A. N., Manova-Todorova, K., Macias, M. J., et al. (2009). 
Nuclear CDKs drive Smad transcriptional activation and turnover in 
BMP and TGF-beta pathways. Cell 139, 757-769. 
Allen, B. L., Tenzen, T. and McMahon, A. P. (2007). The Hedgehog-binding 
proteins Gas1 and Cdo cooperate to positively regulate Shh signaling 
during mouse development. Genes & development 21, 1244-1257. 
Altman, J., Anderson, W. J. and Wright, K. A. (1969). Early effects of x-
irradiation of the cerebellum in infant rats: decimation and reconstitution 
of the external granular layer. Experimental neurology 24, 196-216. 
Bai, C. B., Auerbach, W., Lee, J. S., Stephen, D. and Joyner, A. L. (2002). 
Gli2, but not Gli1, is required for initial Shh signaling and ectopic 
activation of the Shh pathway. Development (Cambridge, England) 
129, 4753-4761. 
Bai, C. B. and Joyner, A. L. (2001). Gli1 can rescue the in vivo function of 
Gli2. Development (Cambridge, England) 128, 5161-5172. 
Bai, C. B., Stephen, D. and Joyner, A. L. (2004). All mouse ventral spinal 
cord patterning by hedgehog is Gli dependent and involves an activator 
function of Gli3. Developmental cell 6, 103-115. 
Banerjee, P. P., Banerjee, S., Tilly, K. I., Tilly, J. L., Brown, T. R. and 
Zirkin, B. R. (1995). Lobe-specific apoptotic cell death in rat prostate 
after androgen ablation by castration. Endocrinology 136, 4368-4376. 
Barry, E. R., Morikawa, T., Butler, B. L., Shrestha, K., de la Rosa, R., Yan, 
K. S., Fuchs, C. S., Magness, S. T., Smits, R., Ogino, S., et al. 
(2013). Restriction of intestinal stem cell expansion and the 
regenerative response by YAP. Nature 493, 106-110. 
Beachy, P. A., Hymowitz, S. G., Lazarus, R. A., Leahy, D. J. and Siebold, 
C. (2010). Interactions between Hedgehog proteins and their binding 
partners come into view. Genes & development 24, 2001-2012. 
Berman, D. M., Desai, N., Wang, X., Karhadkar, S. S., Reynon, M., Abate-
Shen, C., Beachy, P. A. and Shen, M. M. (2004). Roles for Hedgehog 
24 
	  
signaling in androgen production and prostate ductal morphogenesis. 
Developmental biology 267, 387-398. 
Beverdam, A., Claxton, C., Zhang, X., James, G., Harvey, K. F. and Key, 
B. (2013). Yap controls stem/progenitor cell proliferation in the mouse 
postnatal epidermis. The Journal of investigative dermatology 133, 
1497-1505. 
Bhat, K. P., Salazar, K. L., Balasubramaniyan, V., Wani, K., Heathcock, L., 
Hollingsworth, F., James, J. D., Gumin, J., Diefes, K. L., Kim, S. H., 
et al. (2011). The transcriptional coactivator TAZ regulates 
mesenchymal differentiation in malignant glioma. Genes & development 
25, 2594-2609. 
Bhatia, N., Thiyagarajan, S., Elcheva, I., Saleem, M., Dlugosz, A., Mukhtar, 
H. and Spiegelman, V. S. (2006). Gli2 is targeted for ubiquitination and 
degradation by beta-TrCP ubiquitin ligase. The Journal of biological 
chemistry 281, 19320-19326. 
Briscoe, J. and Therond, P. P. (2013). The mechanisms of Hedgehog 
signalling and its roles in development and disease. Nature reviews. 
Molecular cell biology 14, 416-429. 
Cai, J., Zhang, N., Zheng, Y., de Wilde, R. F., Maitra, A. and Pan, D. (2010). 
The Hippo signaling pathway restricts the oncogenic potential of an 
intestinal regeneration program. Genes & development 24, 2383-2388. 
Callus, B. A., Verhagen, A. M. and Vaux, D. L. (2006). Association of 
mammalian sterile twenty kinases, Mst1 and Mst2, with hSalvador via 
C-terminal coiled-coil domains, leads to its stabilization and 
phosphorylation. The FEBS journal 273, 4264-4276. 
Camargo, F. D., Gokhale, S., Johnnidis, J. B., Fu, D., Bell, G. W., 
Jaenisch, R. and Brummelkamp, T. R. (2007). YAP1 increases organ 
size and expands undifferentiated progenitor cells. Current biology : CB 
17, 2054-2060. 
Cao, X., Pfaff, S. L. and Gage, F. H. (2008). YAP regulates neural progenitor 
cell number via the TEA domain transcription factor. Genes & 
development 22, 3320-3334. 
Cavalli, F. M. G., Remke, M., Rampasek, L., Peacock, J., Shih, D. J. H., 
Luu, B., Garzia, L., Torchia, J., Nor, C., Morrissy, A. S., et al. (2017). 
Intertumoral Heterogeneity within Medulloblastoma Subgroups. Cancer 
cell 31, 737-754.e736. 
25 
	  
Chan, E. H., Nousiainen, M., Chalamalasetty, R. B., Schafer, A., Nigg, E. 
A. and Sillje, H. H. (2005). The Ste20-like kinase Mst2 activates the 
human large tumor suppressor kinase Lats1. Oncogene 24, 2076-2086. 
Chan, S. W., Lim, C. J., Guo, K., Ng, C. P., Lee, I., Hunziker, W., Zeng, Q. 
and Hong, W. (2008). A role for TAZ in migration, invasion, and 
tumorigenesis of breast cancer cells. Cancer research 68, 2592-2598. 
Chen, M., Tanner, M., Levine, A. C., Levina, E., Ohouo, P. and Buttyan, R. 
(2009). Androgenic regulation of hedgehog signaling pathway 
components in prostate cancer cells. Cell cycle (Georgetown, Tex.) 8, 
149-157. 
Chuang, P. T. and McMahon, A. P. (1999). Vertebrate Hedgehog signalling 
modulated by induction of a Hedgehog-binding protein. Nature 397, 
617-621. 
Clark, V. E., Erson-Omay, E. Z., Serin, A., Yin, J., Cotney, J., Ozduman, K., 
Avsar, T., Li, J., Murray, P. B., Henegariu, O., et al. (2013). Genomic 
analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, 
AKT1, and SMO. Science (New York, N.Y.) 339, 1077-1080. 
Cooper, A. F., Yu, K. P., Brueckner, M., Brailey, L. L., Johnson, L., 
McGrath, J. M. and Bale, A. E. (2005). Cardiac and CNS defects in a 
mouse with targeted disruption of suppressor of fused. Development 
(Cambridge, England) 132, 4407-4417. 
Cui, C. B., Cooper, L. F., Yang, X., Karsenty, G. and Aukhil, I. (2003). 
Transcriptional coactivation of bone-specific transcription factor Cbfa1 
by TAZ. Molecular and cellular biology 23, 1004-1013. 
Cunha, G. R., Donjacour, A. A., Cooke, P. S., Mee, S., Bigsby, R. M., 
Higgins, S. J. and Sugimura, Y. (1987). The endocrinology and 
developmental biology of the prostate. Endocrine reviews 8, 338-362. 
Cunha, G. R., Donjacour, A. A. and Sugimura, Y. (1986). Stromal-epithelial 
interactions and heterogeneity of proliferative activity within the 
prostate. Biochemistry and cell biology = Biochimie et biologie cellulaire 
64, 608-614. 
Cunha, G. R. and Lung, B. (1978). The possible influence of temporal factors 
in androgenic responsiveness of urogenital tissue recombinants from 
wild-type and androgen-insensitive (Tfm) mice. The Journal of 
experimental zoology 205, 181-193. 
Doles, J., Cook, C., Shi, X., Valosky, J., Lipinski, R. and Bushman, W. 
(2006). Functional compensation in Hedgehog signaling during mouse 
prostate development. Developmental biology 295, 13-25. 
26 
	  
Dong, J., Feldmann, G., Huang, J., Wu, S., Zhang, N., Comerford, S. A., 
Gayyed, M. F., Anders, R. A., Maitra, A. and Pan, D. (2007). 
Elucidation of a universal size-control mechanism in Drosophila and 
mammals. Cell 130, 1120-1133. 
Drakopoulou, E., Outram, S. V., Rowbotham, N. J., Ross, S. E., 
Furmanski, A. L., Saldana, J. I., Hager-Theodorides, A. L. and 
Crompton, T. (2010). Non-redundant role for the transcription factor 
Gli1 at multiple stages of thymocyte development. Cell cycle 
(Georgetown, Tex.) 9, 4144-4152. 
Ehsanian, R., Brown, M., Lu, H., Yang, X. P., Pattatheyil, A., Yan, B., 
Duggal, P., Chuang, R., Doondeea, J., Feller, S., et al. (2010). YAP 
dysregulation by phosphorylation or DeltaNp63-mediated gene 
repression promotes proliferation, survival and migration in head and 
neck cancer subsets. Oncogene 29, 6160-6171. 
Epstein, E., Jr. (2001). Genetic determinants of basal cell carcinoma risk. 
Medical and pediatric oncology 36, 555-558. 
Fan, L., Pepicelli, C. V., Dibble, C. C., Catbagan, W., Zarycki, J. L., Laciak, 
R., Gipp, J., Shaw, A., Lamm, M. L., Munoz, A., et al. (2004). 
Hedgehog signaling promotes prostate xenograft tumor growth. 
Endocrinology 145, 3961-3970. 
Fernandez, L. A., Northcott, P. A., Dalton, J., Fraga, C., Ellison, D., 
Angers, S., Taylor, M. D. and Kenney, A. M. (2009). YAP1 is 
amplified and up-regulated in hedgehog-associated medulloblastomas 
and mediates Sonic hedgehog-driven neural precursor proliferation. 
Genes & development 23, 2729-2741. 
Ferrigno, O., Lallemand, F., Verrecchia, F., L'Hoste, S., Camonis, J., Atfi, 
A. and Mauviel, A. (2002). Yes-associated protein (YAP65) interacts 
with Smad7 and potentiates its inhibitory activity against TGF-
beta/Smad signaling. Oncogene 21, 4879-4884. 
Freestone, S. H., Marker, P., Grace, O. C., Tomlinson, D. C., Cunha, G. R., 
Harnden, P. and Thomson, A. A. (2003). Sonic hedgehog regulates 
prostatic growth and epithelial differentiation. Developmental biology 
264, 352-362. 
Gerling, M., Buller, N. V., Kirn, L. M., Joost, S., Frings, O., Englert, B., 
Bergstrom, A., Kuiper, R. V., Blaas, L., Wielenga, M. C., et al. 
(2016). Stromal Hedgehog signalling is downregulated in colon cancer 
and its restoration restrains tumour growth. Nature communications 7, 
12321. 
27 
	  
Goetz, S. C. and Anderson, K. V. (2010). The primary cilium: a signalling 
centre during vertebrate development. Nature reviews. Genetics 11, 
331-344. 
Gong, X., Qian, H., Cao, P., Zhao, X., Zhou, Q., Lei, J. and Yan, N. (2018). 
Structural basis for the recognition of Sonic Hedgehog by human 
Patched1. Science (New York, N.Y.) 361. 
Gorlin, R. J. (2004). Nevoid basal cell carcinoma (Gorlin) syndrome. Genetics 
in medicine : official journal of the American College of Medical 
Genetics 6, 530-539. 
Grijalva, J. L., Huizenga, M., Mueller, K., Rodriguez, S., Brazzo, J., 
Camargo, F., Sadri-Vakili, G. and Vakili, K. (2014). Dynamic 
alterations in Hippo signaling pathway and YAP activation during liver 
regeneration. American journal of physiology. Gastrointestinal and liver 
physiology 307, G196-204. 
Hahn, H., Wicking, C., Zaphiropoulous, P. G., Gailani, M. R., Shanley, S., 
Chidambaram, A., Vorechovsky, I., Holmberg, E., Unden, A. B., 
Gillies, S., et al. (1996). Mutations of the human homolog of Drosophila 
patched in the nevoid basal cell carcinoma syndrome. Cell 85, 841-851. 
Hao, Y., Chun, A., Cheung, K., Rashidi, B. and Yang, X. (2008). Tumor 
suppressor LATS1 is a negative regulator of oncogene YAP. The 
Journal of biological chemistry 283, 5496-5509. 
Harvey, K. F., Pfleger, C. M. and Hariharan, I. K. (2003). The Drosophila Mst 
ortholog, hippo, restricts growth and cell proliferation and promotes 
apoptosis. Cell 114, 457-467. 
Haycraft, C. J., Banizs, B., Aydin-Son, Y., Zhang, Q., Michaud, E. J. and 
Yoder, B. K. (2005). Gli2 and Gli3 localize to cilia and require the 
intraflagellar transport protein polaris for processing and function. PLoS 
genetics 1, e53. 
Heallen, T., Zhang, M., Wang, J., Bonilla-Claudio, M., Klysik, E., Johnson, 
R. L. and Martin, J. F. (2011). Hippo pathway inhibits Wnt signaling to 
restrain cardiomyocyte proliferation and heart size. Science (New York, 
N.Y.) 332, 458-461. 
Hindley, C. J., Condurat, A. L., Menon, V., Thomas, R., Azmitia, L. M., 
Davis, J. A. and Pruszak, J. (2016). The Hippo pathway member YAP 
enhances human neural crest cell fate and migration. Scientific reports 
6, 23208. 
Hong, J. H., Hwang, E. S., McManus, M. T., Amsterdam, A., Tian, Y., 
Kalmukova, R., Mueller, E., Benjamin, T., Spiegelman, B. M., Sharp, 
28 
	  
P. A., et al. (2005). TAZ, a transcriptional modulator of mesenchymal 
stem cell differentiation. Science (New York, N.Y.) 309, 1074-1078. 
Hossain, Z., Ali, S. M., Ko, H. L., Xu, J., Ng, C. P., Guo, K., Qi, Z., Ponniah, 
S., Hong, W. and Hunziker, W. (2007). Glomerulocystic kidney 
disease in mice with a targeted inactivation of Wwtr1. Proceedings of 
the National Academy of Sciences of the United States of America 104, 
1631-1636. 
Hu, J. K., Du, W., Shelton, S. J., Oldham, M. C., DiPersio, C. M. and Klein, 
O. D. (2017). An FAK-YAP-mTOR Signaling Axis Regulates Stem Cell-
Based Tissue Renewal in Mice. Cell stem cell 21, 91-106.e106. 
Huang, J., Wu, S., Barrera, J., Matthews, K. and Pan, D. (2005). The Hippo 
signaling pathway coordinately regulates cell proliferation and apoptosis 
by inactivating Yorkie, the Drosophila Homolog of YAP. Cell 122, 421-
434. 
Huang, P., Zheng, S., Wierbowski, B. M., Kim, Y., Nedelcu, D., Aravena, 
L., Liu, J., Kruse, A. C. and Salic, A. (2018). Structural Basis of 
Smoothened Activation in Hedgehog Signaling. Cell 174, 312-
324.e316. 
Huangfu, D. and Anderson, K. V. (2005). Cilia and Hedgehog 
responsiveness in the mouse. Proceedings of the National Academy of 
Sciences of the United States of America 102, 11325-11330. 
Ibuki, N., Ghaffari, M., Pandey, M., Iu, I., Fazli, L., Kashiwagi, M., Tojo, H., 
Nakanishi, O., Gleave, M. E. and Cox, M. E. (2013). TAK-441, a novel 
investigational smoothened antagonist, delays castration-resistant 
progression in prostate cancer by disrupting paracrine hedgehog 
signaling. Int J Cancer 133, 1955-1966. 
Isaacs, J. T. (1985). Control of Cell Proliferation and Cell Death in the Normal 
and Neoplastic Prostate. In Benign Prostatic Hyperplasia, pp. 10. 
Jia, J., Zhang, W., Wang, B., Trinko, R. and Jiang, J. (2003). The 
Drosophila Ste20 family kinase dMST functions as a tumor suppressor 
by restricting cell proliferation and promoting apoptosis. Genes & 
development 17, 2514-2519. 
Johnson, R. and Halder, G. (2014). The two faces of Hippo: targeting the 
Hippo pathway for regenerative medicine and cancer treatment. Nature 
reviews. Drug discovery 13, 63-79. 
Johnson, R. L., Rothman, A. L., Xie, J., Goodrich, L. V., Bare, J. W., 
Bonifas, J. M., Quinn, A. G., Myers, R. M., Cox, D. R., Epstein, E. H., 
29 
	  
Jr., et al. (1996). Human homolog of patched, a candidate gene for the 
basal cell nevus syndrome. Science (New York, N.Y.) 272, 1668-1671. 
Justice, R. W., Zilian, O., Woods, D. F., Noll, M. and Bryant, P. J. (1995). 
The Drosophila tumor suppressor gene warts encodes a homolog of 
human myotonic dystrophy kinase and is required for the control of cell 
shape and proliferation. Genes & development 9, 534-546. 
Kanai, F., Marignani, P. A., Sarbassova, D., Yagi, R., Hall, R. A., Donowitz, 
M., Hisaminato, A., Fujiwara, T., Ito, Y., Cantley, L. C., et al. (2000). 
TAZ: a novel transcriptional co-activator regulated by interactions with 
14-3-3 and PDZ domain proteins. The EMBO journal 19, 6778-6791. 
Kango-Singh, M., Nolo, R., Tao, C., Verstreken, P., Hiesinger, P. R., 
Bellen, H. J. and Halder, G. (2002). Shar-pei mediates cell 
proliferation arrest during imaginal disc growth in Drosophila. 
Development (Cambridge, England) 129, 5719-5730. 
Karhadkar, S. S., Bova, G. S., Abdallah, N., Dhara, S., Gardner, D., Maitra, 
A., Isaacs, J. T., Berman, D. M. and Beachy, P. A. (2004). Hedgehog 
signalling in prostate regeneration, neoplasia and metastasis. Nature 
431, 707-712. 
Kasper, M., Schnidar, H., Neill, G. W., Hanneder, M., Klingler, S., Blaas, L., 
Schmid, C., Hauser-Kronberger, C., Regl, G., Philpott, M. P., et al. 
(2006). Selective modulation of Hedgehog/GLI target gene expression 
by epidermal growth factor signaling in human keratinocytes. Molecular 
and cellular biology 26, 6283-6298. 
Kijima, C., Miyashita, T., Suzuki, M., Oka, H. and Fujii, K. (2012). Two 
cases of nevoid basal cell carcinoma syndrome associated with 
meningioma caused by a PTCH1 or SUFU germline mutation. Familial 
cancer 11, 565-570. 
Kong, S. (2018). Loss of YAP/TAZ impaired the proliferation and 
differentiation ability of neural progenitor cells. bioRxiv. 
Kool, M., Jones, D. T., Jager, N., Northcott, P. A., Pugh, T. J., Hovestadt, 
V., Piro, R. M., Esparza, L. A., Markant, S. L., Remke, M., et al. 
(2014). Genome sequencing of SHH medulloblastoma predicts 
genotype-related response to smoothened inhibition. Cancer cell 25, 
393-405. 
Lai, Z. C., Wei, X., Shimizu, T., Ramos, E., Rohrbaugh, M., Nikolaidis, N., 
Ho, L. L. and Li, Y. (2005). Control of cell proliferation and apoptosis 
by mob as tumor suppressor, mats. Cell 120, 675-685. 
30 
	  
Lamm, M. L., Catbagan, W. S., Laciak, R. J., Barnett, D. H., Hebner, C. M., 
Gaffield, W., Walterhouse, D., Iannaccone, P. and Bushman, W. 
(2002). Sonic hedgehog activates mesenchymal Gli1 expression during 
prostate ductal bud formation. Developmental biology 249, 349-366. 
Lavado, A., Park, J. Y., Pare, J., Finkelstein, D., Pan, H., Xu, B., Fan, Y., 
Kumar, R. P., Neale, G., Kwak, Y. D., et al. (2018). The Hippo 
Pathway Prevents YAP/TAZ-Driven Hypertranscription and Controls 
Neural Progenitor Number. Developmental cell. 
Lee, J. J., Perera, R. M., Wang, H., Wu, D. C., Liu, X. S., Han, S., Fitamant, 
J., Jones, P. D., Ghanta, K. S., Kawano, S., et al. (2014a). Stromal 
response to Hedgehog signaling restrains pancreatic cancer 
progression. Proc Natl Acad Sci U S A 111, E3091-3100. 
Lee, J. J., Rothenberg, M. E., Seeley, E. S., Zimdahl, B., Kawano, S., Lu, 
W. J., Shin, K., Sakata-Kato, T., Chen, J. K., Diehn, M., et al. (2016). 
Control of inflammation by stromal Hedgehog pathway activation 
restrains colitis. Proceedings of the National Academy of Sciences of 
the United States of America 113, E7545-e7553. 
Lee, K. P., Lee, J. H., Kim, T. S., Kim, T. H., Park, H. D., Byun, J. S., Kim, 
M. C., Jeong, W. I., Calvisi, D. F., Kim, J. M., et al. (2010). The Hippo-
Salvador pathway restrains hepatic oval cell proliferation, liver size, and 
liver tumorigenesis. Proceedings of the National Academy of Sciences 
of the United States of America 107, 8248-8253. 
Lee, M. J., Byun, M. R., Furutani-Seiki, M., Hong, J. H. and Jung, H. S. 
(2014b). YAP and TAZ regulate skin wound healing. The Journal of 
investigative dermatology 134, 518-525. 
Lei, Q. Y., Zhang, H., Zhao, B., Zha, Z. Y., Bai, F., Pei, X. H., Zhao, S., 
Xiong, Y. and Guan, K. L. (2008). TAZ promotes cell proliferation and 
epithelial-mesenchymal transition and is inhibited by the hippo pathway. 
Molecular and cellular biology 28, 2426-2436. 
Li, N., Lim, G., Chen, L., McCabe, M. F., Kim, H., Zhang, S. and Mao, J. 
(2013). Spinal expression of Hippo signaling components YAP and TAZ 
following peripheral nerve injury in rats. Brain research 1535, 137-147. 
Lian, I., Kim, J., Okazawa, H., Zhao, J., Zhao, B., Yu, J., Chinnaiyan, A., 
Israel, M. A., Goldstein, L. S., Abujarour, R., et al. (2010). The role of 
YAP transcription coactivator in regulating stem cell self-renewal and 
differentiation. Genes & development 24, 1106-1118. 
Lim, A., Shin, K., Zhao, C., Kawano, S. and Beachy, P. A. (2014). Spatially 
restricted Hedgehog signalling regulates HGF-induced branching of the 
adult prostate. Nature cell biology 16, 1135-1145. 
31 
	  
Lin, C., Yao, E., Zhang, K., Jiang, X., Croll, S., Thompson-Peer, K. and 
Chuang, P. T. (2017). YAP is essential for mechanical force production 
and epithelial cell proliferation during lung branching morphogenesis. 
eLife 6. 
Liu, A., Wang, B. and Niswander, L. A. (2005). Mouse intraflagellar transport 
proteins regulate both the activator and repressor functions of Gli 
transcription factors. Development (Cambridge, England) 132, 3103-
3111. 
Liu, C. Y., Zha, Z. Y., Zhou, X., Zhang, H., Huang, W., Zhao, D., Li, T., 
Chan, S. W., Lim, C. J., Hong, W., et al. (2010). The hippo tumor 
pathway promotes TAZ degradation by phosphorylating a 
phosphodegron and recruiting the SCF{beta}-TrCP E3 ligase. The 
Journal of biological chemistry 285, 37159-37169. 
Lu, L., Finegold, M. J. and Johnson, R. L. (2018). Hippo pathway 
coactivators Yap and Taz are required to coordinate mammalian liver 
regeneration. Experimental & molecular medicine 50, e423. 
Mahoney, J. E., Mori, M., Szymaniak, A. D., Varelas, X. and Cardoso, W. 
V. (2014). The hippo pathway effector Yap controls patterning and 
differentiation of airway epithelial progenitors. Developmental cell 30, 
137-150. 
Mahoney, W. M., Jr., Hong, J. H., Yaffe, M. B. and Farrance, I. K. (2005). 
The transcriptional co-activator TAZ interacts differentially with 
transcriptional enhancer factor-1 (TEF-1) family members. The 
Biochemical journal 388, 217-225. 
Makita, R., Uchijima, Y., Nishiyama, K., Amano, T., Chen, Q., Takeuchi, T., 
Mitani, A., Nagase, T., Yatomi, Y., Aburatani, H., et al. (2008). 
Multiple renal cysts, urinary concentration defects, and pulmonary 
emphysematous changes in mice lacking TAZ. American journal of 
physiology. Renal physiology 294, F542-553. 
Mao, J., Ligon, K. L., Rakhlin, E. Y., Thayer, S. P., Bronson, R. T., 
Rowitch, D. and McMahon, A. P. (2006). A novel somatic mouse 
model to survey tumorigenic potential applied to the Hedgehog 
pathway. Cancer research 66, 10171-10178. 
Mitani, A., Nagase, T., Fukuchi, K., Aburatani, H., Makita, R. and Kurihara, 
H. (2009). Transcriptional coactivator with PDZ-binding motif is 
essential for normal alveolarization in mice. American journal of 
respiratory and critical care medicine 180, 326-338. 
Morin-Kensicki, E. M., Boone, B. N., Howell, M., Stonebraker, J. R., Teed, 
J., Alb, J. G., Magnuson, T. R., O'Neal, W. and Milgram, S. L. (2006). 
32 
	  
Defects in yolk sac vasculogenesis, chorioallantoic fusion, and 
embryonic axis elongation in mice with targeted disruption of Yap65. 
Molecular and cellular biology 26, 77-87. 
Motoyama, J., Heng, H., Crackower, M. A., Takabatake, T., Takeshima, K., 
Tsui, L. C. and Hui, C. (1998a). Overlapping and non-overlapping 
Ptch2 expression with Shh during mouse embryogenesis. Mechanisms 
of development 78, 81-84. 
Motoyama, J., Milenkovic, L., Iwama, M., Shikata, Y., Scott, M. P. and Hui, 
C. C. (2003). Differential requirement for Gli2 and Gli3 in ventral neural 
cell fate specification. Developmental biology 259, 150-161. 
Motoyama, J., Takabatake, T., Takeshima, K. and Hui, C. (1998b). Ptch2, a 
second mouse Patched gene is co-expressed with Sonic hedgehog. 
Nature genetics 18, 104-106. 
Murakami, M., Nakagawa, M., Olson, E. N. and Nakagawa, O. (2005). A 
WW domain protein TAZ is a critical coactivator for TBX5, a 
transcription factor implicated in Holt-Oram syndrome. Proceedings of 
the National Academy of Sciences of the United States of America 102, 
18034-18039. 
Oh, H. and Irvine, K. D. (2008). In vivo regulation of Yorkie phosphorylation 
and localization. Development (Cambridge, England) 135, 1081-1088. 
Oka, T., Mazack, V. and Sudol, M. (2008). Mst2 and Lats kinases regulate 
apoptotic function of Yes kinase-associated protein (YAP). The Journal 
of biological chemistry 283, 27534-27546. 
Okada, A., Charron, F., Morin, S., Shin, D. S., Wong, K., Fabre, P. J., 
Tessier-Lavigne, M. and McConnell, S. K. (2006). Boc is a receptor 
for sonic hedgehog in the guidance of commissural axons. Nature 444, 
369-373. 
Pan, Y., Bai, C. B., Joyner, A. L. and Wang, B. (2006). Sonic hedgehog 
signaling regulates Gli2 transcriptional activity by suppressing its 
processing and degradation. Molecular and cellular biology 26, 3365-
3377. 
Pantalacci, S., Tapon, N. and Leopold, P. (2003). The Salvador partner 
Hippo promotes apoptosis and cell-cycle exit in Drosophila. Nature cell 
biology 5, 921-927. 
Park, H. L., Bai, C., Platt, K. A., Matise, M. P., Beeghly, A., Hui, C. C., 
Nakashima, M. and Joyner, A. L. (2000). Mouse Gli1 mutants are 
viable but have defects in SHH signaling in combination with a Gli2 
mutation. Development (Cambridge, England) 127, 1593-1605. 
33 
	  
Park, K. S., Martelotto, L. G., Peifer, M., Sos, M. L., Karnezis, A. N., 
Mahjoub, M. R., Bernard, K., Conklin, J. F., Szczepny, A., Yuan, J., 
et al. (2011). A crucial requirement for Hedgehog signaling in small cell 
lung cancer. Nature medicine 17, 1504-1508. 
Park, R., Moon, U. Y., Park, J. Y., Hughes, L. J., Johnson, R. L., Cho, S. H. 
and Kim, S. (2016). Yap is required for ependymal integrity and is 
suppressed in LPA-induced hydrocephalus. Nature communications 7, 
10329. 
Peng, Y. C. and Joyner, A. L. (2015). Hedgehog signaling in prostate 
epithelial-mesenchymal growth regulation. Developmental biology 400, 
94-104. 
Pepinsky, R. B., Zeng, C., Wen, D., Rayhorn, P., Baker, D. P., Williams, K. 
P., Bixler, S. A., Ambrose, C. M., Garber, E. A., Miatkowski, K., et al. 
(1998). Identification of a palmitic acid-modified form of human Sonic 
hedgehog. The Journal of biological chemistry 273, 14037-14045. 
Perler, F. B. (1998). Protein splicing of inteins and hedgehog autoproteolysis: 
structure, function, and evolution. Cell 92, 1-4. 
Persson, M., Stamataki, D., te Welscher, P., Andersson, E., Bose, J., 
Ruther, U., Ericson, J. and Briscoe, J. (2002). Dorsal-ventral 
patterning of the spinal cord requires Gli3 transcriptional repressor 
activity. Genes & development 16, 2865-2878. 
Petrova, R., Garcia, A. D. and Joyner, A. L. (2013). Titration of GLI3 
repressor activity by sonic hedgehog signaling is critical for maintaining 
multiple adult neural stem cell and astrocyte functions. The Journal of 
neuroscience : the official journal of the Society for Neuroscience 33, 
17490-17505. 
Podlasek, C. A., Barnett, D. H., Clemens, J. Q., Bak, P. M. and Bushman, 
W. (1999). Prostate development requires Sonic hedgehog expressed 
by the urogenital sinus epithelium. Developmental biology 209, 28-39. 
Poon, C. L., Mitchell, K. A., Kondo, S., Cheng, L. Y. and Harvey, K. F. 
(2016). The Hippo Pathway Regulates Neuroblasts and Brain Size in 
Drosophila melanogaster. Current biology : CB 26, 1034-1042. 
Praskova, M., Xia, F. and Avruch, J. (2008). MOBKL1A/MOBKL1B 
phosphorylation by MST1 and MST2 inhibits cell proliferation. Current 
biology : CB 18, 311-321. 
Pressey, J. G., Anderson, J. R., Crossman, D. K., Lynch, J. C. and Barr, F. 
G. (2011). Hedgehog pathway activity in pediatric embryonal 
34 
	  
rhabdomyosarcoma and undifferentiated sarcoma: a report from the 
Children's Oncology Group. Pediatric blood & cancer 57, 930-938. 
Pu, Y., Huang, L. and Prins, G. S. (2004). Sonic hedgehog-patched Gli 
signaling in the developing rat prostate gland: lobe-specific suppression 
by neonatal estrogens reduces ductal growth and branching. 
Developmental biology 273, 257-275. 
Qi, X., Schmiege, P., Coutavas, E. and Li, X. (2018). Two Patched 
molecules engage distinct sites on Hedgehog yielding a signaling-
competent complex. Science (New York, N.Y.) 362. 
Ragni, C. V., Diguet, N., Le Garrec, J. F., Novotova, M., Resende, T. P., 
Pop, S., Charon, N., Guillemot, L., Kitasato, L., Badouel, C., et al. 
(2017). Amotl1 mediates sequestration of the Hippo effector Yap1 
downstream of Fat4 to restrict heart growth. Nature communications 8, 
14582. 
Ramamurthy, V. P., Ramalingam, S., Kwegyir-Afful, A. K., Hussain, A. and 
Njar, V. C. (2017). Targeting of protein translation as a new treatment 
paradigm for prostate cancer. Current opinion in oncology. 
Reginensi, A., Enderle, L., Gregorieff, A., Johnson, R. L., Wrana, J. L. and 
McNeill, H. (2016). A critical role for NF2 and the Hippo pathway in 
branching morphogenesis. Nature communications 7, 12309. 
Reginensi, A., Scott, R. P., Gregorieff, A., Bagherie-Lachidan, M., Chung, 
C., Lim, D. S., Pawson, T., Wrana, J. and McNeill, H. (2013). Yap- 
and Cdc42-dependent nephrogenesis and morphogenesis during 
mouse kidney development. PLoS genetics 9, e1003380. 
Ren, F., Zhang, L. and Jiang, J. (2010). Hippo signaling regulates Yorkie 
nuclear localization and activity through 14-3-3 dependent and 
independent mechanisms. Developmental biology 337, 303-312. 
Rhim, A. D., Oberstein, P. E., Thomas, D. H., Mirek, E. T., Palermo, C. F., 
Sastra, S. A., Dekleva, E. N., Saunders, T., Becerra, C. P., 
Tattersall, I. W., et al. (2014). Stromal elements act to restrain, rather 
than support, pancreatic ductal adenocarcinoma. Cancer Cell 25, 735-
747. 
Rohatgi, R., Milenkovic, L. and Scott, M. P. (2007). Patched1 regulates 
hedgehog signaling at the primary cilium. Science (New York, N.Y.) 
317, 372-376. 
Rosenbluh, J., Nijhawan, D., Cox, A. G., Li, X., Neal, J. T., Schafer, E. J., 
Zack, T. I., Wang, X., Tsherniak, A., Schinzel, A. C., et al. (2012). 
35 
	  
beta-Catenin-driven cancers require a YAP1 transcriptional complex for 
survival and tumorigenesis. Cell 151, 1457-1473. 
Rowbotham, N. J., Hager-Theodorides, A. L., Furmanski, A. L., Ross, S. 
E., Outram, S. V., Dessens, J. T. and Crompton, T. (2009). Sonic 
hedgehog negatively regulates pre-TCR-induced differentiation by a 
Gli2-dependent mechanism. Blood 113, 5144-5156. 
Sabol, M., Trnski, D., Musani, V., Ozretic, P. and Levanat, S. (2018). Role 
of GLI Transcription Factors in Pathogenesis and Their Potential as 
New Therapeutic Targets. International journal of molecular sciences 
19. 
Sanchez, P., Hernandez, A. M., Stecca, B., Kahler, A. J., DeGueme, A. M., 
Barrett, A., Beyna, M., Datta, M. W., Datta, S. and Ruiz i Altaba, A. 
(2004). Inhibition of prostate cancer proliferation by interference with 
SONIC HEDGEHOG-GLI1 signaling. Proc Natl Acad Sci U S A 101, 
12561-12566. 
Sasaki, H., Nishizaki, Y., Hui, C., Nakafuku, M. and Kondoh, H. (1999). 
Regulation of Gli2 and Gli3 activities by an amino-terminal repression 
domain: implication of Gli2 and Gli3 as primary mediators of Shh 
signaling. Development (Cambridge, England) 126, 3915-3924. 
Schlegelmilch, K., Mohseni, M., Kirak, O., Pruszak, J., Rodriguez, J. R., 
Zhou, D., Kreger, B. T., Vasioukhin, V., Avruch, J., Brummelkamp, 
T. R., et al. (2011). Yap1 acts downstream of alpha-catenin to control 
epidermal proliferation. Cell 144, 782-795. 
Seidel, C., Schagdarsurengin, U., Blumke, K., Wurl, P., Pfeifer, G. P., 
Hauptmann, S., Taubert, H. and Dammann, R. (2007). Frequent 
hypermethylation of MST1 and MST2 in soft tissue sarcoma. Molecular 
carcinogenesis 46, 865-871. 
Shaw, A., Gipp, J. and Bushman, W. (2009). The Sonic Hedgehog pathway 
stimulates prostate tumor growth by paracrine signaling and 
recapitulates embryonic gene expression in tumor myofibroblasts. 
Oncogene 28, 4480-4490. 
Sheng, T., Li, C., Zhang, X., Chi, S., He, N., Chen, K., McCormick, F., 
Gatalica, Z. and Xie, J. (2004). Activation of the hedgehog pathway in 
advanced prostate cancer. Mol Cancer 3, 29. 
Shin, K., Lim, A., Zhao, C., Sahoo, D., Pan, Y., Spiekerkoetter, E., Liao, J. 
C. and Beachy, P. A. (2014). Hedgehog signaling restrains bladder 
cancer progression by eliciting stromal production of urothelial 
differentiation factors. Cancer Cell 26, 521-533. 
36 
	  
Siegel, R. L., Miller, K. D. and Jemal, A. (2018). Cancer statistics, 2018. CA: 
a cancer journal for clinicians 68, 7-30. 
Smelkinson, M. G., Zhou, Q. and Kalderon, D. (2007). Regulation of Ci-
SCFSlimb binding, Ci proteolysis, and hedgehog pathway activity by Ci 
phosphorylation. Developmental cell 13, 481-495. 
Smyth, I., Narang, M. A., Evans, T., Heimann, C., Nakamura, Y., Chenevix-
Trench, G., Pietsch, T., Wicking, C. and Wainwright, B. J. (1999). 
Isolation and characterization of human patched 2 (PTCH2), a putative 
tumour suppressor gene inbasal cell carcinoma and medulloblastoma 
on chromosome 1p32. Human molecular genetics 8, 291-297. 
Solanki, A., Lau, C. I., Saldana, J. I., Ross, S. and Crompton, T. (2017). 
The transcription factor Gli3 promotes B cell development in fetal liver 
through repression of Shh. The Journal of experimental medicine 214, 
2041-2058. 
Solanki, A., Yanez, D. C., Ross, S., Lau, C. I., Papaioannou, E., Li, J., 
Saldana, J. I. and Crompton, T. (2018). Gli3 in fetal thymic epithelial 
cells promotes thymocyte positive selection and differentiation by 
repression of Shh. Development (Cambridge, England) 145. 
Sommer, A. and Lemmon, M. A. (2018). Smoothening out the patches. 
Science (New York, N.Y.) 362, 26-27. 
Song, H., Mak, K. K., Topol, L., Yun, K., Hu, J., Garrett, L., Chen, Y., Park, 
O., Chang, J., Simpson, R. M., et al. (2010). Mammalian Mst1 and 
Mst2 kinases play essential roles in organ size control and tumor 
suppression. Proceedings of the National Academy of Sciences of the 
United States of America 107, 1431-1436. 
St John, M. A., Tao, W., Fei, X., Fukumoto, R., Carcangiu, M. L., 
Brownstein, D. G., Parlow, A. F., McGrath, J. and Xu, T. (1999). Mice 
deficient of Lats1 develop soft-tissue sarcomas, ovarian tumours and 
pituitary dysfunction. Nature genetics 21, 182-186. 
Steinhardt, A. A., Gayyed, M. F., Klein, A. P., Dong, J., Maitra, A., Pan, D., 
Montgomery, E. A. and Anders, R. A. (2008). Expression of Yes-
associated protein in common solid tumors. Human pathology 39, 
1582-1589. 
Sugimura, Y., Cunha, G. R. and Donjacour, A. A. (1986a). Morphogenesis 
of ductal networks in the mouse prostate. Biology of reproduction 34, 
961-971. 
37 
	  
---- (1986b). Morphological and histological study of castration-induced 
degeneration and androgen-induced regeneration in the mouse 
prostate. Biology of reproduction 34, 973-983. 
Sugimura, Y., Cunha, G. R., Donjacour, A. A., Bigsby, R. M. and Brody, J. 
R. (1986c). Whole-mount autoradiography study of DNA synthetic 
activity during postnatal development and androgen-induced 
regeneration in the mouse prostate. Biology of reproduction 34, 985-
995. 
Sun, Y., Yong, K. M., Villa-Diaz, L. G., Zhang, X., Chen, W., Philson, R., 
Weng, S., Xu, H., Krebsbach, P. H. and Fu, J. (2014). Hippo/YAP-
mediated rigidity-dependent motor neuron differentiation of human 
pluripotent stem cells. Nature materials 13, 599-604. 
Svard, J., Heby-Henricson, K., Persson-Lek, M., Rozell, B., Lauth, M., 
Bergstrom, A., Ericson, J., Toftgard, R. and Teglund, S. (2006). 
Genetic elimination of Suppressor of fused reveals an essential 
repressor function in the mammalian Hedgehog signaling pathway. 
Developmental cell 10, 187-197. 
Takahashi, Y., Miyoshi, Y., Takahata, C., Irahara, N., Taguchi, T., Tamaki, 
Y. and Noguchi, S. (2005). Down-regulation of LATS1 and LATS2 
mRNA expression by promoter hypermethylation and its association 
with biologically aggressive phenotype in human breast cancers. 
Clinical cancer research : an official journal of the American Association 
for Cancer Research 11, 1380-1385. 
Tapon, N., Harvey, K. F., Bell, D. W., Wahrer, D. C., Schiripo, T. A., Haber, 
D. and Hariharan, I. K. (2002). salvador Promotes both cell cycle exit 
and apoptosis in Drosophila and is mutated in human cancer cell lines. 
Cell 110, 467-478. 
Taylor, F. R., Wen, D., Garber, E. A., Carmillo, A. N., Baker, D. P., Arduini, 
R. M., Williams, K. P., Weinreb, P. H., Rayhorn, P., Hronowski, X., et 
al. (2001). Enhanced potency of human Sonic hedgehog by 
hydrophobic modification. Biochemistry 40, 4359-4371. 
Tenzen, T., Allen, B. L., Cole, F., Kang, J. S., Krauss, R. S. and McMahon, 
A. P. (2006). The cell surface membrane proteins Cdo and Boc are 
components and targets of the Hedgehog signaling pathway and 
feedback network in mice. Developmental cell 10, 647-656. 
Theil, T., Kaesler, S., Grotewold, L., Bose, J. and Ruther, U. (1999). Gli 
genes and limb development. Cell and tissue research 296, 75-83. 
Tian, Y., Kolb, R., Hong, J. H., Carroll, J., Li, D., You, J., Bronson, R., 
Yaffe, M. B., Zhou, J. and Benjamin, T. (2007). TAZ promotes PC2 
38 
	  
degradation through a SCFbeta-Trcp E3 ligase complex. Molecular and 
cellular biology 27, 6383-6395. 
Torre, L. A., Bray, F., Siegel, R. L., Ferlay, J., Lortet-Tieulent, J. and 
Jemal, A. (2015). Global cancer statistics, 2012. CA Cancer J Clin 65, 
87-108. 
Tostar, U., Malm, C. J., Meis-Kindblom, J. M., Kindblom, L. G., Toftgard, 
R. and Unden, A. B. (2006). Deregulation of the hedgehog signalling 
pathway: a possible role for the PTCH and SUFU genes in human 
rhabdomyoma and rhabdomyosarcoma development. The Journal of 
pathology 208, 17-25. 
Tzelepi, V., Karlou, M., Wen, S., Hoang, A., Logothetis, C., Troncoso, P. 
and Efstathiou, E. (2011). Expression of hedgehog pathway 
components in prostate carcinoma microenvironment: shifting the 
balance towards autocrine signalling. Histopathology 58, 1037-1047. 
Udan, R. S., Kango-Singh, M., Nolo, R., Tao, C. and Halder, G. (2003). 
Hippo promotes proliferation arrest and apoptosis in the Salvador/Warts 
pathway. Nature cell biology 5, 914-920. 
Varelas, X., Sakuma, R., Samavarchi-Tehrani, P., Peerani, R., Rao, B. M., 
Dembowy, J., Yaffe, M. B., Zandstra, P. W. and Wrana, J. L. (2008). 
TAZ controls Smad nucleocytoplasmic shuttling and regulates human 
embryonic stem-cell self-renewal. Nature cell biology 10, 837-848. 
Vassilev, A., Kaneko, K. J., Shu, H., Zhao, Y. and DePamphilis, M. L. 
(2001). TEAD/TEF transcription factors utilize the activation domain of 
YAP65, a Src/Yes-associated protein localized in the cytoplasm. Genes 
& development 15, 1229-1241. 
Vokes, S. A., Ji, H., McCuine, S., Tenzen, T., Giles, S., Zhong, S., 
Longabaugh, W. J., Davidson, E. H., Wong, W. H. and McMahon, A. 
P. (2007). Genomic characterization of Gli-activator targets in sonic 
hedgehog-mediated neural patterning. Development (Cambridge, 
England) 134, 1977-1989. 
Vokes, S. A., Ji, H., Wong, W. H. and McMahon, A. P. (2008). A genome-
scale analysis of the cis-regulatory circuitry underlying sonic hedgehog-
mediated patterning of the mammalian limb. Genes & development 22, 
2651-2663. 
von Gise, A., Lin, Z., Schlegelmilch, K., Honor, L. B., Pan, G. M., Buck, J. 
N., Ma, Q., Ishiwata, T., Zhou, B., Camargo, F. D., et al. (2012). 
YAP1, the nuclear target of Hippo signaling, stimulates heart growth 
through cardiomyocyte proliferation but not hypertrophy. Proceedings of 
39 
	  
the National Academy of Sciences of the United States of America 109, 
2394-2399. 
Wang, B., Fallon, J. F. and Beachy, P. A. (2000). Hedgehog-regulated 
processing of Gli3 produces an anterior/posterior repressor gradient in 
the developing vertebrate limb. Cell 100, 423-434. 
Wang, B. and Li, Y. (2006). Evidence for the direct involvement of {beta}TrCP 
in Gli3 protein processing. Proceedings of the National Academy of 
Sciences of the United States of America 103, 33-38. 
Wei, X., Shimizu, T. and Lai, Z. C. (2007). Mob as tumor suppressor is 
activated by Hippo kinase for growth inhibition in Drosophila. The 
EMBO journal 26, 1772-1781. 
Wojcinski, A., Lawton, A. K., Bayin, N. S., Lao, Z., Stephen, D. N. and 
Joyner, A. L. (2017). Cerebellar granule cell replenishment postinjury 
by adaptive reprogramming of Nestin(+) progenitors. Nature 
neuroscience 20, 1361-1370. 
Wu, S., Huang, J., Dong, J. and Pan, D. (2003). hippo encodes a Ste-20 
family protein kinase that restricts cell proliferation and promotes 
apoptosis in conjunction with salvador and warts. Cell 114, 445-456. 
Xie, J., Murone, M., Luoh, S. M., Ryan, A., Gu, Q., Zhang, C., Bonifas, J. 
M., Lam, C. W., Hynes, M., Goddard, A., et al. (1998). Activating 
Smoothened mutations in sporadic basal-cell carcinoma. Nature 391, 
90-92. 
Xin, M., Kim, Y., Sutherland, L. B., Qi, X., McAnally, J., Schwartz, R. J., 
Richardson, J. A., Bassel-Duby, R. and Olson, E. N. (2011). 
Regulation of insulin-like growth factor signaling by Yap governs 
cardiomyocyte proliferation and embryonic heart size. Science signaling 
4, ra70. 
Xu, M. Z., Yao, T. J., Lee, N. P., Ng, I. O., Chan, Y. T., Zender, L., Lowe, S. 
W., Poon, R. T. and Luk, J. M. (2009). Yes-associated protein is an 
independent prognostic marker in hepatocellular carcinoma. Cancer 
115, 4576-4585. 
Xu, T., Wang, W., Zhang, S., Stewart, R. A. and Yu, W. (1995). Identifying 
tumor suppressors in genetic mosaics: the Drosophila lats gene 
encodes a putative protein kinase. Development (Cambridge, England) 
121, 1053-1063. 
Yagi, R., Chen, L. F., Shigesada, K., Murakami, Y. and Ito, Y. (1999). A WW 
domain-containing yes-associated protein (YAP) is a novel 
transcriptional co-activator. The EMBO journal 18, 2551-2562. 
40 
	  
Yi, J., Lu, L., Yanger, K., Wang, W., Sohn, B. H., Stanger, B. Z., Zhang, M., 
Martin, J. F., Ajani, J. A., Chen, J., et al. (2016). Large tumor 
suppressor homologs 1 and 2 regulate mouse liver progenitor cell 
proliferation and maturation through antagonism of the coactivators 
YAP and TAZ. Hepatology (Baltimore, Md.) 64, 1757-1772. 
Yimlamai, D., Christodoulou, C., Galli, G. G., Yanger, K., Pepe-Mooney, 
B., Gurung, B., Shrestha, K., Cahan, P., Stanger, B. Z. and 
Camargo, F. D. (2014). Hippo pathway activity influences liver cell fate. 
Cell 157, 1324-1338. 
Yu, M. and Bushman, W. (2013). Differential stage-dependent regulation of 
prostatic epithelial morphogenesis by Hedgehog signaling. 
Developmental biology 380, 87-98. 
Yu, M., Gipp, J., Yoon, J. W., Iannaccone, P., Walterhouse, D. and 
Bushman, W. (2009). Sonic hedgehog-responsive genes in the fetal 
prostate. The Journal of biological chemistry 284, 5620-5629. 
Yuan, M., Tomlinson, V., Lara, R., Holliday, D., Chelala, C., Harada, T., 
Gangeswaran, R., Manson-Bishop, C., Smith, P., Danovi, S. A., et 
al. (2008). Yes-associated protein (YAP) functions as a tumor 
suppressor in breast. Cell death and differentiation 15, 1752-1759. 
Yui, S., Azzolin, L., Maimets, M., Pedersen, M. T., Fordham, R. P., Hansen, 
S. L., Larsen, H. L., Guiu, J., Alves, M. R. P., Rundsten, C. F., et al. 
(2018). YAP/TAZ-Dependent Reprogramming of Colonic Epithelium 
Links ECM Remodeling to Tissue Regeneration. Cell stem cell 22, 35-
49.e37. 
Zaidi, S. K., Sullivan, A. J., Medina, R., Ito, Y., van Wijnen, A. J., Stein, J. 
L., Lian, J. B. and Stein, G. S. (2004). Tyrosine phosphorylation 
controls Runx2-mediated subnuclear targeting of YAP to repress 
transcription. The EMBO journal 23, 790-799. 
Zhang, H., Deo, M., Thompson, R. C., Uhler, M. D. and Turner, D. L. 
(2012). Negative regulation of Yap during neuronal differentiation. 
Developmental biology 361, 103-115. 
Zhang, H., Pasolli, H. A. and Fuchs, E. (2011). Yes-associated protein (YAP) 
transcriptional coactivator functions in balancing growth and 
differentiation in skin. Proceedings of the National Academy of 
Sciences of the United States of America 108, 2270-2275. 
Zhang, Y., Bulkley, D. P., Xin, Y., Roberts, K. J., Asarnow, D. E., Sharma, 
A., Myers, B. R., Cho, W., Cheng, Y. and Beachy, P. A. (2018). 
Structural Basis for Cholesterol Transport-like Activity of the Hedgehog 
Receptor Patched. Cell. 
41 
	  
Zhao, B., Li, L., Tumaneng, K., Wang, C. Y. and Guan, K. L. (2010). A 
coordinated phosphorylation by Lats and CK1 regulates YAP stability 
through SCF(beta-TRCP). Genes & development 24, 72-85. 
Zhao, B., Wei, X., Li, W., Udan, R. S., Yang, Q., Kim, J., Xie, J., Ikenoue, T., 
Yu, J., Li, L., et al. (2007). Inactivation of YAP oncoprotein by the 
Hippo pathway is involved in cell contact inhibition and tissue growth 
control. Genes & development 21, 2747-2761. 
Zhao, B., Ye, X., Yu, J., Li, L., Li, W., Li, S., Yu, J., Lin, J. D., Wang, C. Y., 
Chinnaiyan, A. M., et al. (2008). TEAD mediates YAP-dependent gene 
induction and growth control. Genes & development 22, 1962-1971. 
Zhao, R., Fallon, T. R., Saladi, S. V., Pardo-Saganta, A., Villoria, J., Mou, 
H., Vinarsky, V., Gonzalez-Celeiro, M., Nunna, N., Hariri, L. P., et al. 
(2014). Yap tunes airway epithelial size and architecture by regulating 
the identity, maintenance, and self-renewal of stem cells. 
Developmental cell 30, 151-165. 
Zhou, D., Conrad, C., Xia, F., Park, J. S., Payer, B., Yin, Y., Lauwers, G. Y., 
Thasler, W., Lee, J. T., Avruch, J., et al. (2009). Mst1 and Mst2 
maintain hepatocyte quiescence and suppress hepatocellular 
carcinoma development through inactivation of the Yap1 oncogene. 
Cancer cell 16, 425-438. 
Zhou, Z., Hao, Y., Liu, N., Raptis, L., Tsao, M. S. and Yang, X. (2011). TAZ 
is a novel oncogene in non-small cell lung cancer. Oncogene 30, 2181-
2186. 
 
42 
	  
Chapter 2 Stromal Hedgehog signaling maintains smooth muscle and 
hampers micro-invasive prostate cancer 1 
 
INTRODUCTION 
Prostate cancer (PCa) is the second leading cause of cancer-related mortality 
in men in the United States (Siegel et al., 2016) and the second most common 
malignancy in men worldwide (Torre et al., 2015). Although prostate 
carcinoma arises from the epithelium, numerous studies have revealed the 
potential influence of reciprocal interactions between prostate stromal cells 
(fibroblasts and smooth muscle cells or SMCs) and cancer epithelial cells on 
tumor progression (Barron and Rowley, 2012; Franco and Hayward, 2012). 
For example, human prostate carcinoma-associated fibroblasts, but not 
normal prostate fibroblasts, induce substantial growth and neoplasia of 
nonmalignant human prostate epithelial cell lines in tissue recombinants in 
mice (Olumi et al., 1999). Furthermore, the proportion of reactive stroma within 
human PCa samples has prognostic value for PCa-specific death (Ayala et al., 
2003; Ayala et al., 2011). Unlike normal prostate stroma that is primarily 
composed of mature SMCs, the reactive stroma of human PCa has been 
described as enriched with myofibroblasts and fibroblasts, and depleted of 
mature SMCs (Tuxhorn et al., 2002). In the normal adult mouse prostate, our 
recent study identified four stromal subtypes: SMCs that express smooth 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
1	  Yang, Z., Peng, Y. C., Gopalan, A., Gao, D., Chen, Y. and Joyner, A. L. 
(2017). Stromal hedgehog signaling maintains smooth muscle and hampers 
micro-invasive prostate cancer. Disease Models & Mechanisms 10, 39-52. 
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preparation of the manuscript. Drs. Yu-Ching Peng, Anuradha Gopalan, and 
Yu Chen provided valuable scientific advice.	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muscle actin (SMA), fibroblasts scattered between prostate ducts, and two 
additional Vimentin-expressing ductal fibroblast-like cell types; “wrapping cells” 
that wrap the outside of the smooth muscle (SM) layer and “subepithelial cells” 
situated between the SM and the epithelium (Peng et al., 2013) (Fig. 2.1). 
Furthermore, genetic inducible fate mapping (GIFM) studies during 
regeneration of the adult prostate raised the possibility that each stromal 
subtype has a distinct stem/progenitor cell (Peng et al., 2013) (Fig. 2.1). The 
relationship between the different stromal lineages and cancer reactive 
stromal cells are not known, nor whether a particular subtype is tumor 
protective.  
 
The Hedgehog (HH) signaling pathway plays a pivotal role in development 
and regeneration of the adult prostate, and abnormal HH signaling has been 
implicated in multiple carcinomas including PCa (Gonnissen et al., 2013; Lim 
et al., 2014; Peng and Joyner, 2015; Shaw and Bushman, 2007). In mammals, 
three HH ligands, Sonic (SHH), Indian (IHH), and Desert (DHH), exert their 
function by binding to the receptor Patched (PTCH), which relieves inhibition 
of the transmembrane protein Smoothened (SMO). SMO activation leads to 
the formation of GLI2 and GLI3 transcriptional activators, which induce target 
genes including Gli1 and Ptch1. Because Gli1 expression is dependent on 
GLI2 and GLI3 activators, it is a sensitive readout of high level HH signaling 
(Bai et al., 2002; Bai et al., 2004). The HH signaling pathway has stage-
specific roles during prostate development (Berman et al., 2004; Peng and 
Joyner, 2015; Yu and Bushman, 2013). During embryonic development HH 
signaling acts on the mesenchyme to promote ductal extension and branching, 
whereas at the early postnatal stage HH plays an inhibitory role on ductal 
44 
	  
morphogenesis. In the adult mouse prostate, our previous study showed that 
SHH is secreted by basal epithelial cells and signals to progenitors of all four 
stromal subtypes (Peng et al., 2013). A separate study using an IhhCreER 
knock-in allele revealed that during adult prostate regeneration Ihh is 
preferentially expressed by epithelial cells between growing buds, and 
functional studies indicate that IHH negatively regulates epithelial bud 
formation by down-regulating stromal Hgf (Lim et al., 2014). Any specific 
function of HH signaling in the stromal changes seen during PCa progression, 
however, has not been addressed experimentally.  
 
Several studies have provided evidence for paracrine HH signaling in human 
and mouse PCa (Fan et al., 2004; Ibuki et al., 2013; Shaw et al., 2009), a 
cellular relationship resembling the epithelial-to-stromal HH signaling in 
developing and adult mouse prostates (Berman et al., 2004; Peng et al., 2013). 
Autocrine HH signaling in PCa epithelial cells has also been reported (Chen et 
al., 2009; Karhadkar et al., 2004; Sanchez et al., 2004), particularly in 
advanced and metastatic PCa specimens (Chen et al., 2009; Sheng et al., 
2004; Tzelepi et al., 2011). Given the questionable reliability of antibodies to 
HH pathway components, the highly heterogeneous nature of PCa, and the 
difficulty of effectively separating tumor cells from the stroma, we have taken 
advantage of mouse genetic tools to study HH signaling in vivo during PCa 
progression in mouse models. 
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Figure 2.1 Schematic of SHH signaling in the adult prostate and model of 
stromal regeneration 
(Adapted from (Peng et al., 2013)) 
 
Shh is expressed in the basal cells (BCs), while Gli1 is expressed in all four 
stromal subtypes: subepithelial cell (Sub), smooth muscle cell (SMC), 
wrapping cell (Wrap), and interstitial fibroblast (IF). Gli1 expression is enriched 
in Subs. Curved arrows indicate the proposed model that SHH signals to four 
lineage-restricted unipotent stromal stem/progenitor cells. SMCs are 
replenished by pre-existing SMCs (red arrow), and the other subtypes are 
replenished by distinct stem/progenitor cells (white arrows). BM, basement 
membrane; LC, luminal cell. 
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Several recent functional studies using mouse genetic carcinoma models 
found that stromal HH signaling reduces pancreas and bladder cancer 
progression (Lee et al., 2014; Mathew et al., 2014; Rhim et al., 2014; Shin et 
al., 2014), consistent with the poor outcomes of HH inhibitors in pancreas 
cancer clinical trials (Rosow et al., 2012). Specifically, genetic deletion of Shh 
in pancreatic cancer cells decreases survival and enhances tumor progression 
(Lee et al., 2014; Rhim et al., 2014), and deletion of Smo in bladder stromal 
cells promotes carcinogenesis (Shin et al., 2014). In addition, pharmacological 
modulation of the HH pathway in mice revealed accelerated or delayed 
pancreatic cancer development following SMO inhibitor or HH agonist 
treatment, respectively (Lee et al., 2014; Rhim et al., 2014). In a xenograft 
model, ablation of the HH co-receptors Gas1 and Boc in mouse embryonic 
fibroblasts (MEFs) promoted the co-injected human pancreatic cancer cell 
lines to grow pancreatic tumors, whereas elimination of HH signaling by 
deletion of Gas1, Boc, and Cdon in MEFs inhibited pancreatic tumor growth, 
indicating a dose-dependent role of HH signaling in differentially regulating 
pancreatic cancer progression (Mathew et al., 2014). In PCa, however, 
functional studies using mouse models have not clarified the role of HH 
signaling in tumorigenesis. While conditional expression of oncogenic SmoM2 
in the mouse prostate epithelium does not lead to mouse prostatic 
intraepithelial neoplasia (mPIN) or cancer (Mao et al., 2006), xenograft 
experiments using PCa cell lines have indicated a pro-tumor effect of HH 
signaling (Fan et al., 2004; Karhadkar et al., 2004), and one study using 
retroviral expression of SHH in the prostate reported cancer formation (Chen 
et al., 2006). Given the contradictory findings for the function of HH signaling 
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in PCa, it is important to test whether excess HH signaling in the stroma 
changes tumor progression in a mouse model of PCa.  
 
We have characterized the phenotype of the stromal cells in three mouse 
models of PCa, and found that the proportions of cells with a SM- or fibroblast-
like character were distinct to each model. In PB-MYC and to a lesser extent 
ERG/PTEN, but not TRAMP tumors, SMCs are greatly depleted, recapitulating 
a loss of mature SMCs seen in human PCa. Using genetic fate mapping, we 
found that SMCs are largely lost without contributing to the fibroblast-like 
reactive stroma that is increased between ducts in PB-MYC tumors, but 
contribute to the expanded SM and also give rise to a specific subset of 
intraductal stromal cells in TRAMP tumors. We found that HH signaling is 
increased in stromal cells in all three models, especially those adjacent to 
tumor cells. In PB-MYC and TRAMP tumors, Ihh and Dhh rather than Shh are 
the main ligands expressed by tumor cells. In human PCa, IHH is the highest 
expressed and the level of HH signaling positively correlates with the amount 
of stromal gene expression. To test whether stromal HH signaling can alter 
PCa progression, an activated form of the HH receptor was expressed in Gli1-
expressing stromal cells of PB-MYC tumors. We found that excess HH 
signaling in prostate stromal cells has an inhibitory effect on cancer 
progression, potentially due to maintenance of SM that may prevent micro-
invasion of tumors. Our studies provide new insights into the heterogeneity of 
stromal cells in three mouse models and in human PCa and the possible 
importance of particular stromal cell types in tumor progression, and also 
place the HH signaling pathway as a candidate of possible therapeutic value 
for treating PCa patients.  
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RESULTS 
	  
Advanced Human Prostate Tumors Show A Decrease In Smooth Muscle 
In order to understand the degree to which mouse PCa models reflect the 
stromal changes seen in human PCa, since the proportions of SM and 
fibroblasts in the normal human prostate are different from mouse, we first 
characterized human PCa protein and RNA expression databases for changes 
in stromal markers. Using ACTA2 (SMA) and Calponin (CNN1) as SM markers 
in an analysis of human PCa specimens in the Human Protein Atlas 
(http://www.proteinatlas.org), we found the expected large proportion of SM in 
the normal human prostate, and disruption of the well organized SM layers in 
PCa samples, especially more advanced tumors (Fig. 2.2A-F; Fig. 2.3; Fig. 
2.4). The mature SM marker CNN1 was consistently decreased (Fig. 2.2A-C; 
Fig. 2.3) as previously reported (Tuxhorn et al., 2002), and the area of ACTA2 
expression seemed decreased in most but not all PCa samples (Fig. 2.2D-F; 
Fig. 2.4). However, the proportions of ACTA2-expressing and non-expressing 
cells varied both within samples from the same patient and between patients 
(Fig. 2.4H-J,H’-J’), thus it was difficult to determine if SMCs are depleted in 
tumors. Using Vimentin (VIM) as a fibroblast marker, we found that VIM was 
maintained in non-epithelial cells and possibly increased in some samples in 
the remaining stroma between glands (Fig. 2.2G-I; Fig. 2.5). Overall, higher-
grade tumors appeared to have a greater disruption of the stromal 
cytoarchitecture (Fig. 2.2A-I; Fig. 2.3; Fig. 2.4; Fig. 2.5).  
 
As a complementary approach to analyzing human PCa stromal content, we 
analyzed RNA-sequencing (RNA-seq) data from the TCGA dataset (n=27 
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normal and 330 primary PCa samples) (Abeshouse et al., 2015), and found a 
significant decrease in expression of the SM markers ACTA2 and CNN1, as 
well as the fibroblast marker VIM in PCa compared to normal prostate 
samples (Fig. 2.2J). In addition, the expression levels of CNN1 and ACTA2 
(but not VIM) were progressively lower in patients with higher Gleason scores, 
with a significant decrease seen in Gleason >=8 compared to most other 
stages (Fig. 2.2K; Fig. 2.6A). There was the expected corresponding decrease 
in basal cell markers (KRT5 and TP63) and increase in expression of luminal 
cytokeratin markers in tumor cells (KRT8 and KRT18) (Fig. 2.6B). There also 
was a greater correlation between tumors with high ACTA2 or CNN1 
expression and basal cell gene expression (Pearson coefficient = 0.343 or 
0.381 for ACTA2 or CNN1 with KRT5; = 0.299 or 0.319 for ACTA2 or CNN1 
with TP63) than for VIM and basal markers (Pearson coefficient = 0.144 for 
VIM-KRT5; = 0.097 VIM-TP63), and a trend towards a negative correlation for 
the luminal marker KRT18 with ACTA2 and no correlation with CNN1 
(Pearson coefficient = -0.139 or -0.067 for ACTA2 or CNN1 with KRT18) 
(Table 2.1).  
 
As an additional means to address stromal gene expression levels and clinical 
outcome, we analyzed RNA microarray data from the MSKCC Prostate 
Oncogenome Project (n=29 normal, 131 primary tumors, and 19 metastases) 
(Taylor et al., 2010). Interestingly metastatic PCa samples expressed 
significantly lower levels of CNN1 and ACTA2 compared to primary tumor 
samples and normal (Fig. 2.2L). Furthermore, Kaplan-Meier analysis revealed 
that patients with lower expression levels of CNN1 and ACTA2 but not VIM 
had a significantly shorter relapse-free time (Fig. 2.2M; Fig. 2.6C).  All together, 
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these results show that more advanced PCa samples with a higher Gleason 
score or metastasis stage have lower levels of expression of two SM markers 
(ACTA2 and CNN1), indicating either a reduction in the number of SMCs or 
the expression of these genes is decreased in the remaining cells.   
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Figure 2.2 Human prostate tumors show disruption of stromal 
architecture with a decrease in smooth muscle. 
	  
(A-I) Immunohistochemistry (IHC) of CNN1 (A-C), ACTA2 (D-F), and VIM (G-I) 
in human normal prostate, low- or medium-grade and high-grade prostate 
tumor samples from the Human Protein Atlas. Numbers on top right corner of 
each panel indicates the patient ID number. Scale bar, 100 µm. (J) The mRNA 
expressions of stromal marker genes (CNN1, ACTA2, and VIM) from TCGA 
RNA-seq data with 330 primary PCa samples (Tumor) and 27 normal controls 
(Normal). (K) The mRNA expression of CNN1 in PCa samples graded with 
Gleason scores from TCGA RNA-seq data. (L) The mRNA expressions of 
stromal marker genes from MSKCC Prostate Oncogenome Project. (J-L) 
*P<0.05; **P<0.01; ****P<0.0001. Data are presented as mean ± s.d. Each 
data point represents one sample. (M) Kaplan-Meier relapse-free (months) 
analysis of patient data from PCa samples from MSKCC Prostate 
Oncogenome Project with CNN1 low-expression (n = 38) and high-expression 
(n = 93); p value is calculated via Mantel-Cox (log rank) test. 
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Figure 2.3 CNN1 is consistently decreased in human PCa samples. 
	  
Immunohistochemistry (IHC) of CNN1 in human normal prostate (A, B), low-
grade (C-G) and high-grade (H, I) prostate tumor samples from the Human 
Protein Atlas. Numbers on top right corner of each panel indicates the patient 
ID number. Scale bar, 100 µm. 
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Figure 2.4 ACTA2 is decreased in most but not all human PCa samples. 
 
IHC of ACTA2 in human normal prostate (A, B), low-grade (C-E) and high-
grade (F-J) prostate tumor samples from the Human Protein Atlas. H’, I’, and J’ 
are samples from the same patients with H, I, and J, respectively. Numbers on 
top right corner of each panel indicates the patient ID number. Scale bar, 100 
µm.  
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Figure 2.5 VIM is maintained in human PCa samples. 
	  
IHC of VIM in human normal prostate (A, B), low- or medium-grade (C-F) and 
high-grade (G-I) prostate tumor samples from the Human Protein Atlas. 
Numbers on top right corner of each panel indicates the patient ID number. 
Scale bar, 100 µm. 
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Figure 2.6 Stromal markers expressions are decreased in human primary 
PCa samples. 
	  
(A) The mRNA expressions of stromal cell marker genes in PCa samples 
graded with Gleason scores from TCGA RNA-seq data. (B) The mRNA 
expressions of basal and luminal cell marker genes in PCa samples from 
TCGA RNA-seq data with 330 primary PCa samples and 27 normal controls. 
(C) Kaplan-Meier relapse-free (months) analysis of patient data from PCa 
samples from MSKCC Prostate Oncogenome Project with stromal markers 
having low-expression (n = 38) and high-expression (n = 93); p values are 
calculated via Mantel-Cox (log rank) test. 
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Table 2.1 The Pearson correlation coefficient of gene expressions in the 
TCGA PCa dataset. 
	  
 (A) Pearson correlation coefficient between stromal (SMC and fibroblast) 
and epithelial (basal and luminal) marker gene mRNA expressions.  
 
Pearson 
coefficient 
CNN1 ACTA2 VIM KRT5 TP63 KRT8 KRT18 
CNN1 1.000       
ACTA2 0.959 1.000      
VIM 0.555 0.628 1.000     
KRT5 0.381 0.343 0.144 1.000    
TP63 0.319 0.299 0.097 0.860 1.000   
KRT8 0.048 -0.018 -0.089 0.021 -0.154 1.000  
KRT18 -0.067 -0.139 -0.195 -0.116 -0.309 0.838 1.000 
 
(B) Pearson correlation coefficient between HH pathway genes and 
prostate stromal and epithelial marker gene mRNA expressions.  
 
Pearson 
correlation 
coefficient 
SHH IHH DHH GLI1 
CNN1 -0.030 -0.072 0.450 0.379 
ACTA2 -0.024 -0.076 0.422 0.483 
VIM 0.126 -0.021 0.560 0.595 
GLI1 0.181 0.189 0.309 1.000 
KRT5 0.016 -0.082 0.001 0.047 
TP63 0.014 -0.095 -0.017 0.045 
KRT8 -0.040 0.083 0.025 -0.123 
KRT18 -0.048 0.056 -0.054 -0.232 
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PB-MYC and ERG/PTEN but not TRAMP mouse PCa models display 
extensive disruption of smooth muscle 
To investigate whether mouse PCa models have similar stromal alterations to 
those seen in human PCa, especially as mouse normal prostate has less SM 
than human, we analyzed the stromal characteristics of three distinct mouse 
lines. Two transgenic lines were investigated that use a Probasin gene 
regulatory element to drive expression of the oncogenes MYC (PB-MYC) 
(Ellwood-Yen et al., 2003) or SV40 large/small T antigen (Transgenic 
Adenocarcinoma Mouse Prostate or TRAMP) (Greenberg et al., 1995) in the 
dorsolateral epithelium of mouse prostate, and one conditional genetic model 
(ERG/PTEN) that mimics the TMPRSS2-ERG fusion loci that are seen in 
about fifty percent of human PCa (Clark et al., 2007; Hermans et al., 2006) by 
misexpressing the ETS transcription factor ERG (Chen et al., 2013) combined 
with Pten deletion in luminal cells (Tmprss2CreER-GFP/+; R26LSL-ERG-GFP/ LSL-ERG-
GFP; Ptenflox/flox mice administered tamoxifen at 4 weeks of age). Unlike normal 
mouse prostates with a thin single layer of epithelium (Fig. 2.7A,A’; Fig. 2.8A), 
all three models displayed extensive mPIN featuring stratified epithelial cells 
with prominent nuclear atypia forming cribriform and/or tufting confined within 
the basement membrane. Such multifocal proliferative lesions were found to 
affect most of the dorsolateral ducts in PB-MYC (n=52 mice, 35-49 weeks old; 
Fig. 2.7B,B’; Fig. 2.8B) and almost all dorsolateral ducts in ERG/PTEN (n=9, 
12-41 weeks old; Fig. 2.7D,D’; Fig, 2.7C). In late stage prostate tumors of PB-
MYC mice (n=8 mice, 44-49 weeks old), micro-invasive carcinoma (MIC) was 
seen with nests of atypical tumor cells (EpCAM+ and CK5-) infiltrating into the 
stroma and forming irregular contours (Fig. 2.7C,C’; Fig. 2.8B). Using an SMA 
antibody to label SMCs, we found that the SM layer in PB-MYC tumors were 
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much thinner than normal and contained many gaps (Fig. 2.7G,H,I; Fig. 
2.8E,F). In ERG/PTEN tumors, the disruption of the SM layers was less 
dramatic; the majority of ducts had an intact SM layer but some ducts had a 
discontinuous SM layer (Fig. 2.7J; Fig. 2.8G). In addition, in contrast to the 
normal prostate, VIM-positive fibroblast-like cells were abundant in both PB-
MYC and ERG/PTEN prostates, filling up the space between tumor ducts (Fig. 
2.7H-J). Furthermore, the interductal stromal cells showed an increase in 
expression of Collagen 1 (COL1) in PB-MYC and to a lesser extent in 
ERG/PTEN tumors (Fig. 2.9B-B”,C-C”) compared to WT (Fig. 2.9A-A”). Thus, 
these two models, and particularly PB-MYC, recapitulate many of the stromal 
alterations reported in human PCa, and therefore are valuable tools to study 
PCa stromal features and functions.  
 
The tumors in TRAMP mutants had a distinct stromal character to that in PB-
MYC and ERG/PTEN mice, even when the neuroendocrine tumors were not 
included in the analysis. In TRAMP prostates, most areas with mPIN (n=35 
mice, 20-33 weeks old; Fig. 2.7E,E’) showed an increase in the thickness of 
the SM layer surrounding the ducts (Fig. 2.7K; Fig. 2.8H) and SMA+ cells 
invaded between epithelial folds compared to normal prostates (Fig. 2.7G; Fig. 
2.8E). Interestingly, in more advanced TRAMP tumors (28-33 weeks) there 
were regions with complex polypoid intraductal adenomatous-stromal 
proliferation with minimal cytologic atypia, referred to as Intraductal Adenoma 
with Stroma (IAS) as they contained proliferating masses of stromal cells that 
invaded between the epithelial layers within ducts (n=21 mice; Fig. 2.7F,F’; Fig. 
2.8H). The majority of stromal cells in IAS expressed either SMA, VIM, and/or 
COL1 strongly (Fig. 2.7L; Fig. 2.9E-E’), indicating the stromal cells that 
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invaded IAS lesions of TRAMP prostates have features of SMCs and/or 
fibroblasts. Also unlike in the PB-MYC and ERG/PTEN models, TRAMP 
tumors had few VIM+ or COL1+ interductal fibroblasts (Fig. 2.9D). The 
exception was in rare areas where the SM layer was partially disrupted (Fig. 
2.10H). Thus, only in some areas of TRAMP tumors did the stromal character 
have similarities to the PB-MYC and ERG/PTEN models. Unlike human PCa, 
however, in all three PCa models CNN1 expression largely overlapped with 
SMA expression (Fig. 2.8I-L). 
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Figure 2.7 PB-MYC, ERG/PTEN, and TRAMP PCa models have distinct 
stromal characteristics. 
	  
(A-F) H&E staining of dorsolateral prostate (DLP) sections from tissues of WT 
(A), PB-MYC/+ (B, C), ERG/PTEN (D), and TRAMP/+ (E, F) mice. (A’-F’) 
Magnification of areas within dashed lines in A-F. (G-L) Immunofluorescent (IF) 
staining of DLP sections for SMA (green), Vimentin (VIM, red), and DAPI 
(blue). Arrows in K indicate SMCs invading between epithelial folds. *= 
Infiltrating nests of tumor cells; plus symbols (+) indicate blood vessels Scale 
bars, 50 µm. 
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Figure 2.8 PB-MYC, ERG/PTEN, and TRAMP PCa models have distinct 
cytoarchitecture and stromal cell contents. 
	  
(A-D) H&E staining of DLP sections from tissues of WT (A), PB-MYC/+ (B), 
ERG/PTEN (C), and TRAMP/+ (D) mice. (E-L) Immunofluorescent (IF) 
staining of DLP sections for (E-H) SMA (red) and DAPI (blue); (I-L) CNN1 
(green), SMA (red), and DAPI (blue). Scale bars, 200 µm.  
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Figure 2.9 Interductal reactive stroma in PB-MYC and ERG/PTEN and IAS 
stroma in TRAMP tumors have an increased expression of Collagen 1 
compared to normal interductal fibroblasts. 
 
IF staining of DLP sections from tissues of (A-A”) 30-week old WT, (B-B”) 45-
week old PB-MYC, (C-C”) 22-week old ERG/PTEN, and (D,E-E’) 30-week old 
TRAMP mice, for (A-A”) SMA (red), COL1 (green), and DAPI (blue). (B-D) 
show regions of mPIN; (E-E’) shows a region of IAS. Scale bars, 50 µm. 
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SMCs are largely lost in PB-MYC prostate tumors whereas some form 
the stroma in TRAMP IAS lesions 
Since SM is significantly reduced in PB-MYC tumors, we used GIFM to test 
whether SMA+ cells are lost or change fate into cancer reactive stroma. 
Tamoxifen was administered to Sma-CreER/+;R26tdTomato/+;PB-MYC/+ (Sma-
GIFM;PB-MYC) mice and control Sma-CreER/+;R26tdTomato/+ (Sma-GIFM;WT) 
littermates at 4 weeks of age (Fig. 2.10A). In prostates of Sma-GIFM;PB-MYC 
mice at 6 weeks of age, soon after the initiation of MYC transgene expression 
and two weeks after administration of tamoxifen, the histology and distribution 
of tdT+ cells was comparable to that of control Sma-GIFM;WT mice (Fig.2.9), 
and tdT specifically labeled the majority of SMCs (Fig. 2.10C). Strikingly, Sma-
GIFM;PB-MYC mice at 45 weeks had a huge reduction in the number of tdT-
labeled SMA+/COL1+ cells surrounding the mPIN or MIC lesions (Fig. 
2.10D,E; Fig. 2.11). There were only rare tdT+ reactive stromal cells 
interspersed between ducts, and they all expressed VIM+ and a rare subset 
expressed SMA weakly (Fig. 2.11A-A’’,B-B’’). This result indicates that SMA-
positive lineage cells were prominently reduced in number during tumor 
progression, and they are not a major cell-of-origin for reactive stroma in PB-
MYC tumors.  
 
Since TRAMP have a large increase in SM and stromal cells invade into IASs, 
we also fate mapped the SMA-lineage cells in TRAMP to test whether they 
expand only in the SM layer or give rise to other cancer reactive stroma. The 
increased SM layers surrounding mPIN and most IASs remained largely 
positive for tdT and SMA (Fig. 2.10F,G). In addition to expanding the SM, 
some cells marked by Sma-GIFM (many positive for COL1 and negative or 
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only weakly positive for SMA) extended into subepithelial folds of mPIN 
lesions (Fig. 2.10F) and were present within IASs (Fig. 2.10G; Fig. 2.12A-
A’’,E-E”). 71% of the intraductal masses (15/21 from 5 mice) had extensive tdT 
labeling (Fig. 2.12A-A”,B; Table 2.2) while 29% did not (Fig. 2.12C,D), 
indicating that SMCs are a major cell-of-origin of the stromal cells within IASs 
in TRAMP tumors. However, none of the fibroblasts between the ducts were 
labeled with tdT, indicating that as in PB-MYC tumors, the interductal cancer 
stromal cells have a separate cell-of-origin. In addition, in rare regions where 
the SM layer was diminished there were few fate-mapped cells (Fig. 2.10H). 
Among the tdT+ IASs, 10/15 expressed SMA (Table 2.2), suggesting that 
some SMA-expressing cells turned off SMA while giving rise to cancer reactive 
stroma. In summary, our two fate-mapping studies indicate that the character 
of the epithelial tumor cells could regulate the fate of SMCs in prostate tumor 
stroma.  
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Figure 2.10 SMA-expressing cells are largely lost in PB-MYC tumors 
while some transform into cancer stroma in TRAMP IAS lesions. 
 
(A) Schematic showing experimental design. (B) IF staining of DLP sections 
from 30 week old Sma-CreER/+;R26tdTomato/+ (Sma-GIFM;WT) mice for tdT 
(red), SMA (green), and DAPI (blue). (C-E) IF staining of 6 week old (C) and 
45 week old (D,E) Sma-CreER/+;R26tdTomato/+;PB-MYC/+ (Sma-GIFM;PB-MYC) 
mice for tdT (red), SMA (green), and DAPI (blue). Plus symbols (+) indicate 
blood vessels. (F-H) IF staining of DLP sections from 30 week old Sma-
GIFM;WT (Sma-CreER/+;R26tdTomato/+) (F) and Sma-GIFM;TRAMP (Sma-
CreER/+;R26tdTomato/+;TRAMP/+) (G,H) mice for tdTomato (tdT, red), SMA 
(green), and DAPI (blue). Dashed line in H indicates a region where the SM 
layer is diminished. Scale bar, 50 µm. 
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Figure 2.11 SMA-expressing cells are mostly lost in PB-MYC. 
 
IF staining of DLP sections from tissues of 45-week old Sma-GIFM;PB-MYC 
mice. (A-A”) tdT (red), VIM (green), EpCAM (magenta), and DAPI (blue). 
Arrows indicate the rare tdT+ VIM+ EpCAM- stromal cells in the center of the 
image where many VIM+ fibroblast-like cells are present. (B-B’’) tdT (red), 
SMA (green), EpCAM (magenta), and DAPI (blue). Arrows indicate rare 
stromal cells expressing tdT that are weakly SMA+ and EpCAM-. (C-C”) tdT 
(red), SMA (green), VIM (white), and DAPI (blue). Arrows indicate rare SM-like 
cells that express tdT and are weakly VIM+. (D-D”) tdT (red), SMA (green), 
COL1 (white), and DAPI (blue). Arrows indicate fate mapped stromal cells in 
the SM layer expressing tdT that are COL1+. Plus symbols (+) indicate blood 
vessels. Scale bar, 50 µm. 
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Figure 2.12 Some SMA-expressing cells contribute to the stroma in IAS 
of TRAMP tumors. 
 
IF staining of DLP sections from tissues of 30-week old Sma-GIFM;TRAMP 
mice. (A-A”, B-D) tdT (red), SMA (green), EpCAM (magenta), and DAPI (blue). 
(E-E”) tdT (red), SMA (green), COL1 (white), and DAPI (blue). Scale bar, 50 
µm. 
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Table 2.2 The SMA+ lineage is a major cell-of-origin for stromal cells in 
IAS of TRAMP PCa. 
Quantification of IAS ducts from five Sma-GIFM; TRAMP (Sma-CreER/+; 
R26tdTomato/+; TRAMP/+) mice.  
 
Animal ID #IAS Ducts in Sma-GIFM; TRAMP 
tdT+  
SMA+ 
tdT+  
SMA- 
tdT-  
SMA+ 
tdT-  
SMA- 
Subtotal 
T67 2 1 0 0 3 
T171 0 2 1* 2 5 
T183 1 0 0 0 1 
T213 2** 1*** 0 2**** 5 
T800 5 1 0 1 7 
Sum 10 5 1 5 21 
GIFM+ 15/21;  
10/15 SMA+, 5/15 SMA- 
GIFM- 6/21;  
1/6 SMA+, 5/6 SMA- 
 
 
* This IAS duct has ~60% of the intraductal stromal cells that are SMA+. 
** In one out of the two IAS ducts, ~50% of the intraductal stromal cells are 
tdT+.  
*** This IAS duct has only 30% of the intraductal stromal cells that are SMA+, 
and thus is considered as SMA-.  
**** In one out of the two IAS ducts, only 30% of the intraductal stromal cells 
are SMA+, and thus is considered as SMA-. 
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Gli1 is increased and restricted to stromal cells in PCa 
Given the correlation between reduced SM layers and higher-grade tumors 
and functional relationship in the prostate between SHH and expansion of the 
stroma during development, we next asked whether HH signaling is altered in 
mouse PCa compared to the normal adult prostate. Our previous study using 
knock-in reporter mice revealed that Gli1nlacZ (Bai et al., 2002) is expressed by 
a subset of all four stromal subtypes in normal adult mouse prostate (Peng et 
al., 2013) (Fig.2.12A,A’; Fig. 2.14A). Unlike previous studies using RNA in situ 
hybridization or questionable antibodies to analyze human tumors samples 
(Fan et al., 2004; Sanchez et al., 2004), the nuclear-localized lacZ protein 
allows the cell type expressing Gli1 to be unambiguously identified. In areas of 
mPIN (n=12 mice, 35-49 weeks; Fig. 2.13B,B’; Fig. 2.14B) or MIC (n= 6 mice, 
45-49 weeks, Fig. 2.13C,C’; Fig. 2.14C) of PB-MYC tumors, Gli1nlacZ was 
expressed in scattered cells in the stroma, primarily adjacent to the tumor 
epithelium. As in wild-type (WT) mice, all Gli1+ cells were negative for the 
epithelial marker EpCAM (Fig. 2.14A-C), demonstrating that Gli1+ cells are 
stromal cells. We also examined Gli1 expression in the prostate stroma of 
ERG/PTEN mice carrying a Gli1GFP allele (referred to as Gli1GFP;ERG/PTEN). 
Although almost all epithelial cells express a high level of nuclear-localized 
GFP (ERG-GFP and CreER-GFP), any stromal GFP+ cells should reflect 
expression of Gli1, since ERG/PTEN alone has no GFP+ stromal cells (n= 5 
mice, 12-41 weeks; Fig. 2.14F-F”). As in PB-MYC tumors, a high proportion of 
ERG/PTEN tumor stromal cells near mPIN lesions expressed Gli1GFP, 
including SMCs (Fig. 2.14G-G”).  
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In TRAMP mPIN lesions, Gli1nlacZ expression was enriched in the stromal cells 
closest to the tumor epithelium, including the SMCs cells invading between 
epithelial folds (n=8 mice, 25-33 weeks; Fig. 2.13D,D’; Fig. 2.14D). Strikingly, 
many tumor stromal cells in IASs expressed Gli1nlacZ, although cells at a 
distance from tumor cells did not (n=4 mice, 28-33 weeks; Fig. 2.13E,E’; Fig. 
2.14E). Thus, an increase in HH signaling specifically in the stroma (SMCs 
and fibroblasts) near tumor cells appears to be a consistent finding in mouse 
models of PCa. 
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Figure 2.13 Gli1nlacZ is expressed in the stromal cells and ShhnlacZ is 
expressed in the basal epithelial cells in both PB-MYC and TRAMP 
prostate tumors. 
	  
(A-E) X-Gal staining (blue) of DLP sections from tissues of Gli1nlacZ/+ (A), 
Gli1nlacZ/+;PB-MYC/+ (B, C), and Gli1nlacZ/+;TRAMP/+ (D, E) mice. (A’-E’) 
Magnification of areas within dashed lines in A-E. (F-J) X-Gal staining (blue) of 
DLP sections from tissues of ShhnlacZ/+ (F), ShhnlacZ/+;PB-MYC/+ (G, H), and 
ShhnlacZ/+;TRAMP/+ (I, J) mice. (F’-J’) Magnification of areas of dashed lines in 
F-J. *= Infiltrating nests of tumor cells. Scale bars, 50 µm. 
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Figure 2.14 Gli1 expresssion is restricted to the stroma in all three PCa 
models. 
 
(A-E) IF staining for bGAL (green), the enzyme product of lacZ, EpCAM 
(magenta), and DAPI (blue), showing that Gli1+ cells are non-epithelial cells in 
PB-MYC and TRAMP tumors. *= Infiltrating nests of tumor cells. (F-F”, G-G”) 
IF staining of DLP sections from ERG/PTEN (F-F”) and Gli1Gfp;ERG/PTEN (G-
G”) mice for GFP (green), SMA (red), and DAPI (blue). Arrows indicate GFP+ 
SMA+ stromal cells, and arrowheads indicate GFP+ SMA- stromal cells. Scale 
bars, 50 µm.  
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IHH and DHH contribute to HH signaling to the stroma of mouse PCa 
We next tested whether SHH could be the ligand responsible for Gli1 
expression near tumor cells by examining ShhnlacZ (Gonzalez-Reyes et al., 
2012) expression in PB-MYC and TRAMP tumors. As in WT prostate (Peng et 
al., 2013) (Fig. 2.13F,F’; Fig. 2.15A,F), ShhnlacZ expression was detected in the 
majority of CK5+ basal cells in PB-MYC mPIN lesions, although a few cells 
were only positive for either CK5 or ShhnlacZ (n=6 mice, 35-42 weeks; Fig. 
2.13G,G’; Fig. 2.15B,G). In areas of MICs, ShhnlacZ expressing cells were rare 
(n=5 mice, 35-42 weeks; Fig. 2.13H,H’), consistent with the loss of cells with a 
basal phenotype, as indicated by few CK5-expressing cells (Fig. 2.15C,H). 
Similarly in TRAMP mPIN lesions, ShhlacZ expression was detected in CK5+ 
basal cells, (n=5 mice, 20-32 weeks; Fig. 2.13I,I’). The number of basal cells, 
however, was greatly diluted out by the increase in CK8+ luminal cells (Fig. 
2.15D,I). In IASs, ShhlacZ expression was detected only in the rare CK5+ basal 
cells that remained (n=5 mice, 20-32 weeks, Fig. 2.13J,J’; Fig. 2.15E,J).  
 
Our results from PB-MYC and TRAMP PCa models suggest that paracrine HH 
signaling is retained in tumors, but raises the question of whether SHH is the 
primary ligand since few ShhnlacZ-expressing cells remained in tumors. One 
possible explanation for the extensive Gli1 expression despite little Shh in both 
PCa models is that another HH ligand is expressed. Using in situ hybridization 
(ISH), we first confirmed an increase in cells expressing Gli1 (Fig. 2.16A-C,A’-
C’; Fig. 2.17A-C,A’-C’), and also found that Shh expression was maintained in 
PB-MYC tumors (Fig. 2.16E,E’; Fig. 2.17E,E’) but almost absent in TRAMP 
tumors (Fig. 2.16F,F’; Fig. 2.17F,F’) compared with WT (Fig. 2.16D,D’; Fig. 
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2.17D,D’). As expected, Sma mRNA in stromal cells was markedly decreased 
in PB-MYC tumors (Fig. 2.16N; Fig. S9N) and increased in TRAMP tumors 
(Fig. 2.16O; Fig. 2.17O) compared to WT (Fig. 2.16M; Fig. 2.17M). 
Interestingly, whereas we detected little expression of Ihh or Dhh in the 
epithelium of normal prostates (Fig. 2.16G,G’,J,J’), Ihh was abundant in PB-
MYC (Fig. 2.16H,H’; Fig. 2.17H,H’) and somewhat increased in TRAMP (Fig. 
2.16I,I’; Fig. 2.17I,I’) tumor epithelium, and Dhh was detected in the tumor 
epithelium of both PB-MYC and TRAMP models, especially in TRAMP mPIN 
lesions (Fig. 2.16K,K’,L,L’; Fig. 2.17K,K’,L,L’). qRT-PCR analysis of RNA 
isolated from whole dorsal prostates of WT, TRAMP, and PB-MYC tumors 
confirmed that Ihh expression is highest in PB-MYC and Dhh is highest in 
TRAMP tumors and both are increased compared to normal prostate (Fig. 
2.18). In summary, our results have uncovered that Ihh and Dhh expression 
are increased in the epithelium of two mouse PCa models as compared to the 
normal prostates, with Ihh increased more in PB-MYC than TRAMP tumors.   
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Figure 2.15 ShhnlacZ is expressed in the few basal epithelial cells in both 
PB-MYC and TRAMP prostate tumors. 
 
(A-E) IF staining of DLP sections from tissues of ShhnlacZ/+ (A), ShhnlacZ/+; PB-
MYC/+ (B, C), and ShhnlacZ/+; TRAMP/+ (D, E) mice for CK5 (green), a basal 
epithelial cell marker, bGAL (red), and DAPI (blue), showing that Shh+ cells 
are basal cells. (F-J) IF staining for CK8 (red), a luminal epithelial marker, CK5 
(green), and DAPI (blue), showing the proportion of basal cells is greatly 
decreased in tumor lesions. Note that red staining in E is background. Arrows 
indicate CK5+/bGAL+ cells; arrowheads indicate CK5+/bGAL- cells. * = 
infiltrating nests of tumor cells. Scale bars, 50 µm. 
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Figure 2.16 Ihh and Dhh are upregulated in tumor epithelium of PB-MYC 
and TRAMP PCa models. 
 
mRNA in situ hybridization (blue) of Gli1 (A-C), Shh (D-F), Ihh (G-I), Dhh (J-L) 
on DLP sections from WT (A, D, G, J), PB-MYC/+ MIC lesions (B, E, H, K), 
and TRAMP/+ IAS lesions (C, F, I, L), counter-stained with fast red. (A’-L’) -
Magnifications of areas of dashed lines in A-L. (M-O) Sma mRNA in situ 
hybridization (blue) co-stained with IHC of EpCAM. * = infiltrating nests of 
tumor cells. Scale bars, 50 µm. 
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Figure 2.17 Ihh and Dhh are upregulated in tumor mPIN epithelium of 
both PB-MYC and TRAMP. 
 
mRNA in situ hybridization (blue) of Gli1 (A-C), Shh (D-F), Ihh (G-I), Dhh (J-L) 
on DLP sections from WT (A, D, G, J), PB-MYC/+ mPIN lesions (B, E, H, K), 
and TRAMP/+ mPIN lesions (C, F, I, L), counter-stained with fast red. (A’-L’) -
Magnifications of areas of dashed lines in A-L. (M-O) Sma mRNA in situ 
hybridization (blue) co-stained with immunohistochemistry (IHC) of EpCAM. 
Scale bars, 50 µm. 
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Figure 2.18 Ihh and Dhh are upregulated in PB-MYC and TRAMP tumors 
compared to normal prostate. 
 
Gene expression levels of Shh, Ihh, and Dhh in WT, PB-MYC, and TRAMP 
prostates measured by qRT-PCR. 
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HH signaling in human PCa correlates with stromal content and is driven 
mainly by DHH 
Our expression studies using mouse tumor sections raise the question of 
whether the genes encoding any of the HH ligands and GLI1 are increased in 
a subset of human PCa. Analysis of the TCGA dataset (n=330) of primary 
PCa samples (Abeshouse et al., 2015) and the MSKCC Prostate 
Oncogenome Project (n=29 normal, 131 primary tumors, and 19 metastases) 
(Taylor et al., 2010) revealed that the overall expression of IHH, but not SHH 
or DHH is significantly increased in tumor samples compared to normal 
prostate samples (Fig. 2.19A). However, there were no significant differences 
in the expression of HH genes between tumor samples with various Gleason 
scores (Fig. 2.19B) or between primary and metastasis tumors (Fig. 2.19C). 
GLI1 expression was the same in normal prostate and all types of tumor 
samples (Fig. 2.19), which could indicate an actual increase in stromal 
expression since the proportion of stromal cells is reduced. Indeed, there was 
a positive correlation between tumors with high expression of stromal markers 
and GLI1 (Pearson coefficient = 0.483 or 0.379 or 0.595 for ACTA2 or CNN1 
or VIM with GLI1; Table 2.1B). There was also a correlation between DHH 
expression, and to a lesser extent IHH or SHH, with GLI1 expression levels 
(Pearson coefficient = 0.309 or 0.198 or 0.181 for DHH or IHH or SHH with 
GLI1; Table 2.1B). There was also a strong correlation between DHH and 
ACTA or VIM (Pearson coefficient = 0.422 or 0.560 for ACTA2 or VIM with 
DHH). Curiously, there were poor correlations between the levels of DHH and 
luminal markers (Pearson coefficient = 0.025 or -0.054 for KRT8 or KRT18 
with DHH) or basal markers (Pearson coefficient = 0.001 or -0.017 for KRT5 or 
TP63 with DHH) in tumor samples (Table 2.1B), indicating that DHH 
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expression is induced in a tumor context-dependent manner. Thus, mRNA 
expression data from human primary PCa samples indicate that the level of 
HH signaling (GLI1 expression) correlates with the proportion of stromal cells 
in a tumor, and IHH is increased more than the other HH ligands in tumors 
compared to normal prostate.  
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Figure 2.19 IHH is increased in the TCGA human primary PCa samples. 
	  
(A, B) The mRNA expressions of HH pathway genes in human PCa from 
TCGA RNA-seq data with 330 primary PCa samples (Tumor) and 27 normal 
controls (Normal) (A), or PCa samples categorized by Gleason scores 
(Gleason 3+3, 3+4, 4+3, and >=8) (B). (C) The mRNA expressions of HH 
pathway genes in human PCa from the MSKCC Prostate Oncogenome 
Project with 131 primary PCa samples (Primary Tumor), 19 Metastasis 
samples (Metastasis), and 27 normal controls (Normal). *P<0.05. Data are 
presented as mean ± s.d. Each data point represents one sample. 
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Gene expression profile of Gli1-expressing stromal cells is altered in PB-
MYC tumors 
In order to analyze the expression profile of mouse PCa stromal cells, we used 
the Gli1GFP/+ knock-in reporter line (Brownell et al., 2011) to isolate the subset 
of stromal cells undergoing HH signaling to compare the transcriptomes 
between PB-MYC PCa and normal prostate (~45 weeks of age) using RNA-
seq. Unsupervised hierarchical clustering of all genes with significant 
differences in gene expression showed a clear separation between the two 
populations (Fig. 2.20A). Analysis of variance correcting for multiple 
hypothesis testing identified 243 genes with significantly different expression 
(p<0.05 and FDR<0.05) between WT and PB-MYC cells expressing Gli1GFP at 
a level of ≥ 2 fold (281 genes ≥ 1.5 fold) (Table 2.3A), with the majority of the 
genes expressed more strongly in WT cells (Fig. 2.20A). Interestingly, Acta2 
and Cnn1 were decreased by 21 and 12 fold, respectively, in stromal Gli1-
expressing tumor cells compared to WT, and VIM was not significantly altered 
(Table 2.3B). The decrease in SM gene expression likely reflects the decrease 
in the proportion of SMCs in PB-MYC tumors. Consistent with our conclusions 
based on RNA in situ analysis, the three Hh genes were not expressed in 
stromal Gli1-expressing cells (Table 2.3B). Pathway analysis (p<0.1 and 
FDR<0.1) identified 6 pathway differences (Fig. S14B), with a top pathway 
being focal adhesion that was reduced in PB-MYC Gli1GFP-expressing cells 
(Fig. 2.20B,C), consistent with the greater dispersion of stromal cells in tumors.  
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Figure 2.20 Altered gene expression profile of Gli1-expressing stromal 
cells in PB-MYC tumors. 
 
(A) Analysis of Variance correcting for multiple hypothesis testing identified 
288 genes with significantly different expression between WT and PB-MYC 
Gli1GFP-expressing cells (q<0.05). (B) Pathway analysis (q<0.1) identified 6 
differentially represented (≥2 fold). %, percentage of genes in pathway that 
are differentially expressed; FDR, false discovery rate. (C) Genes in the focal 
adhesion pathway that are differentially detected (p<0.05, q<0.1) between WT 
and PB-MYC Gli1GFP-expressing cells. 
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Table 2.3 List of differentially expressed genes between WT and PB-MYC 
Gli1GFP-expressing cells. 
(A) List of genes with significant differential expressions (p<0.05, 
FDR<0.05, fold change >1.5) 
See Appendix Table 2.3A. 
 
(B) Stromal marker genes and HH pathway genes 
 
# Gene Symbol P-value  
(Tumor vs. WT) 
FDR step up  
(Tumor vs. WT) 
Fold change 
(Tumor vs. WT) 
1 Cnn1 0.0121 0.1631 -11.92 
2 Acta2 0.0072 0.1339 -21.16 
3 Vim 0.4523 0.6558 -1.17 
4 Shh 0.1183 0.3998 -3604.97 
5 Ihh 0.7145 0.8515 -5.99 
6 Dhh 0.4274 0.6368 -15.16 
7 Gli1 0.2558 0.5693 1.28 
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Enhanced HH signaling in the PB-MYC stroma impedes PCa progression 
and maintains the SM 
Given the extensive reduction of SM and presence of local MIC in advanced 
PB-MYC tumors, and reduction in SM gene expression in more advanced 
human PCa samples, we reasoned that the damaged SM layers could 
facilitate the invasion of prostate tumor cells, since they must cross the SM 
layer surrounding the ductal glands. Furthermore, given the correlation 
between high DHH and GLI1 expression and higher stromal content of human 
PCa samples, we hypothesized that increasing stromal HH signaling would 
decrease tumor progression by maintaining or increased SM. To test this 
hypothesis, we used Cre/loxP to genetically increase HH signaling in the 
stroma of PB-MYC tumors by administering tamoxifen to Gli1CreER/+;R26LSL-
SmoM2-YFP/+;PB-MYC/+ (SmoM2;PB-MYC) and R26LSL-SmoM2-YFP/+;PB-MYC/+ 
(PB-MYC) littermates at 4 weeks to induce expression of a constitutively active 
SMO (SmoM2) (Mao et al., 2006) in a subset of stromal cells (Fig. 2.21A). The 
severity of tumors was assessed at 44 to 46 weeks in a blinded fashion based 
on tissue pathology. Four categories of mPIN lesions and MIC were graded 
according to the degree of architectural and cytologic abnormalities and the 
extent of ducts affected. Low-grade mPIN (LGPIN) was defined as having 1 to 
2 layers of cells and mild nuclear atypia (Fig. 2.21B,B’). High grade mPIN 
lesions were divided into three grades: HGPIN1 lesions were focal and had 
increased nuclear atypia with 2 or more layers of cells often in papillary, tufting, 
or cribriform arrangements (Fig. 2.21C,C’). HGPIN2 lesions were more 
extensive and had obvious nuclear atypia and the cells filled or almost filled 
the ductal lumens in papillary or cribriform patterns (Fig. 2.21D,D’). HGPIN3 
lesions were the most extensive and had more severe atypia, filled the ductal 
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lumens, and some cells bulged into the surrounding stroma but without the 
clear invasion seen in MIC (Fig. 2.21E,E’). Strikingly, mice with active HH 
signaling in the stroma (SmoM2;PB-MYC) showed a significant decrease in 
tumor grade compared with PB-MYC littermates (Fig. 2.21G) (Mann-Whitney 
U test: U=53, n1=n2=14, p=0.0096 two-tailed). Thus increased HH signaling in 
PB-MYC stroma can suppress progression of PCa.  
 
Since MIC is less likely to occur in PB-MYC tumors with increased stromal HH 
signaling (Fig. 2.13F), we then asked whether the SMC content of tumors was 
altered by HH activation. The SMA+ area was quantified in SmoM2;PB-MYC 
mice and PB-MYC littermates (N=6 mice, 44-45 weeks), as well as their non-
tumor littermate controls, Gli1CreER/+;R26LSL-SmoM2-YFP/+ (SmoM2) (N=5 mice, 45 
weeks) and R26LSL-SmoM2-YFP/+ (WT) mice (N=3 mice, 45 weeks). Whereas PB-
MYC tumors had the expected large decrease in SMCs and gaps in the SM 
layer compared with normal prostates (Fig. 2.22A,A’,C,C’), PB-MYC tumors 
with stromal SmoM2-expression had strikingly more normal SM layers (Fig. 
2.22C-D,C’-D’). Quantification of the SMA+ area with respect to total cell 
number (estimated from the number of DAPI+ nuclei) showed an increase 
(p=0.049) in SmoM2;PB-MYC mice compared with PB-MYC mice (Fig. 2.22E), 
although SMA+ area relative to stromal cell number (EpCAM-) did not show a 
significant increase (Fig. 2.22F). This result could in part be due to a 
contribution of immune cells to the stromal cell count. The increase of SM in 
SmoM2;PB-MYC tumors is unlikely due to enhanced HH signaling via SmoM2 
expression as the SMCs are not specifically enriched with SmoM2-YFP-
positive cells, and both SMA+ and SMA- stromal cells expressed SmoM2-YFP 
(Fig. 2.23). These results suggest that HH signaling maintains the SM layers in 
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PCa and has an inhibitory effect on invasive cancer, possibly via maintaining 
the SM layers as barriers to prevent tumor epithelial cells from invading into 
the stroma.  
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Figure 2.21 Ectopic HH signaling in the stroma reduces PB-MYC prostate 
tumor progression. 
 
(A-E) H&E staining of DLP sections from tissues of either SmoM2;PB-MYC 
(Gli1CreER/+;R26LSL-SmoM2-YFP/+;PB-MYC/+) or PB-MYC (R26LSL-SmoM2-YFP/+;PB-
MYC/+) mice, representing lesions of different severity; low-grade mPIN 
(LGPIN or LG) (A), high-grade 1 mPIN (HGPIN grade 1 or HG 1) (B), high-
grade 2 mPIN (HGPIN grade 2 or HG 2) (C), high-grade 3 mPIN (HGPIN 
grade 3 or HG 3) (D), and MIC (E). (A’-E’) Magnification of areas of dashed 
lines in A-E. Arrows= micro-invasive carcinoma. Scale bars, 50 µm. (F) Dot 
plot of each mouse with a certain grade of tumor lesion, showing inverse 
correlation between tumor severity and HH signaling. Each dot represents one 
mouse. ** P<0.01; N=14 mice for each of SmoM2;PB-MYC and PB-MYC 
groups. 
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Figure 2.22 Enhanced HH signaling in the stroma of PB-MYC prostates 
increases stromal cells including SMCs. 
 
(A-D) IF staining of DLP sections from WT (R26LSL-SmoM2-YFP/+) (A), SmoM2 
(Gli1CreER/+; R26LSL-SmoM2-YFP/+) (B), PB-MYC (R26LSL-SmoM2-YFP/+; PB-MYC/+) 
(C), and SmoM2;PB-MYC (Gli1CreER/+; R26LSL-SmoM2-YFP/+; PB-MYC/+) (D) mice 
for SMA (red) and DAPI (blue). Scale bars, 50 µm. (E-F) Quantification of the 
SMA+ area per total cell number (E) or per stromal cell number (F). (G) The 
percentage of stromal cells within total cells. *P<0.05; **P<0.01; ***P<0.001; 
****P<0.0001. Data are presented as mean ± s.d. Each data point represents 
the average of 4 sections from one mouse. 
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Figure 2.23 SmoM2 is expressed in both SMA+ and SMA- stromal cells of 
PB-MYC prostate tumors. 
 
IF staining of DLP sections from tissues of 6-week old (A-A’’) and 45-week old 
(B-B’’) SmoM2;PB-MYC (Gli1CreER/+; R26LSL-SmoM2-YFP/+; PB-MYC/+) mice for 
YFP (green), DAPI (blue), and SMA (red) or VIM (magenta). Arrows indicate 
YFP+ VIM+ (A-A’’) or YFP+ SMA+ (B-B’’) stromal cells. Arrowheads indicate 
YFP+ SMA- (A-A’’) or YFP- VIM+ (B-B’’) stromal cells. Scale bar, 50 µm. 
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Enhanced HH signaling in the stroma of PB-MYC tumors increases the 
stromal cell number  
Although PB-MYC tumors have a prominent reduction of SMCs, the proportion 
of all cells (epithelial + stromal) that were stromal (EpCAM-) was significantly 
increased in both SmoM2;PB-MYC (p<0.0001) and PB-MYC (p<0.0001) 
prostates compared to non-tumor controls, and was significantly higher in 
SmoM2;PB-MYC than PB-MYC tumors (p=0.0004) (Fig. 2.22G). There was 
also a small increase in the proportion of stromal cells in SmoM2 non-tumor 
prostates compared with WT (p=0.01) (Fig. 2.22G). These results indicate that 
the major effect of increasing HH signaling in the stroma of PB-MYC is to 
increase the proportion of stromal cells.  
 
The observed increase in stromal cells in SmoM2;PB-MYC prostates could be 
due to an increase in proliferation (1 hr pulse EdU) or decrease in cell death 
induced by HH activation. In SmoM2 and WT prostates, few EdU+ cells were 
detected (Fig. 2.24A,B,E,F), whereas SmoM2;PB-MYC and PB-MYC tumors 
had the expected significantly higher level of cell proliferation (p=0.001 and 
p=0.0007, respectively). Curiously, the percentage of EdU+ stromal cells was 
significantly reduced (p=0.018) in the stroma of SmoM2;PB-MYC mice 
compared to PB-MYC in late stage tumors (Fig. 2.24C,D,E), and in epithelial 
cells was slightly but not significantly (p=0.37) lower (Fig. 2.24F). TUNEL 
labeling of dying cells did not reveal an obvious difference between 
SmoM2;PB-MYC and PB-MYC tumors (Fig. 2.24G,H). Thus, the main cellular 
changes that lead to the increase in PCa stroma likely occur at an earlier 
stage in tumor progression, or represent mainly that stromal cells are 
maintained when HH signaling is increased.   
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Figure 2.24 Enhanced stromal HH signaling in PB-MYC prostates does 
not increase stromal cell proliferation in late stage tumors. 
 
(A-D) IF staining of DLP sections from WT (A), SmoM2 (B), PB-MYC (C), and 
SmoM2;PB-MYC (D) mice for EdU (green), SMA (red), and DAPI (blue). Scale 
bar, 50 µm. Arrows indicate EdU+ epithelial cells; arrowheads indicate EdU+ 
stromal cells. (E-F) Quantification of the percentage of EdU+ stromal cells (E) 
or EdU+ epithelial cells (F). *P<0.05; **P<0.01; ***P<0.001. (G-H) TUNEL 
staining (green) with SMA (red) and DAPI (blue) of DLP sections from PB-
MYC (G) and SmoM2;PB-MYC (H) mice. Arrows indicate TUNEL+ epithelial 
cells; arrowheads indicate TUNEL+ stromal cells. 
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DISCUSSION 
In three mouse models of PCa, including one with highly recurrent mutations 
in human PCa (ERG/PTEN), we found distinct contributions of SM-like and 
fibroblast-like cells to the stroma, yet HH signaling (Gli1nlacZ expression) was 
restricted to stromal cells, especially near the tumor epithelium. Whereas 
TRAMP tumors had an increase in SMCs and little change in interductal 
fibroblasts, PB-MYC and to a lesser extent ERG/PTEN had a decrease in 
SMCs and an accompanying increase in fibroblast-like stromal cells between 
the ducts. RNA-seq analysis of Gli1GFP-labeled cells of PB-MYC and normal 
prostate similarly revealed a major decrease in SM genes, and the fibroblast 
gene Vim was not altered. Based on the Human Protein Atlas and RNA data 
analysis, we confirmed that human PCa tumors have a dramatic disruption of 
the SM layers and a clear decrease in the mature SM marker Calponin 
(CNN1) in advanced tumors, consistent with a previous report (Tuxhorn et al., 
2002). ACTA2 (SMA) staining revealed the SM layers were disrupted and the 
proportion of cells were decreased in most advanced tumor samples, whereas 
VIM was maintained in the remaining stromal cells. Analysis of TCGA, the 
largest RNA-seq dataset of primary PCa samples (Abeshouse et al., 2015), 
revealed a decrease in ACTA2 and CNN1 but not VIM expression in more 
advanced tumors (higher Gleason score), suggesting the proportion of SMCs 
in human tumors, or at least the expression levels of the cell type specific 
genes are decreased. In a separate RNA expression data set (Taylor et al., 
2010) ACTA2 and CNN1 but not VIM expression were found to be significantly 
lower in metastatic samples compared to primary tumors. In addition, we 
found correlations between higher luminal or lower basal cell gene expression 
and lower SM gene expression. Our study thus demonstrates that PCa in PB-
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MYC mice nicely models the decrease in SM layers seen in more advanced 
human PCa.  
 
Using GIFM, we traced the fate of SMA-expressing cells in vivo during mouse 
tumor progression and found that the labeled cells are largely lost in PB-MYC 
tumors without changing fate and giving rise to cancer reactive stroma. In 
TRAMP tumors, in contrast, labeled SMCs not only expand the SM layers, but 
also contribute to cancer stromal cells, specifically in IAS and not between 
ducts. Thus, in TRAMP tumors, some labeled SMCs change their fate to 
fibroblasts and/or myofibroblast-like cells and migrate into IASs. However, 
SMCs in TRAMP tumors, as in PB-MYC tumors, do not contribute to 
interductal stromal cells. We propose that the fate of SMC is likely determined 
by the molecular character of the tumor epithelial cells. It will be interesting to 
determine if the cell-of-origin of interductal stroma is the stem/progenitor cell 
that a fate mapping study indicates is restricted to the interductal fibroblast 
lineage (Peng et al., 2013). Furthermore, if each stromal lineage has a distinct 
expression signature, it should be possible to predict the cell of origin of 
reactive stroma in human PCa samples. 
 
In both TRAMP and PB-MYC models of PCa, we found that the proportion of 
epithelial cells expressing ShhnlacZ decreases greatly during tumor progression, 
whereas the two alternate ligands, Ihh and Dhh are prominently expressed by 
tumor cells but not normal prostate luminal cells (Fig. 2.16; Fig. 2.14). 
Consistent with this result, Shh expression is decreased and Ihh increased in 
the LADY prostate tumor model compared to normal prostate based on qRT-
PCR of whole tumor tissue (Gipp et al., 2007; Kasper et al., 1998). Analysis of 
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TCGA RNA-seq data revealed that IHH is increased in human PCa compared 
to normal prostate (Fig. 2.6). Furthermore, the level of DHH, and to a lesser 
extent IHH, is positively correlated with GLI1 (HH signaling), as well as the 
level of stromal gene expression (Table 2.1B). Thus, HH signaling appears to 
be a predictor of the amount of stroma in a tumor. Finally, our examination of 
gene expression on mouse sections revealed a paracrine mode of HH 
signaling from tumor cells to stroma.  
 
A majority of the studies on the role of HH signaling using PCa cell lines have 
suggested that HH pathway blockade via cyclopamine treatment suppresses 
tumor growth. Using an in vivo genetic mouse model that reflects the changes 
in stromal content of human PCa, however, we found that aberrant activation 
of HH signaling in the Gli1-expressing subset of stromal cells in PB-MYC 
tumors results in decreased tumor progression, revealing that tumor stroma 
can restrain PCa progression. We propose that the partially restored SM 
layers act as a barrier to prevent epithelial cells from invading into the stroma 
(Fig. 2.25). It is also possible that SMCs secrete factors, such as pro-
differentiation proteins, that restrain tumor progression (Fig. 2.25). Together 
with several recent studies showing that inhibition of HH signaling in the 
stroma of pancreas and bladder cancers decreases survival (Lee et al., 2014; 
Rhim et al., 2014; Shin et al., 2014), our findings offer an explanation for the 
unsuccessful clinical trials using small-molecule HH antagonists for PCa. 
Further research in genetic models that represent later stages of human PCa 
will provide additional evidence for the value of altering HH function for PCa 
patients.   
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Figure 2.25 Schematic diagram of the proposed model mechanism for 
enhanced HH signaling in PB-MYC stroma to restrain prostate tumor 
progression. 
 
(A) In the normal prostate, the epithelium has a single layer of luminal cells 
and basal cells, and the surrounding stroma is composed of smooth muscle 
cells and fibroblasts. Shh is expressed in basal epithelial cells, and Gli1 
expression (indicated by dark blue color of cell nuclei) is restricted in a subset 
of each subtype of stromal cells. 
(B) In the PB-MYC tumor with micro-invasive carcinoma (MIC) lesions, tumor 
epithelial cells hyper-proliferate and form multi-layer tumor epithelium. The 
amount of smooth muscle is largely reduced, and the fibroblast-like subtypes 
increase in number. Some invasive tumor cells invade into the surrounding 
stroma (indicated by arrow) and form the MIC lesions.  
(C) When HH signaling in the stroma is enhanced through over-expression of 
SmoM2 (indicated by red outline of cell membrane) in the Gli1-expressing 
subset of the stromal cells in the PB-MYC tumor, the smooth muscle layer is 
partially restored, which may act as a barrier to prevent tumor epithelial cells 
from invading into the stroma (indicated by the arrow and red X) and forming 
MIC lesions. An alternative possible mechanism is that smooth muscle cells 
can secret certain factors to inhibit the tumor epithelial cell expansion or 
dedifferentiation that can restrain tumor progression (indicated by the dashed 
line). 
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MATERIALS AND METHODS 
 
Mice 
The following mouse lines were used: TRAMP/+ (Greenberg et al., 1995), PB-
MYC/+ (Ellwood-Yen et al., 2003), ShhnlacZ/+ (Gonzalez-Reyes et al., 2012), 
Gli1nlacZ/+ (Bai et al., 2002), Gli1GFP/+ (Brownell et al., 2011), Gli1CreER/+ (Ahn 
and Joyner, 2005), Sma-CreER/+ (Wendling et al., 2009), Ptenflox/flox (Trotman 
et al., 2003), R26LSL-ERG-GFP/ LSL-ERG-GFP (Chen et al., 2013), Rosa26 (R26) 
reporter mice (Madisen et al., 2010; Soriano, 1999; Srinivas et al., 2001), and 
Tmprss2CreER-GFP/+ was generated by knock-in of a CreERT2-IRES-EGFP 
cassette with a splice acceptor into the first intron of the Tmprss2 gene, after 
exon 1 which is non-coding (Gao et. al. in press). Tamoxifen (Sigma, T5648) 
was dissolved in corn oil and administered by oral gavage (250 µg g-1). Mouse 
husbandry and all experiments were performed in accordance with MSKCC 
IACUC-approved protocols.  
 
Tissue Processing 
Animals were anesthetized and transcardially perfused with PBS followed by 
chilled 4% paraformaldehyde. Prostates were harvested and postfixed for 15-
20 min (normal prostate) or 2–3 h (tumor) or overnight (RNA in situ and some 
IHC), and cryoprotected in 30% sucrose before freezing in Cryo-OCT. Frozen 
prostates were sectioned at either 8 µm (pathology) or 12 µm on a cryostat, 
and sections of the dorsolateral prostates were used for all analyses.  
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Microscopy 
Mosaic fluorescence images were taken on an inverted microscope (Zeiss, 
Observer.Z1) using Zen software (Zeiss). Bright-field images were taken with 
10X or 20X objectives.  
 
Immunofluorescent staining 
Cryosections were stained with the following primary antibodies: SMA (1:500; 
Sigma-Aldrich; F3777, C6198), Vimentin (1:500; Cell Signaling; 5741), 
Calponin (1:500; Abcam; ab46794), Collagen type I alpha 2 (1:500; Rockland; 
600-401-103-0.1), bGAL (1:1,000; Thermo Fisher Scientific; PA1-21477), 
EpCAM (1:200; eBioscience; 14–5791-82), GFP/YFP (1:1,000; Nacalai 
Tesque; 0440484), CK5 (1:2,000; Covance; PRB-160P), and CK8 (1:500; 
Developmental Studies Hybridoma Bank; TROMA-1). Secondary antibodies 
for double labeling were donkey anti-species conjugated with Alexa Fluor 488 
or 555 (1:1,000; Molecular Probes). Nuclei were counterstained with DAPI. 
 
X-GAL Staining 
Sections were post-fixed with paraformaldehyde for 5 min, washed twice in X-
GAL buffer (2 mM MgCl2, 0.1% Igepal Ca-30, 0.05% sodium deoxycholate in 
PBS) for 10 min, and stained in X-GAL staining solution (1 mg ml-1 X-GAL, 0.2 
mM potassium ferricyanide, 0.17 mM potassium ferrocyanide in X-GAL buffer) 
for 12–14 h at 37 °C. X-GAL–stained sections were counterstained with 0.1% 
Nuclear Fast Red (Poly Scientific, s248).  
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Flow Cytometry and RNA-sequencing 
To isolate HH-responding (Gli1-expressing) stromal cells, prostates of 
Gli1GFP/+; PB-MYC/+ and Gli1GFP/+ mice were freshly harvested and processed 
into a single cell suspension, and then subject to FACS (fluorescence 
activated cell sorting) to isolate GFP+ cells. RNA was extracted from GFP+ 
cells from individual prostates, then pooled to have a minimum of 4 ng and 
subject to RNA-sequencing analysis (MSKCC Genomics Core Facility). 
Alignment of raw data, principal component analysis, and unsupervised 
hierarchical clustering were performed in Partek Flow. Pathway analysis was 
performed in DAVID.  
 
Quantification and statistical analysis 
To quantify the area of cells expressing SMA, 20x mosaic photographs of four 
region-matched dorsolateral prostate sections were taken from each male 
mouse, and the SMA+ pixel area was measured using Photoshop. The 
numbers of DAPI+ nuclei in the epithelium (EpCAM+) and stroma (EpCAM-) 
were measured using Cell Profiler. To quantify the EdU+ cells in each 
compartment, 20x mosaic photographs of four region-matched dorsolateral 
prostate sections were taken from each male, and EdU+/EpCAM+ and 
EdU+/EpCAM- cells were counted manually using Stereo Investigator (MBF 
Bioscience). At least three mice were analyzed for each group in each 
experiment. Data are presented as mean ± s.d. (standard deviation). 
Statistical analyses were performed using GraphPad Prism version 6.0. 
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EdU (5-ethynyl-2’-deoxyuridine) Injection and Staining  
For assessing cell proliferation, EdU (Invitrogen, E10187) was given at 100 mg 
g-1 by i.p. injection 1 h before euthanasia. Click-it EdU assay with Alexa Fluor 
488 (Invitrogen, C10337) was used according to the protocol of the 
manufacturer. 
 
TUNEL Staining 
For TUNEL staining, slides were permeabilized with 0.5% TritonX-100, pre-
incubated with Tdt buffer (30 mM Tris·HCl, 140 mM sodium cacodylate and 1 
mM CoCl2) for 15 min at room temperature, and incubated for I h at 37 °C in 
TUNEL reaction solution (Tdt buffer containing TUNEL enzyme and 
dUTPbiotin; Roche Applied Science). Then slides were incubated with 
Streptavidin Alexa Fluoro 647 (Invitrogen, S-32357) for 1 h. 
 
mRNA in situ hybridization 
RNA in situ hybridization analysis was performed based on standard protocols 
(Birren et al., 1993; Keil et al., 2012) with minor modifications, using antisense 
RNA probes for Shh, Dhh and Ihh (Echelard et al., 1993), Gli1 (Hui et al., 
1994), and a Sma probe made using RT-PCR and the following primers: 5’-
TGG CTT CGC TGT CTA CCT TC-3’ and 5’- CGA TGT TAA TAC GAC TCA 
CTA TAG GGT GAA GTC AGT GTC GAT TTT TCC-3’. 
 
RNA isolation and real-time polymerase chain reaction (qRT-PCR)  
Total RNA from dorsal prostates was isolated using miRNeasy mini kit 
(QIAGEN, 217004). For reverse transcription-PCR reactions, 8 µg total RNA 
was reverse transcribed using iScript cDNA systhesis kit (Bio Rad, 170-8891). 
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qRT-PCR was performed using PowerUp SYBR Green Master Mix 
(ThermoFisher Scientific, A25742) and GAPDH as an internal control. Each 
PCR was run in duplicate. Primer sequences were as follows: Shh forward 5’- 
AAAGCTGACCCCTTTAGCCTA-3’, Shh reverse 5’- 
TTCGGAGTTTCTTGTGATCTTCC-3’, Ihh forward 5’- 
CTCTTGCCTACAAGCAGTTCA-3’, Ihh reverse 5’- 
CCGTGTTCTCCTCGTCCTT-3’, Dhh forward 5’- 
CTTGGCACTCTTGGCACTATC-3’, Dhh reverse 5’- 
GACCCCCTTGTTACCCTCC-3’, Gapdh forward 5’- 
CCAAGGTGTCCGTCGTGGATCT-3’, and Gapdh reverse 5’- 
GTTGAAGTCGCAGGAGACAACC-3’. 
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Chapter 3 YAP is involved in regeneration of the injured neonatal 
cerebellum 2 	  
INTRODUCTION 
The cerebellum (CB) not only has a principal role in motor coordination and 
balance control (Huang et al., 2013), but also is linked with a wide range of 
higher order cognitive and social functions (Fatemi et al., 2012; Marek et al., 
2018; Steinlin, 2007; Stoodley et al., 2017; Tavano et al., 2007; Tsai et al., 
2012; Tsai et al., 2018; Wang et al., 2014). Development of the CB in both 
human and mouse is a protracted process, much of which spans from late 
embryonic to early postnatal stages	  (Altman and Bayer, 1997; Dobbing and 
Sands, 1973; Rakic and Sidman, 1970). Therefore, the CB is particularly 
vulnerable to clinical and environmental insults. Indeed, preterm birth has 
been linked to cerebellar hypoplasia and multiple neurological dysfunctions 
(Allen, 2008; Tam, 2013; Wang et al., 2009; Wang et al., 2014). Thus it is 
crucial to determine whether the CB has the capability of self-repair, and if so 
to dissect the molecular mechanisms that underlie such a recovery process.  
 
The mouse CB originates from the anterior hindbrain and undergoes 
substantial growth in the first two postnatal weeks. Prior to birth, the Atoh1-
expressing granule cell precursors (GCPs) migrate over the surface of the CB 
at embryonic day (E) 13.5 – 15.5. After birth, GCPs rapidly proliferate in the 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
2 Attribution of data: All experiments were designed and performed by Zhaohui 
Yang. Daniel Stephen helped with sectioning some of the samples. Dr. 
Alexandra Joyner oversaw the design and interpretation of experimental 
results, provided scientific advice and assisted with the preparation of the 
manuscript. Dr. Alexander Wojcinski assisted with the interpretation of some of 
the results.	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external granule cell layer (EGL) in response to Sonic Hedgehog (SHH) 
secreted by Purkinje cells (PCs) (Corrales et al., 2006; Lewis et al., 2004; 
Sillitoe and Joyner, 2007). Until approximately postnatal day (P) 15, post-
mitotic GCPs migrate past the underlying Purkinje cell layer (PCL) towards the 
internal granule cell layer (IGL) where they complete differentiation and 
maturation (Sillitoe and Joyner, 2007) (Fig. 3.1).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1 Schematic of early postnatal cerebellar cytoarchitecture. 
 
In the first two postnatal weeks, Granule Cell Precursors (GCPs) rapidly 
proliferate in the External Granule cell Layer (EGL) in response to Sonic 
Hedgehog (SHH) secreted by Purkinje cells (PCs). Post-mitotic GCPs then 
migrate along Bergmann glial fibers and past the underlying Purkinje Cell 
Layer (PCL) into the Internal Granule cell Layer (IGL) where they complete 
differentiation and maturation. Nestin-expressing progenitors are located in 
three sites, PCL, White Matter (WM), and right beneath the EGL. SHH 
stimulates proliferation of PCL and WM NEPs, which generate astrocytes and 
Bergmann glia or astrocytes and interneurons, respectively.  
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Recent studies uncovered a previously unappreciated regenerative ability of 
the murine CB. It was first shown in the infant rat that the EGL undergoes a 
major reconstitution several days after depletion by irradiation, but the long 
term consequences were not determined (Altman et al., 1969). More recently, 
we showed that the CB of neonatal mouse is capable of substantial recovery 
of its adult size and morphology after significant ablation of GCPs in the EGL 
or PCs soon after birth (Bayin et al., 2018; Wojcinski et al., 2017). The 
regeneration of GCPs after depletion via irradiation is dependent on the 
Nestin-expressing progenitors (NEPs) derived from the ventricular zone during 
mid-embryogenesis that proliferate in the postnatal CB (Buffo and Rossi, 
2013; Fleming et al., 2013; Milosevic and Goldman, 2004). There are two main 
subsets of NEPs residing in PCL and white matter (WM) (Fleming et al., 2013; 
Li et al., 2013; Wojcinski et al., 2017) (Fig. 3.1; Fig. 3.2). Under normal 
conditions, NEPs in the PCL give rise to astroglia (astrocytes and Bergmann 
glia) in vivo, whereas NEPs in the WM produce interneurons and astroglia 
(Parmigiani et al., 2015; Wojcinski et al., 2017). However, when GCPs in the 
EGL are depleted by irradiation at P1, NEPs in the PCL sense the injury and 
respond by increasing cell proliferation and then migrating into the EGL where 
they switch cell fate to produce GCs that contribute to the IGL (Fig. 3.2) 
(Wojcinski et al., 2017). At the same time, NEPs in WM and IGL transiently 
reduce their production of interneurons and astrocytes (Fig. 3.2). Although it 
has been shown that SHH signaling is required for NEPs to replenish the 
injured EGL (Wojcinski et al., 2017), and a SHH agonist protects the neonatal 
CB by preserving its volume and inhibiting Purkinje cell death (Nguyen et al., 
2018), the full molecular repertoire underlying the regenerative capacity of 
NEPs is not known. 
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Figure 3.2 Model of the cellular responses during regeneration of the 
developing cerebellum after irradiation at P1. 
(Adopted from (Wojcinski et al., 2017)) 
 
Depletion of the External Granule Layer (EGL) during the first days of 
postnatal cerebellar development results in upregulation of Sonic Hedgehog 
(SHH) signaling in the Purkinje Cell Layer (PCL), which leads to the expansion 
and migration of Nestin-Expressing Progenitors (NEPs) in the PCL that 
normally produce Astrocytes (Astro) and Bergmann Glia (Bg). Once in the 
EGL, NEP-derived cells progressively lose their Neural Stem Cell markers 
(SOX2 and Nestin), initiate expression of Granule Cell lineage-specific genes 
(Pax6 and Atoh1) and expand to replenish the EGL. Concomitantly, White 
Matter (WM) NEPs likely have reduced SHH resulting in a transient reduction 
in production of interneurons and astrocytes. Thus, injury of the EGL 
stimulates a cell-cell communication system that coordinates the responses of 
the different NEP populations during recovery, leading to a reset of the 
postnatal developmental clock of the cerebellum to re-establish the correct 
proportions of cerebellar cell types and ensure normal cerebellar circuit 
formation.  
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The Hippo signaling pathway is a key regulator of size control of many organs	  
(Halder and Johnson, 2011; Pan, 2010) through regulating cell proliferation 
and apoptosis	  (Udan et al., 2003; Wu et al., 2003). In mammals, upon 
activation of a conserved kinase cascade consisting of the serine/threonine 
kinases MST1/2 (mammalian Ste2-like kinases) and LATS1/2 (large tumor 
suppressor kinase 1/2), the transcriptional cofactor Yes-associated protein 
(YAP) is phosphorylated, sequestered by 14-3-3 in the cytoplasm, and 
targeted for degradation in a ubiquitin-proteasome-dependent manner	  (Callus 
et al., 2006; Chan et al., 2005; Wu et al., 2003; Zhao et al., 2010).	  Conversely, 
in the absence of Hippo signaling, dephosphorylated YAP translocates into the 
nucleus and forms complexes with the TEAD/TEF family transcription factors 
to activate downstream transcriptional programs that promote cell proliferation 
and organ growth (Wang et al., 2009). TAZ (transcriptional coactivator with 
PDZ binding motif; also called WWTR1, for WW-domain containing 
transcription regulator 1), a paralog of YAP in mammals, is regulated in a 
similar manner. Although YAP is known to regulate the renewal of many tissue 
types, including liver, incisors, and the colonic epithelium (Hu et al., 2017; Lu 
et al., 2018; Yui et al., 2018), the role of YAP in mammalian brain development 
and regeneration remains poorly studied. Conditional genetic ablation of Yap 
in radial glial progenitor cells (using Nestin-cre) was found to cause 
hydrocephalus and a subtle defect in the proliferation of cortical neural 
progenitors, but no major anatomical changes in the brain (Park et al., 2016). 
On the other hand, inactivation of LATS1/2 from the same (Nestin+) neural 
progenitor population during brain development in mouse results in YAP/TAZ-
driven global hypertranscription with upregulation of many target genes related 
to cell growth and proliferation as revealed by cell-number normalized 
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transcriptome analysis, which in turn inhibits the differentiation of neural 
progenitors and promotes a transient over-proliferation (Lavado et al., 2018). 
In an ex vivo model, it was shown that Yap over-expression increases the 
proliferation of cultured GCPs, while shRNA knockdown of Yap decreases 
proliferation (Fernandez et al., 2009). Moreover, Yap over-expression seemed 
to protect cultured GCPs from irradiation-induced damage by sustaining their 
proliferation and survival (Fernandez et al., 2012). However, the potential 
functions of YAP and TAZ in development and regeneration of the neonatal 
CB have not been tested in vivo. 
 
Here we utilized genetic modulations of YAP and TAZ in mice and revealed an 
essential role of YAP in mammalian CB regeneration and mild cellular effects 
during CB development. Loss of YAP at P0 in NEPs or GCPs in conditional 
knockout (cKO) mice resulted in only mild alterations of differentiation of NEPs 
and GCPs and no alteration of the size or morphology of the adult CB. In 
contrast, YAP was found to play a prominent role in injury-induced 
regeneration of the CB. Loss of YAP in NEPs disrupted restoration of 
cerebellar size with pronounced reduction in the IGL and disorganization of 
PCs and Bergmann glial fibers. The poor recovery of the CB was associated 
with elevated death of the NEPs in the PCL 1 day after irradiation and later 
death of NEPs after they entered the EGL. Surprisingly, loss of Taz in addition 
to Yap at P0 in NEPs did not alter development or restrict the recovery of the 
CB after EGL injury. Rather, TAZ ablation appeared to partially rescue the 
poor recovery of the CB observed in Yap Nes-cKO, indicating that TAZ and 
YAP have distinct functions during CB regeneration. Our study identified Hippo 
as a key molecular signaling pathway underlying regeneration of the postnatal 
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CB. Our discovery also raises the possibility that inhibiting the Hippo signaling 
pathway could potentially reverse cerebellar hypoplasia after injury through 
structural and functional restoration. 
 
RESULTS 
YAP and TAZ expressions are enriched in NEPs in the neonatal CB 
As a first step in studying the function of YAP in the developing and 
regenerating CB, we characterized the expression of the protein in Nestin-CFP 
reporter mice using immunofluorescence (IF). It was previously reported that 
YAP is expressed in GCPs (Fernandez et al., 2009), but expression in NEPs 
was not addressed. In the CB of normal P4 mice, a low level of nuclear YAP 
was detected in some NEPs (CFP+ cells) whereas in GCPs in the EGL little or 
no YAP was detected (Fig. 3.3A,A’,A”). Since NEPs contribute to regeneration 
of the irradiated (IR) mouse CB, we asked whether YAP expression changes 
in NEPs during their adaptive reprogramming following irradiation of the CB. 
When the cerebella of mice were irradiated at P1 (IR mice) and analyzed at 
P4, nuclear YAP was detected mainly in NEPs (CFP+ cells) and little 
expression was seen in GCPs (Fig. 3.3B,B’,B”). Intriguingly, in IR mice most of 
the CFP+ NEPs that had entered the EGL showed nuclear expression of YAP 
(Fig. 3.3B,B’,B”), indicating that YAP could play a role in the adaptive 
reprogramming response of NEPs to EGL ablation. Unlike YAP, nuclear 
located TAZ expression was obvious in NEPs of both Non-IR and IR cerebella, 
in addition to in the NEPs that had entered the EGL (Fig. 3.3C-D,C’-D’,C”-D”).  
 
To confirm that Yap and Taz are expressed at higher levels in NEPs than 
GCPs, we carried out quantitative RT-PCR (qRT-PCR) of mRNA from FACS-
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sorted Nestin-CFP+ NEPs and Atoh1-GFP+ GCPs from P4 IR and Non-IR 
mice. Indeed, Yap and Taz mRNA were significantly lower in GCPs than in 
NEPs of Non-IR and IR mice, and there were no significant changes after 
irradiation (Fig. 3.3E,F). Consistent with the antibody staining and qRT-PCR 
results, analysis of RNA-seq data from Nestin-CFP+ NEPs isolated by FACS 
from P5 IR and Non-IR mice (Wojcinski et al., 2017) showed the Yap and Taz 
transcripts were present in NEPs, with no significant changes after irradiation 
and lower numbers of reads for Taz (Table 3.1). The DNA-binding TEAD 
family transcription factors Tead1 and Tead2 transcripts were abundant while 
Tead3 was minimal (Table 3.1), indicating that TEAD1/2 are the main binding 
partners for YAP/TAZ in neonatal NEPs. The Hippo target gene Birc5 was 
present and appears to be slightly upregulated in irradiated NEPs, but a 
second target gene Ctgf had little expression (Table 3.1). Together, these data 
demonstrate that the cell type that predominantly expresses Yap and Taz is 
NEPs, and thus YAP and TAZ could play a role in the regeneration of the EGL 
by NEPs following irradiation.  
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Figure 3.3 Nuclear YAP and TAZ are mainly detected in NEPs in the 
postnatal CB.  
	  
(A-D) Immunofluorescence (IF) detection of YAP (A-B) and TAZ (C-D), co-
stained for CFP and DAPI, on midsagittal sections of cerebella from Non-IR 
and IR Nestin-CFP reporter mice at P4. Arrows and arrowheads indicate 
Nestin (CFP) positive cells in the Purkinje cell layer (PCL) or EGL, respectively 
that also have nuclear YAP or TAZ. Scale bar, 50 mm. (E-F) qRT-PCR 
analysis of the mRNA expression of Yap (E) and Taz (F) relative to Gapdh in 
FACS isolated NEPs (Nestin-CFP+) and GCPs (Atoh1-GFP+) from Non-IR 
and IR mice at P4. Data are presented as mean ± S.D., and statistical analysis 
by two-way ANOVA. Each data point represents one animal. 
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Table 3.1 Read number of Hippo pathway genes from RNA-sequencing of 
Non-IR and IR NEPs from P5 Nes-CFP mice. 
 
Gene Non-IR NEPs IR NEPs 
Unadjusted 
p value 
Yap 3203 3051 0.88 
Taz 2129 2211 0.73 
Tead1 8018 8137 0.91 
Tead2 7219 7587 0.64 
Tead3 648 490 0.08 
Ctgf 72 86 0.50 
Birc5 2687 3125 0.19 
Gapdh 2081 2212 0.60 
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YAP regulates differentiation of NEPs during normal CB development   
Given the potential role of YAP in NEPs during development and/or 
regeneration, we determined whether Yap is required for growth or 
differentiation of the CB. Yap was mutated in NEPs at P0 using a mosaic 
mutant analysis approach (MASTR,	  mosaic mutant analysis with spatial and 
temporal control of recombination) (Lao et al., 2012; Wojcinski et al., 2017) 
(Fig. 3.4A). An inducible FLP site-specific recombinase expressed from a 
Nestin transgene was used to induce sustained expression of a protein fusion 
between GFP and CRE (referred to as GFPcre) following injection of 
tamoxifen (Tm), which then induces recombination of a Yap floxed allele 
(Reginensi et al., 2013), resulting in visualization of the mutant cells and their 
descendants based on GFP expression (Fig. 3.4A). Tm was administered to 
Nes-FlpoER/+;R26FSF-GFPcre/+;Yapflox/flox (Nes-mYap cKO) mice and littermate 
controls (Nes-FlpoER/+;Yapflox/flox, or R26FSF-GFPcre/+;Yapflox/flox, or Yapflox/flox) at 
P0, and the size of the adult CB was measured based on the area of midline 
sections at P30 (Fig. 3.4B). Despite the obvious expression of YAP in most of 
the NEPs, the size of Nes-mYap cKO cerebella was similar to controls (Fig. 
3.4C,D,E).  
 
Since the loss of YAP in NEPs did not affect the size of the P30 CB, we tested 
whether it affected differentiation of NEPs in the developing CB at P8 by 
determining the distribution of NEPs and their descendants in different layers 
of the CB. Quantification of the GFPcre+ NEPs in lobule 4/5 of P8 Nes-mYap 
cKOs and controls (Nes-FlpoER/+;R26FSF-GFPcre/+ or Nes-m) indicated an 
increase in the number of mutant cells present at P8, and demonstrated a 
significant increase in the number of GFP+ cells in the molecular layer (ML) 
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normalized to the area of the lobule analyzed, as well as the percentage of 
cells in the layer (Fig. 3.4H,I; Fig. 3.5A,B). There was a concomitant decrease 
in the percentage of cells in the IGL+WM layers, but not the total number of 
cells, indicating that the significant change in Nes-mYap cKOs is an increase 
in the production of cells destined to the ML (Fig. 3.4J; Fig. 3.5A,B). 
Consistent with the GFP+ cells in the ML being interneurons produced by WM 
NEPs, there was also a significant increase in the number of cells in the ML 
that expressed PAX2, a marker of differentiating interneurons (Fig. 3.4K). The 
number of PAX2+ cells was slightly higher in the IGL and WM, consistent with 
an overall increase in production of interneurons in the absence of Yap (Fig. 
3.4L; Fig. 3.5C,D). Quantification of S100β+ astrocytes among the GFP+ 
populations in lobule 4/5 revealed an increase in the number of astrocytes in 
the PCL (Fig. 3.4M; Fig. 3.5E,F). These data suggest that YAP normally plays 
a role in attenuating production of interneurons and astrocytes. 
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Figure 3.4 YAP affects differentiation of NEPs during normal postnatal 
CB development. 
 
(A) Schematic of the MASTR technique. (B) Schematic showing experimental 
design. (C-D) Hematoxylin and eosin (H&E) stained midsagittal sections of 
Nes-mYap cKO and control cerebella at P30. Scale bar, 500 µm. (E) Graph of 
the area of midsagittal sections from Nes-mYap cKOs (n = 6) and littermate 
controls (n = 4) at P30. p = 0.1309. (F-G) Representative images from lobule 
4/5 showing IF staining of GFP and DAPI on midsagittal sections from a Nes-
m control and a Nes-mYap cKO at P8. Shades of highlights indicate the 
partition of different layers (EGL, ML, PCL, IGL and WM) within the lobule. 
Scale bar, 100 µm. (H-M) Graphs of the number of GFP+ cells in all the layers 
(H) or in the ML (I) or IGL+WM (J), the number of PAX2+ GFP+ cells in the ML 
(K) and IGL+WM (L), and the number of S100β+ GFP+ cells in the PCL (M), 
per 0.1 mm2 of the total area analyzed in lobule 4/5 from Nes-m controls (n = 3) 
and Nes-mYap cKOs (n = 4) at P8. (H) p = 0.1996;; (J) p = 0.6065; (L) P = 
0.3548; (M) P = 0.0791. Statistical analysis is conducted by unpaired t test. 
Data are presented as mean ± standard deviation (S.D.), and each data point 
represents one animal. 
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Figure 3.5 YAP has mild effects on differentiation of NEPs during normal 
postnatal CB development. 
 
Graphs of the normalized number and percentage of GFP+ cells in different 
layers (A,B), the number and percentage of PAX2+ GFP+ double cells (C,D) 
or S100β+ GFP+ double cells (E,F) within each layer, per 0.1 mm2 of the total 
area analyzed in lobule 4/5 of midsagittal sections from Nes-m controls (n=3) 
and Nes-mYap cKOs (n = 4) at P8. (A) * p = 0.0217, F (5, 15) = 3.722. Data 
are presented as mean ± S.D., and statistical analysis by two-way ANOVA. 
Each data point represents one animal.  
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YAP regulates differentiation of GCPs during normal development  
In order to determine whether YAP plays a role in GCPs during CB 
development, we generated two mutants. First, we deleted Yap from the 
ATOH1-expressing rhombic lip lineage when GCPs and the cerebellar nuclei 
neurons are generated in the embryo and analyzed the size of the P30 CB in 
Atoh1-Cre/+;Yapflox/flox (Atoh1-Yap cKO) mice compared to Yapflox/flox littermate 
controls. Consistent with the weak expression of Yap mRNA in GCPs (Fig. 
3.3A-B,A’-B’,A”-B”), P30 Atoh1-Yap cKOs showed no reduction in the area of 
the midline, or the IGL area or IGL/CB ratio (Fig. 3.6A-G). This lack of a 
phenotype is similar to mice lacking Yap in NEPs (Fig. 3.4C-E), showing that 
loss of YAP in the Atoh1-lineage does not have a major effect on growth of the 
CB during development.  
 
We next used the MASTR approach with an Atoh1-FlpoER to determine 
whether differentiation of GCPs is altered when Yap is removed. Tm was 
administered at P0 to Atoh1-FlpoER/+;R26FSF-GFPcre/+;Yapflox/flox (Atoh1-mYap 
cKO) mice and controls (Atoh1-FlpoER/+; R26FSF-GFPcre/+ or Atoh1-m), and 
then EdU was injected 1 hour prior to sacrifice at P8. The EdU+ outer EGL 
(oEGL) consists of actively proliferating GCPs, and the percentage of post-
mitotic GFP+ GCs in the EdU-negative “inner layers” including inner EGL 
(iEGL), ML, IGL, and WM was determined amongst all GFP+ cells (Fig. 3.6H-I, 
H’-I’). Interestingly, we found that the percentage of GFP+ cells in the “inner 
layers” was significantly higher in Atoh1-mYap cKOs compared to controls 
(Fig. 3.6J), indicating an increase in differentiation, or decrease in self-renewal 
of GCPs. The proliferation index (percent of EdU+ GFP+ cells among all 
GFP+ cells in the oEGL) was similar between Atoh1-mYap cKO and controls 
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(Fig. 3.6K), showing that Yap does not regulate the proliferation rate. Taken 
together, these data indicate YAP plays a minor but negative role on 
differentiation of GCPs into granule neurons. Given this role, all be it mild, of 
Yap in promoting GCP self-renewal, one might have expected a growth defect 
in Atoh1-Yap cKOs. One possibility is that this phenotype is only expressed in 
a mosaic situation, where there is completion between the scattered mutant 
cells and their surrounding wild type neighbors. 
 
In order to determine whether TAZ plays a redundant role in GCPs during CB 
development, we deleted both Taz and Yap from the ATOH1-expressing 
lineage and analyzed the size of the P30 CB in Atoh1-
Cre/+;Yapflox/flox;Tazflox/flox (Atoh1-YapTaz cKO) mice compared to 
Yapflox/flox;Tazflox/flox littermate controls. Similar to Yap mutant alone, P30 
Atoh1-YapTaz cKOs showed no reduction in the area of the midline, or the 
IGL area or IGL/CB ratio (Fig. 3.6L-R). This result suggests that neither YAP 
nor TAZ in the Atoh1-lineage has a major role on growth of the CB during 
development.  
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Figure 3.6 YAP regulates differentiation of GCPs during normal 
development of CB.  
 
(A-D) H&E staining (A-B) and IF detection of the granule cells marker NeuN 
(C-D) on midsagittal sections of cerebella from Atoh1-Yap cKOs and littermate 
control (Ctrl) mice at P30. Scale bars, 500 µm. (E-G) Graphs of the area of the 
midline of the CB (E), the area of the IGL (F), and IGL/CB area ratio (G) in 
Atoh1-Yap cKO (n = 4) and littermate controls (n = 4) at P30. (E) p = 0.8554; 
(F) p = 0.1727; (G) p = 0.1155. (H-I) Representative images from lobule 4/5 
showing IF staining for GFP, EdU, and DAPI on midsagittal sections from an 
Atoh1-m control and Atoh1-mYap cKO at P8. (H’-I’) Magnification of areas 
within dotted lines in H-I. Yellow dashed lines indicate the EGL and the border 
of the outer- and inner-EGL. Scale bars, 100 µm. (J-K) Graphs of the percent 
of differentiated GFP+ cells (in all layers except the oEGL) among all GFP+ 
cells (J) and proliferation index (G) in the midline of the CB in Atoh1-m controls 
(n = 3) and Atoh1-mYap cKOs (n = 3) at P8. (K) p = 0.4670. (L-O) H&E 
staining (L-M) and IF detection of NeuN (N-O) on midsagittal sections of 
cerebella from Atoh1-YapTaz cKOs and littermate control (Ctrl) mice at P30. 
Scale bars, 500 µm. (P-R) Graphs of the area of the midline of the CB (P), the 
area of the IGL (Q), and IGL/CB area ratio (R) in Atoh1-YapTaz cKO (n = 6) 
and littermate controls (n = 6) at P30. (P) p = 0.3110; (Q) p = 0.4977; (R) p = 
0.1807. Data are presented as mean ± S.D., and statistical analysis by 
unpaired t test. Each data point represents one animal. 
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Loss of YAP in the NEP lineage hampers postnatal cerebellum 
regeneration 
To determine any role of YAP in NEPs during injury-induced regeneration of 
the EGL, we mutated Yap in NEPs by administering Tm to Nes-mYap cKOs 
and littermate controls P0 and X-ray irradiating them at P1, and then 
measuring the size of CB at P30 (Fig. 3.7A). Significantly, although Yap 
deletion does not reduce CB growth during development (Fig. 3.4A-E; Fig. 
3.7), Nes-mYap cKO showed a significant reduction in recovery after 
irradiation compared to IR littermate controls (Fig. 3.7). The size of the CB 
(area of the midline) of IR mutants was reduced to 41.3 ± 2.10% of Non-IR 
littermate mutants compared to 50.4 ± 2.75% for IR littermate controls 
compared to Non-IR controls (p = 0.0403) (Fig. 3.7B-F; Fig. 3.8A). Even more 
prominent was a significant reduction in the area of the IGL (p = 0.0005), and 
IGL/CB ratio (p < 0.0001) in Nes-mYap cKOs compared to controls (Fig. 3.7G-
L; Fig. 3.8B-C). Furthermore, the Calbindin+ Purkinje cells failed to form a 
single cell layer in the Nes-mYap cKO CB; instead, the individual Purkinje cells 
were disorganized and dispersed throughout the entire WM-IGL-ML layers 
(Fig. 3.8D-G,D’-G’). The GFAP+ Bergmann glial fibers also appeared 
disorganized and disoriented in the Nes-mYap cKO CB (Fig. 3.8H-K, H’-K’). 
Furthermore, by measuring the IGL area of the CB at P12 and P16, we found 
that Nes-mYap cKOs and littermate controls had a similar IR/Non-IR ratio in 
IGL area at P12 and the CB appeared to be getting smaller at P16 (Fig. 3.9). 
Together, these data indicate a crucial role of YAP in NEPs at a late stage in 
the recovery of postnatal CB growth and cellular organization after IR-induced 
injury to the EGL.  
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Figure 3.7 Loss of YAP in the NEP lineage hampers postnatal cerebellum 
regeneration. 
 
(A) Schematic showing experimental design. (B-E) H&E staining of midsagittal 
sections of the CB from Non-IR and IR animals at P30. Scale bar, 500 µm. (F) 
Graph of the area of midline sections of the CB as a percentage of IR/Non-IR 
animals. P = 0.0403. (G-J) IF detection of NeuN on midsagittal sections of the 
CB from Non-IR and IR animals at P30. Scale bar, 500 µm. (K-L) Graphs of 
the ratio of the area of the midline IGL of IR/Non-IR animals (K) and IGL/CB 
ratio (L) from Nes-mYap cKOs (Non-IR, n = 6; IR, n = 4) and littermate 
controls (Non-IR, n = 4; IR, n = 5) at P30. Data are presented as mean ± S.D., 
and statistical analysis by unpaired t test. Each data point represents one 
animal, and is calculated as the value for each IR mouse (average of 3 
sections) divided by the mean for all the Non-IR littermates, X 100.  
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Figure 3.8 Loss of YAP hinders injury-induced regeneration of the CB 
and disrupts the layered cytoarchitecture. 
 
(A-C) Graphs of the midline CB area (A), the IGL area (B), and IGL/CB area 
ratio (C) from Nes-mYap cKOs (Non-IR, n = 6; IR, n = 4) and littermate 
controls (Non-IR, n = 4; IR, n = 5) at P30. Data are presented as mean ± S.D., 
and statistical analysis by two-way ANOVA. Each data point represents one 
animal. (D-K) Representative images from lobule 4/5 showing IF staining for 
Calbindin (CALB) (D-G) and GFAP (H-K) on midsagittal sections from Nes-
mYap cKOs and littermate controls at P30. (D’-G’) Magnification of areas 
within dotted lines in D-G. (H’-K’, H”-K”) Magnification of areas within dotted 
lines in H-K. Scale bars, 50 µm.  
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Figure 3.9 The defect in recovery from IR in Yap mutants occurs late. 
 
Graph showing the IGL area of IR mice as a percentage of the mean of Non-
IR littermates for Nes-mYap cKOs (red) and controls (blue) at three 
developmental ages (P12, P16, and P30). P12, p = 0.9150; P16, p = 0.1002. 
P12 Nes-mYap cKO: Non-IR, n = 4; IR, n = 4; P12 littermate control: n = 3; IR, 
n = 4; P16 Nes-mYap cKO: Non-IR, n = 3; IR, n = 3; P16 littermate control: n = 
3; IR, n = 3; P30 Nes-mYap cKO: Non-IR, n = 6; IR, n = 4; P16 littermate 
control: n = 4; IR, n = 5. Data are presented as mean ± S.D., and statistical 
analysis by unpaired t-test. Each data point represents one animal.  
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Loss of YAP results in an increase in cell death in NEPs at P2 and in the 
EGL at P12 following IR-induced injury at P1 
To dissect the cellular mechanism underlying the reduced recovery of Nes-
mYap cKOs after IR, we first examined whether YAP plays a role in 
maintaining the survival of NEPs in the PCL following IR. As expected, cell 
death (TUNEL+ particles) was minimal in the CB of Non-IR Nes-mYap cKOs 
and littermate controls given Tm at P0, and cell death was prominent in the 
EGL of IR mice (Fig. 3.10A-F). In addition, Nes-mYap cKOs showed a 1.6-fold 
increase (p = 0.0039) in the density of TUNEL+ cells within the PCL compared 
to IR controls (Fig. 3.10D,E,F). This result indicates that YAP protects NEPs 
from apoptosis following IR, similar to what was observed for GCPs in culture 
(Fernandez et al., 2012).   
 
Next we examined whether YAP is required for migration of NEPs into the 
EGL. The distribution of GFP+ NEP-lineage cells in the different layers of 
lobule 4/5 was quantified in both Nes-mYap cKO and Nes-m control mice at 
P8 (Fig. 3.10A). Unlike the increase in production of interneurons and 
astrocytes in Non-IR Nes-mYap cKOs compared to controls (Fig. 3.4; Fig. 
3.5), the distribution of NEPs in the different layers of the CB in IR mice was 
similar between the two genotypes, including in the EGL, with a slight change 
in the total number of GFP+ cells (Fig. 3.10G-L; Fig. 3.11A-C). This result 
suggests that the initial response of NEPs to irradiation does not depend on 
YAP, including the migration of NEPs from the PCL into the EGL to repopulate 
the GCPs.  
141 
	  
 
 
 
 
 
 
 
 
 
Figure 3.10 Loss of YAP results in more cell death in the PCL after IR-
induced injury. 
 
(A) Schematic showing experimental design. (B-E) Representative images 
from lobule 4/5 showing IF staining of TUNEL, SOX2, and DAPI on midsagittal 
sections from Nes-mYap cKOs and littermate controls at P2. Grey shadow 
highlights the PCL of the lobule. Arrows indicate TUNEL+ particles in the PCL. 
Scale bar, 100 µm. (F) Graph of the number of TUNEL+ particles in the PCL of 
the midline CB from Nes-mYap cKOs (Non-IR, n = 3; IR, n = 3) and littermate 
controls (Non-IR, n = 3; IR, n = 3) at P2. (G-J) Representative images from 
lobule 4/5 showing IF staining of GFP and DAPI on midsagittal CB sections 
from Nes-m controls and Nes-mYap cKOs at P8. Grey shadow highlights the 
EGL of the lobule. Scale bar, 100 µm. (K-L) Graphs of the number of GFP+ 
cells normalized to total area measured in the EGL (K) and the percent of 
GFP+ cells in the EGL among the total number of GFP+ cells (L) from Nes-m 
controls (Non-IR, n = 3; IR, n = 3) and Nes-mYap cKOs (Non-IR, n = 4; IR, n = 
3) at P8. Data are presented as mean ± S.D., and statistical analysis by two-
way ANOVA. Each data point represents one animal.  
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Figure 3.11 Injury of EGL overrides the requirement for YAP in 
differentiation of NEPs. 
 
(A) Graph of the total number of GFP+ cells per 0.1 mm2 of the total area 
analyzed in lobule 4/5. (B-G) Graphs of the number and percentage of GFP+ 
cells in different layers (B,C), the number and percentage of PAX2+ GFP+ 
double cells (D,E) or S100β+ GFP+ double cells (F,G) within each layer per 
0.1 mm2 of the total area analyzed in lobule 4/5 from midsagittal sections of 
Nes-m controls (n=3) and Nes-mYap cKOs (n = 3) at P8. (A) P = 0.2816. (B) * 
P = 0.0180, F (4, 12) = 4.562. (D) * P = 0.0290, F (4, 12) = 3.927. Data are 
presented as mean ± S.D., and statistical analysis by two-way ANOVA. Each 
data point represents one animal.  
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To determine whether the loss of YAP alters the differentiation of NEPs into 
interneurons and astrocytes during irradiation-induced recovery of the CB, we 
quantified the normalized number and the percentage of GFP+ cells that were 
PAX2+ interneurons or S100β+ astrocytes in each layer of lobule 4/5. Unlike 
in Non-IR mice, although the number of PAX2+ interneurons showed a 
significant difference between Yap mutant and control mice, no difference was 
observed in the number or percentage of PAX2+ in any of the layers (Fig. 
3.11D,E). Additionally, there was no difference in the production of S100β+ 
astrocytes between Yap mutant and control mice (Fig. 3.11F,G). These results 
indicate that the requirement for YAP in differentiation of NEPs is over-ridden 
when the EGL of the CB is injured.  
 
We next analyzed the CB at P12, when the EGL is being diminished due to 
increased production of GCs. Given the reduction of the IGL in mutants 
compared to control IR P30 mice, we asked whether YAP plays a role in cell 
survival of GCPs. Strikingly, TUNEL staining in the EGL revealed a significant 
increase in the density of TUNEL+ cells within the EGL of Nes-mYap cKOs 
compared to littermate controls after IR (p = 0.0306; Fig. 3.12). The density of 
TUNEL+ cells within the EGL at P8 was similar between controls and mutants, 
consistent with the similar distribution of GFP+ cells (Fig. 3.13). These results 
indicate that YAP is required for the GCPs to maintain cell survival in the EGL 
during injury-induced recovery.  
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Figure 3.12 Loss of YAP results in more cell death in the EGL at P12 after 
IR-induced injury. 
 
(A) Schematic showing experimental design. (B-E) Representative images 
showing IF staining of TUNEL and DAPI on midsagittal sections from Nes-
mYap cKO and littermate controls at P12. Arrows indicate TUNEL+ particles in 
the EGL. Scale bars, 100 µm. (F) Graph of the density of TUNEL+ particles in 
the EGL (the number of TUNEL+ particles per 0.1 mm2 of EGL area) in 
midline CB sections from Nes-mYap cKOs (Non-IR, n = 3; IR, n = 4) and 
littermate controls (Non-IR, n = 4; IR, n = 4) at P12. Data are presented as 
mean ± S.D., and statistical analysis by two-way ANOVA. Each data point 
represents one animal.  
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Figure 3.13 Loss of YAP does not alter cell death in the EGL at P8.  
 
Graph of the density of TUNEL+ particles in the EGL (the number of TUNEL+ 
particles per 0.1 mm2 of EGL area) in midline CB sections from Nes-mYap 
cKOs and littermate controls at P8. Controls: Non-IR, n = 4; IR, n = 4. Nes-
mYap cKO: Non-IR, n = 3; IR, n = 4. Data are presented as mean ± S.D., and 
statistical analysis by two-way ANOVA. Each data point represents one 
animal.  
  
A BP8 P16
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Loss of Taz in Yap mutants does not abrogate NEP-driven recovery after 
irradiation  
Since TAZ and YAP have been found to have both similar and distinct 
requirements in the development or regeneration of various organs (Deng et 
al., 2016; Hossain et al., 2007; Makita et al., 2008; Morin-Kensicki et al., 2006; 
Reginensi et al., 2013; Tian et al., 2007), and TAZ is expressed in NEPs and 
possibly upregulated in the nucleus after irradiation (Fig. 3.3C-D,C’-D’), we 
asked whether TAZ contributes to the regenerative response following 
irradiation in Nes-mYap cKOs. We first tested any requirement for Taz in 
development of the CB and replenishment of the CB after IR by administering 
Tm at P0 to Nes-FlpoER/+;R26FSF-GFPcre/+;Tazflox/flox (Nes-mTaz cKO) mice and 
littermate controls (Nes-FlpoER/+;Tazflox/flox, or R26FSF-GFPcre/+;Tazflox/flox , or 
Tazflox/flox). Similar to Nes-mYap cKOs, conditional deletion of Taz did not 
affect the size or IGL of the P30 CB (Fig. 3.14; Fig. 3.16). However, unlike 
Nes-mYap cKOs, Nes-mTaz cKOs recovered almost as well as littermate 
control mice after IR (Fig. 3.14; Fig. 3.16). We next ablated both Yap and Taz 
from NEPs using Nes-FlpoER/+;R26FSF-GFPcre/+;Yapflox/flox;Tazflox/flox (Nes-
mYapTaz cKO) mice and littermate controls (Nes-
FlpoER/+;Yapflox/flox;Tazflox/flox, or R26FSF-GFPcre/+;Yapflox/flox;Tazflox/flox , or 
Yapflox/flox;Tazflox/flox) given Tm at P0. Surprisingly, ablation of both Yap and Taz 
did not result in a worse recovery of the CB after injury compared to Nes-
mYap cKOs. On the contrary, Nes-mYapTaz cKOs had no significant 
reduction in the area of the midline CB or IGL, but had a significant, although 
small reduction in the IGL/CB area ratio compared to controls (Fig. 3.17; Fig. 
3.18). The genetic loss of Yap and Taz was confirmed via qRT-PCR analysis 
of the Yap mRNA levels in GFPcre+ NEPs of Nes-mYapTaz cKOs compared 
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to Nes-m control mice at P8 (Fig. 3.15). Significantly, the mRNA expression of 
both genes was greatly reduced. The apparent better recovery of Nes-
mYapTaz cKOs compared to Nes-mYap cKOs could indicate that loss of Taz 
partially rescues the poor recovery observed in Nes-mYap cKOs (Fig. 3.18). 
This result would point to an opposing functional role of TAZ towards YAP, 
consistent with a similar finding in chondrocytes where TAZ competes with 
YAP in interacting with a regulator protein that can modulate cell maturation 
(Deng et al., 2016). Alternatively, the difference in genetic backgrounds of the 
single and double mutants could contribute to the degree of recovery of Yap 
mutant NEPs after IR. 
 
Since YAP mildly affects the differentiation of NEPs during normal 
development of the CB, we next examined whether TAZ also has a function in 
regulation of differentiation of NEPs. The distribution of GFP+ NEP-lineage 
cells in the different layers of lobule 4/5 was quantified in both Nes-mYapTaz 
cKO and Nes-m control mice at P8. Similar to Yap single mutants, Nes-
mYapTaz had a slight change in the number of GFP+ cells compared to 
controls (Fig. 3.19A-C). The number and percentage of PAX2+ interneurons 
were also significantly different between mutants and controls (Fig. 3.19D,E), 
however not specifically in the ML as in Yap mutants, suggesting that TAZ 
plays little role in the differentiation of NEPs into interneurons. The number 
and percentage of S100β+ were similar between mutants and controls (Fig. 
3.19F,G), unlike Yap single mutants that have an increase in astrocytes in the 
PCL, indicating that TAZ antagonizes YAP in the function of NEPs in the PCL.  
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Figure 3.14 Loss of Taz does not affect cerebellar growth during 
development and regeneration. 
 
(A-D) H&E staining of midsagittal sections of cerebella from Non-IR and IR 
animals at P30. Scale bars, 500 µm. (E) Graph of the ratio of the area of the 
CB of IR/Non-IR animals in midline sections. p = 0.5866. (F-I) IF detection of 
NeuN on midsagittal sections of the CB from Non-IR and IR animals at P30. 
Scale bar, 500 µm. (J,K) Graphs of the ratio of IGL area of IR/Non-IR mice (J) 
and IGL/CB area (K) from Nes-mTaz cKOs (Non-IR, n = 6; IR, n = 4) and 
littermate controls (Non-IR, n = 4; IR, n = 7) at P30. (J) p = 0.8945; (K) p = 
0.7335. Data are presented as mean ± S.D., and statistical analysis by 
unpaired t test. Each data point represents one animal, and is calculated using 
each IR measurement divided by the mean of Non-IR mice. 
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Figure 3.15 Yap and Taz mRNA are greatly reduced in YapTaz-mutant 
NEPs. 
 
(A-B) qRT-PCR analysis of the mRNA expression of Yap (A) and Taz (B) 
relative to Gapdh in NEPs isolated by FACS (GFP+ cells) from Nes-m (Control 
NEPs) and Nes-mYapTaz (Mutant NEPs) at P8, as well as GCPs (GFP+ cells) 
from Atoh1-Gfp mice. Data are presented as mean ± S.D., and statistical 
analysis by one-way ANOVA.  
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Figure 3.16 Loss of Taz does not affect cerebellar growth during 
development and regeneration.  
 
(A-C) Graphs of the CB area (A), the IGL area (B), and IGL/CB area ratio (C) 
of midline CB sections from Nes-mTaz cKOs (Non-IR, n = 6; IR, n = 4) and 
littermate controls (Non-IR, n = 4; IR, n = 8) at P30. Data are presented as 
mean ± S.D., and statistical analysis by two-way ANOVA. Each data point 
represents one animal.  
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Figure 3.17 Loss of Taz in Yap mutants does not abrogate NEP-driven 
recovery after irradiation.  
 
(A-D) H&E staining of midsagittal sections of the CB from Non-IR and IR 
animals at P30. Scale bars, 500 µm. (E) Graph of the ratio of the midline CB 
area IR mice as a ratio of Non-IR littermates of the same genotype. p = 
0.3815. (F-I) IF detection of NeuN on midsagittal sections of the CB from non-
IR and IR animals at P30. Scale bar, 500 µm. (J,K) Graphs of the area of the 
IGL (J) and IGL/CB area (K) as a ratio of Non-IR littermates of the same 
genotype in midsaggital sections from Nes-mYapTaz cKOs (Non-IR, n = 7; IR, 
n = 6) and littermate controls (Non-IR, n = 4; IR, n = 7) at P30. (J) p = 0.1637; 
(K) p = 0.0383. Data are presented as mean ± S.D., and statistical analysis by 
unpaired t test. Each data point represents one animal, and is calculated using 
each IR divided by the mean of Non-IR X 100. 
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Figure 3.18 Loss of Taz in Yap mutants does not abrogate NEP-driven 
recovery after irradiation. 
 
(A-C) Graphs of the midline CB area (A), the IGL area (B), and IGL/CB area 
as a percentage (C) for IR mice as a ratio of Non-IR littermates of the same 
genotype. Nes-mYazTaz cKOs (Non-IR, n = 7; IR, n = 6) and littermate 
controls (Non-IR, n = 4; IR, n = 7) at P30. Data are presented as mean ± S.D., 
and statistical analysis by two-way ANOVA. Each data point represents one 
animal. (D-F) Graphs of the ratio of IR/Non-IR animals as a percentage for 
midline CB area (D), the IGL area (E), and IGL/CB area ratio (F) from Nes-m 
controls (Non-IR, n = 6; IR, n = 5), Nes-mYap cKO (Non-IR, n = 6; IR, n = 4), 
Nes-mYazTaz cKO (Non-IR, n = 7; IR, n = 6), and Nes-mTaz cKO (Non-IR, n 
= 6; IR, n = 4), at P30. Data are presented as mean ± S.D., and statistical 
analysis by one-way ANOVA. Each data point represents one animal.  
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Figure 3.19 Loss of Yap and Taz mildly affects differentiation of NEPs 
during normal development of CB. 
 
(A) Graph of the total number of GFP+ cells per 0.1 mm2 of the total area 
analyzed in lobule 4/5. (B-G) Graphs of the number and percentage of GFP+ 
cells in different layers (B,C), the number and percentage of PAX2+ GFP+ 
double cells (D,E) or S100β+ GFP+ double cells (F,G) within each layer per 
0.1 mm2 of the total area analyzed in lobule 4/5 from midsagittal sections of 
Nes-m controls (n=3) and Nes-mYapTaz cKOs (n = 3) at P8. (A) P = 0.3430. 
(B) * P = 0.0108, F (4, 12) = 5.294. (D) * P = 0.0353, F (4, 12) = 3.681. (E) * P 
= 0.0405, F (4, 12) = 3.511. Data are presented as mean ± S.D., and statistical 
analysis by two-way ANOVA. Each data point represents one animal.  
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DISCUSSION 
The pivotal role of the Hippo signaling pathway in brain development has been 
extensively studied in Drosophila, a model organism in which the Hippo 
pathway itself was first discovered. For example, disruption of Hippo signaling, 
through either loss-of-function mutations in several core kinases or over-
expression of the Drosophila YAP homolog Yorkie, results in increased 
neuroblast proliferation and substantial brain overgrowth (Poon et al., 2016).  
In the mouse, loss of YAP in cortical neural progenitors leads to subtle defects 
in cortical development (Park et al., 2016), whereas genetic ablation of both 
Yap and Taz in radial glial progenitors results in profound cortical defects, 
(Kong, 2018). The more severe phenotype in YapTaz double mutants 
suggests functional redundancy between YAP and TAZ, or that the time 
difference in the onset of genetic ablation with the different Cre lines used in 
the two studies is critical. In this study, we explored the roles of YAP and TAZ 
in development and postnatal regeneration of the mouse cerebellum. 
Consistent with the subtle role of YAP in cortical development (Park et al., 
2016), YAP ablation from NEPs or GCPs did not affect the overall size of the 
adult CB. We nevertheless observed minor defects in the differentiation of 
NEPs and GCPs (Fig. 3.20). Unlike in cortical development, genetic ablation of 
both Yap and Taz in NEPs or GCPs did not affect growth of the CB, 
suggesting that YAP and TAZ might have distinct functions in different brain 
regions. The difference in severity of the phenotypes, however, could be due 
to the later time of Cre activity onset in our study of the CB. It is likely that 
additional pathways or regulatory cues cooperate with Hippo signaling to 
ultimately ensure normal growth of the CB.  
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Figure 3.20 Model of the cellular responses during the development and 
impaired regeneration of the neonatal cerebellum in Nes-mYap mouse 
after irradiation at P1. 
(Adapted from (Wojcinski et al., 2017)) 
 
In Non-IR Nes-mYap mice, the growth of cerebella is not altered during 
development, with normal CB size and Internal Granule Layer (IGL). Genetic 
ablation of Yap from Nestin-Expressing Progenitors (NEPs) promotes the 
differentiation of White Matter (WM) NEPs into interneurons (INs) in the 
Molecular Layer (ML), and the differentiation of Purkinje Cell Layer (PCL) 
NEPs into astrocytes (Astro).  
In IR Nes-mYap mice, depletion of the External Granule Layer (EGL) during 
the first days of postnatal cerebellar development leads to the expansion and 
migration of NEPs in the PCL that normally produce Astrocytes (Astro) and 
Bergmann Glia (Bg) to the EGL. At P12 in IR Nes-mYap mice have an 
increase in GCP cell death compared to that in control mice that likely 
accounts for the poor recovery of the IGL and much fewer Granule Cells 
(GCs). The differentiation of NEPs, however, is overridden in IR cerebella. 
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Although YAP does not have a major role in growth of the CB during 
development, we demonstrated that it has a minor role in differentiation of 
GCPs and NEPs, and a major requirement for postnatal regeneration following 
irradiation. A similar paradigm has also shown to be true in the liver, as YAP 
seems dispensable for the growth of liver to achieve relatively normal liver to 
body weight ratios during normal development, but is required for its proper 
regeneration (Lu et al., 2018). Moreover, mechanical changes of normal and 
diseased tissues have been shown to alter YAP/TAZ activities and thereby 
change proliferation and differentiation of progenitor cells (Vining and Mooney, 
2017). In particular, YAP activity depends on force-dependent nuclear 
translocation (Elosegui-Artola et al. Cell 2017). Thus it is possible that YAP is 
activated by drastic mechanical changes of tissues caused by acute injury and 
then acts to promote regeneration.  
 
Several lines of evidence suggest an intersection or coupling of the Hedgehog 
(HH) and Hippo pathways in Drosophila and mice (Fernandez et al., 2009; 
Huang and Kalderon, 2014). Specifically, in flies elevated Hh signaling (ptc 
mutants) induces Yorkie target gene activities, while additional Yorkie deletion 
abolishes the effects of excess Hh signaling on cell proliferation and survival 
(Huang and Kalderon, 2014). In cultured mouse GCPs, SHH treatment 
increases the transcription and nuclear localization of YAP protein (Fernandez 
et al., 2009). Our previous study showed that SHH signaling is required for 
NEPs to regenerate the mouse CB (Wojcinski et al., 2017). Thus it is possible 
that SHH signaling activates YAP to promote the survival of GCPs derived 
from NEPs. On the other hand, comparison of Nes-Smo cKO and Nes-Yap 
cKO phenotypes after irradiation of the CB reveals an immediate defect in 
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recovery in the Nes-Smo cKOs, compared to the late defect in Nes-Yap cKOs. 
One possibility is that SHH has other target genes besides Yap that are 
required for proliferation and migration of NEPs.  
 
Using genetic knockout of Yap in the Nestin-expressing NEPs and Atoh1-
expressing GCPs, we found that YAP restricts differentiation of neural 
progenitors and thus likely maintains self-renewal. In particular, loss of YAP 
results in an increase in differentiation of NEPs (PCL NEPs to produce 
astrocytes and WM NEPs to produce interneurons) and GCPs (to produce 
granule cells) between P1 and P8. This finding is consistent with recent 
studies that emphasize the functional role of YAP in modulating a timely 
transition from cell proliferation into differentiation. For example, YAP over-
activation in mouse intestine or chick neural tube leads to expansion of 
progenitor cells and loss of differentiated cells	  (Camargo et al., 2007; Cao et 
al., 2008). It was also shown that cultured myoblasts with YAP overexpression 
failed to differentiate and form myotubes (Watt et al., 2010), and reduced 
Hippo signaling in mouse results in hyper-proliferation and failure of 
differentiation in multiple epithelial cell types (Lee et al., 2008). In a recent 
study, loss of the Hippo pathway kinases LATS1/2 was found to result in 
YAP/TAZ-driven hypertranscription, which resulted in impaired cortical neural 
progenitor differentiation and promotion of a transient over-proliferation 
(Lavado et al., 2018). Together, these lines of evidence provide an 
explanation for the increase in differentiation at the likely expense of self-
renewal when Yap is removed from NEPs or GCPs in a mosaic manner.  
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YAP and TAZ have often been found to have overlapping functions, consistent 
with their significant homology and common binding partners, but some recent 
studies point to distinct roles in addition to overlapping functions of YAP and 
TAZ that appear to be context dependent. For example, Yap null mutant mice 
are embryonical lethals (Morin-Kensicki et al., 2006), whereas Taz nulls only 
show partial embryonic lethality and surviving mice have lung defects and 
kidney disease (Hossain et al., 2007; Makita et al., 2008; Tian et al., 2007). It 
has also been shown that TAZ competes with YAP in an interaction with a 
regulator protein that modulates the maturation of chondrocytes, a critical step 
for skeletal development and bone repair (Deng et al., 2016). Similarly in our 
study, Yap ablation from NEPs leads to poor recovery of the postnatal CB 
following acute injury, but deletion of Taz does not abrogate regeneration. 
Double conditional Yap and Taz mutants instead show a milder phenotype 
than Yap cKOs, indicating that loss of Taz partially rescues the Yap mutant 
phenotype. This finding raises the possibility of antagonizing functions 
between YAP and TAZ in the CB as in the bone compared to overlapping 
functions under other circumstances. Thus it will be important to dissect the 
distinct downstream molecular pathways of the two co-activators to reveal 
context-dependent functions of the Hippo pathway. Leveraging this knowledge 
will pave the road for potential therapeutic intervention for cerebellar 
hypoplasias caused by injury. 
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MATERIALS AND METHODS 
 
Mice 
The following mouse lines were used: Nes-CFP (Mignone et al., 2004), Atoh1-
GFP (Chen et al., 2002), Nestin-FlpoER (Wojcinski et al., 2017), Atoh1-
FlpoER, Rosa26MASTR(frt-STOP-frt-GFPcre) (Lao et al., 2012), Yapflox/flox and 
Yapflox/flox;Tazflox/flox	  (Reginensi et al., 2013), and Atoh1-Cre (Matei et al., 2005). 
Tamoxifen (Sigma, T5648) was dissolved in corn oil at 20 mg/mL and a single 
dose of 200 µg/g was administered to P0 animals by subcutaneous injection. 
Mouse husbandry and all experiments were performed in accordance with 
MSKCC IACUC-approved protocols.  
 
Irradiation 
P1 mice were anesthetized by hypothermia and received a single dose of 4 
Gy irradiation in an X-RAD 225Cx (Precision X-ray) Microirradiator in the 
MSKCC Small-Animal Imaging Core Facility. A 5-mm diameter collimator was 
used to target the CB from the left side of the animal. 
 
Tissue Processing 
For animals younger than P4, brains were dissected out and fixed in 4% 
paraformaldehyde overnight at 4°C. Animals P4-30 were anesthetized and 
transcardially perfused with PBS followed by chilled 4% paraformaldehyde. 
Brains were harvested and post-fixed overnight and cryoprotected in 30% 
sucrose before freezing in Cryo-OCT. Frozen brains were sectioned at 12 µm 
on a cryostat, and sagittal sections of the midline of the CB were used for all 
analyses.  
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Immunofluorescent (IF) staining 
Cryosections were stained overnight at 4°C with the following primary 
antibodies: mouse anti-YAP (Abcam, AB56701), rabbit anti-TAZ (Santa Cruz, 
sc-48805), rat anti-GFP (1:1,000; Nacalai Tesque; 0440484), mouse anti-
NeuN (Millipore, MAB377), rabbit anti-Calbindin D-28K (Swant, CB38), rabbit 
anti-GFAP (Dako, Z0334), rabbit anti-S100β (Dako, Z0311), rabbit anti-PAX2 
(Invitrogen, 71600), and goat anti-SOX2 (R&D System, AF2018). Secondary 
antibodies for double labeling were donkey anti-species conjugated with Alexa 
Fluor 488 or 555 (1:1,000; Molecular Probes). Nuclei were counterstained with 
Hoechst 33258 (Invitrogen, H3569). 
 
Microscopy 
Images were collected either on a DM6000 Leica microscope using Zen 
software (Zeiss), or NanoZoomer 2.0 HT slide scanner (Hamamatsu 
Photonics) using NDP.scan software. All images were taken with 20X 
objectives, and	  processed using NDP.view2 and Photoshop software.	  
 
Flow Cytometry 
Cerebella of Atoh1-GFP and Nes-CFP mice were dissected out under a 
dissecting microscope. Tissues were digested in Trypsin/DNase, and then 
subjected to FACS (fluorescence activated cell sorting) to isolate GFP+ or 
CFP+ cells. RNA was extracted from GFP+ or CFP+ cells of individual 
cerebella and then subject to qRT-PCR analysis.  
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qRT-PCR 
RNA was isolated from FACS-isolated GFP+ cells from P4 Atoh1-GFP mice, 
FACS-isolated CFP+ cells from P4 Nestin-CFP mice, FACS-isolated GFP+ 
cells from Nes-m and Nes-mYap mice at P8, using a miRNeasyMicro Kit 
(Qiagen) according to the manufacturer’s protocol. cDNA was prepared using 
iScript cDNA synthesis kit (Bio-Rad). qRT-PCR was performed using PowerUp 
Sybr Green Master Mix (Applied Biosystems). Fold changes in expression 
were calculated using the ΔΔCt method. The Gapdh gene was used to 
normalize the results. The following primer pairs were used: Yap forward 5′- 
ACCCTCGTTTTGCCATGAAC-3′, Yap reverse 5′- 
TGTGCTGGGATTGATATTCCGTA-3′, Gapdh forward 5′- 
CCAAGGTGTCCGTCGTGGATCT-3′, and Gapdh reverse 5′- 
GTTGAAGTCGCAGGAGACAACC-3’. 
 
Quantification and statistical analysis 
ImageJ software was used to measure the area (mm2) of cerebellar section 
near the midline. For all IF staining, cell counts were obtained using Stereo 
Investigator Software. Three sections per animal and at least three animals 
per genotype and condition were analyzed for quantification. Statistical 
analyses were performed using Prism software (GraphPad) and significance 
was determined at P < 0.05. All statistical analyses were two-tailed. For two-
group comparisons with equal variance as determined by the F-test, an 
unpaired Student’s t test was used. For comparisons among four independent 
groups with equal variance, an unpaired one-way ANOVA was used. For 
comparisons between groups that are split with two independent variables, an 
unpaired two-way ANOVA was used. P values and degrees of freedom are 
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given in the figure legends. Data are presented as mean ± S.D. (standard 
deviation). No statistical methods were used to predetermine the sample size, 
but our sample sizes are similar to those generally employed in the field. No 
randomization was used. Data collection and analysis were not performed 
blind to the conditions of the experiments. 
 
EdU (5-ethynyl-2’-deoxyuridine) Injection and Staining  
For assessing cell proliferation, EdU (Invitrogen, E10187) was given at 100 
mg/g by i.p. injection 1 h before euthanasia. Click-it EdU assay with Sulfo-
Cyanine5 azide (Lumiprobe corporation, A3330) was used according to the 
protocol of the manufacturer. 
 
TUNEL Staining 
For TUNEL staining, slides were permeabilized with 0.5% TritonX-100, pre-
incubated with Tdt buffer (30 mM Tris·HCl, 140 mM sodium cacodylate and 1 
mM CoCl2) for 15 min at room temperature, and incubated for 1 h at 37 °C in 
TUNEL reaction solution containing Terminal Transferase (Roche, 
03333574001) and Digoxigenin-11-dUTP (Sigma-Aldrich, 11093088910). 
Then slides were incubated with anti-digoxigenin-rhodamine (Sigma-Aldrich, 
11207750910) for 1 h. 
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Chapter 4 Conclusions and future directions 
 
The Hedgehog and Hippo pathways are two master regulators with divergent 
effects on tissue growth during development. Active HH signaling promotes 
cell expansion and morphogenesis, while active Hippo signaling contains 
organ growth. Thus, it would be intriguing to investigate further how the HH 
and Hippo pathways coordinate and fine-tune within a network of signaling 
molecules to ensure complete development of organs or organisms and that 
they attain their proper sizes. One possibility is that the HH and Hippo 
pathways exert their functions in a stepwise manner, such that HH stimulates 
major cell expansion of cell number and tissue growth, followed by Hippo 
downregulating or putting the breaks on growth to avoid overgrowth. It is also 
possible that both the HH and Hippo pathways act simultaneously and 
continuously maintain a growth equilibrium throughout the whole 
developmental process, so the growth of organs move on steadily at the 
correct pace until it is halted. Interestingly, the activities of both signaling 
pathways tend to decline with the completion of embryonic development and 
are maintained at low but detectable levels in adults, to regulate tissue 
homeostasis. Even though SHH and Hippo activities remain relatively 
quiescent in normal adult organs, they can be exploited in different biological 
contexts that require rapid cell proliferation and tissue growth, for example, 
organ regeneration and cancer. The work described in my thesis investigated 
both processes, specifically the role of HH signaling in prostate cancer and 
Hippo signaling in cerebellar regeneration. Our findings provide new insights 
into the complex modes of action and functions that developmental signaling 
pathways have in cancer progression and tissue regeneration.  
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Hedgehog signaling in the tumor stroma restrains prostate cancer 
progression in a mouse model 
A majority of the tumor xenograft studies using prostate cancer cell lines 
suggested that HH pathway blockade by cyclopamine suppresses tumor 
growth (Fan et al., 2004; Karhadkar et al., 2004). However, in my thesis work, 
a genetic mouse model showed that ectopic activation of HH signaling in the 
Gli1-expressing subset of stromal cells leads to decreased tumor progression, 
suggesting that the tumor stroma can restrain PCa progression (Yang et al., 
2017). This finding is consistent with several other studies in pancreas and 
bladder cancers, which showed that inhibition of HH signaling in the stroma 
decreases survival (Lee et al., 2014; Rhim et al., 2014; Shin et al., 2014). 
Additionally, in mouse models of colon cancer, stroma-specific HH activation 
inhibits tumor progression, while decreased HH activity accelerates colon 
tumourigenesis (Gerling et al., 2016; Lee et al., 2016). One difference between 
in vitro cell line studies and in vivo mouse studies may rest on the differential 
functions of HH signaling in cancer cells and its surrounding stromal cells. HH 
signaling activation in cancer cells may promote tumorigenesis through cell-
autonomous functions, while HH signaling activation in stromal cells may exert 
cell-non-autonomous effects and inhibit the growth of cancer cells via 
reciprocal signaling. Thus, it will be interesting to systematically dissect the 
functions and interplay of HH signaling in cancer cells and its various types of 
stromal cells through in vivo mouse genetics. Although in vivo models have 
obvious superiorities to in vitro models, caution is still needed for the 
interpretation of studies using mouse models. As demonstrated in the three 
mouse models used in my thesis research, each mouse model exhibits a 
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distinct tumor microenvironment, and the models likely only represent a certain 
subset or a particular stage of the environment in human prostate tumors. 
Indeed, most genetically modified mouse models only simulate a limited part 
of normal cancer progression. Given the lack of reliable and robust prostate 
cancer metastasis mouse models, the effects of HH signaling in tumor 
metastasis are hard to determine.  
 
Besides the extrinsic signaling coming from the stromal microenvironment in 
response to SHH signaling that acts as a brake on overgrowth of prostate 
cancer, an alternative mechanism for size control is intrinsic signaling cues. 
The Hippo pathway is a very appealing potential candidate. Tissue 
regeneration is also a process that requires strict control on cell expansion and 
organ growth. The adult prostate gland has a remarkable capability for 
regeneration with the addition of exogenous testosterone after castration-
induced glandular involution (Isaacs, 1985). Amazingly, such cycles of 
involution and regeneration can be repeated over 30 times, and regenerated 
prostates always appear to completely reconstitute the architecture and 
restore the proper size. Such a precise control on the size of regenerated 
prostates raises an intriguing possibility that the Hippo pathway is likely 
responsible during regeneration to stop growth at the correct time. This idea 
can also be tested in other organs that have similar behavioral patterns of 
regeneration, for example, the liver.  
 
YAP is essential for regeneration of the neonatal cerebellum after injury 
In Chapter 3, I showed that YAP is required for a thorough restoration of 
cerebellum size and structure following irradiation at postnatal day 1 (P1). 
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However, it was not tested whether functional recovery of the cerebellar 
circuits is also affected by YAP ablation. A variety of behavioral tests for motor 
functions could be conducted, including footprint analysis, rotarod test, and 
fore limb grip strength test.  
 
Although my thesis research focused on biological functions of YAP in 
cerebellar regeneration, it is possible that a mechanical force dependent 
mechanism of YAP signaling also plays a role during injury-induced recovery. 
Recently, emerging evidence indicates that the Hippo pathway plays a 
mechano-sensitive signaling mechanism to sense and convert physical 
changes into biochemical, cellular, and morphogenetic events (Elbediwy et al., 
2018; Elosegui-Artola et al., 2017; Koser et al., 2016). Mechanical force is 
transmitted through extracellular matrix-nuclear coupling to stretch the nuclear 
pore resulting in nuclear translocation of YAP (Elosegui-Artola et al., 2017), 
which triggers downstream transcriptional programs for cell proliferation. 
Although the mechanical force-mediated cell proliferation changes are mostly 
documented in epithelial cells in vitro (Benham-Pyle et al., 2015; Gudipaty et 
al., 2017), it is increasingly appreciated that neurodevelopmental processes 
create diverse physical environments and may also take advantage of 
physical changes to direct tissue morphogenesis (Barnes et al., 2017; Vining 
and Mooney, 2017). For example, differential local tissue stiffness guides the 
axonal growth of retinal ganglion cells towards softer tissues in the developing 
Xenopus brain (Koser et al., 2016). Beyond normal biological contexts, tissue 
stiffness also plays a key role in carcinogenesis to mediate brain tumor 
progression (Barnes et al., 2017). Thus, it is possible that irradiation-induced 
injury creates an acute change in the physical environment in the neonatal 
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cerebellum. Consequently, Nestin-expressing progenitors (NEPs) may sense 
such changes through YAP activity and undergo over-proliferation to repair 
tissue damage.   
 
My results showed that ablation of YAP in the irradiated cerebellum resulted in 
pronounced disorganization of Purkinje cells and Bergmann glial fibers in the 
adult stage. This phenotype is likely a secondary effect of the failure of the 
GCPs to generate an internal granule cell layer (IGL) in Yap mutants. 
Alternatively, Yap depletion results in a cell autonomous defect in Bergamnn 
glia, which in turn hinders the migration of GCPs into the IGL. This possibility 
is consistent with the observation that cell death in the Purkinje cell layer of 
Yap mutants is significantly elevated 1 day after irradiation compared to 
littermate controls (Fig. 3.10). Since Bergmann glial cells are situated in the 
Purkinje cell layer, it is possible that the elevated cell death is in the Bergmann 
glial population. Staining using a Bergmann glial markers BLBP can test this 
hypothesis, and the number of + Bergmann glial cells at P3 can be quantified 
to examined whether Yap mutant has less number of Bergmann glial cells.  
 
Although YAP deletion did not affect the initial migration of NEPs into the EGL 
(at P8) after irradiation, it is possible that the migration of NEP-derived GCPs 
into the IGL is defective in Yap mutants. Indeed, YAP has been shown to 
regulate the migration of vascular tip cells and human glioma cells (Sakabe et 
al., 2017; Zhang et al., 2018). Therefore, the poor cerebellar recovery of Yap 
mutants may also be attributed to impairment in migration of NEP progenies 
into the IGL after they reached the EGL. In order to test this hypothesis, live 
imaging of GFP+ NEPs at P12 and P14 can be conducted such that migration 
177 
	  
of NEPs can be observed directly. In addition, co-staining of centrosome 
markers and GFP in P12-P14 cerebella can be used to indicate the direction 
of migration. Alternatively, potential morphological defects in the leading 
processes of Yap-mutant NEPs might also be directly observed.  
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Table 2.3A List of genes with significant differential expressions 
(p<0.05, FDR<0.05, fold change >1.5). 
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Gene Symbol P-value  (Tumor vs. WT) 
FDR step up 
(Tumor vs. WT) 
Fold change 
(Tumor vs. WT) 
Hoxc5 5.58E-06 2.71E-03 18032.52 
Lppr4 2.71E-05 7.51E-03 8630.71 
Hoxc8 6.38E-04 4.38E-02 5598.42 
Hoxc6 1.06E-05 4.15E-03 4929.21 
Has3 2.74E-06 1.63E-03 4143.30 
Apol8 5.02E-05 1.04E-02 4021.21 
Hotair 6.52E-10 6.02E-06 3993.11 
Hoxa4 5.96E-05 1.20E-02 3505.57 
Pydc4 1.53E-07 3.15E-04 3289.95 
Col9a3 4.11E-04 3.57E-02 3175.37 
AU040972 1.42E-04 2.04E-02 3047.99 
Gm20758 3.72E-05 8.52E-03 3013.69 
Hspb9 1.08E-11 1.99E-07 2949.93 
Clec4n 3.00E-04 3.08E-02 2870.50 
Mcm10 3.62E-05 8.52E-03 2607.49 
Cyp3a41a 2.63E-05 7.49E-03 2343.74 
Sall4 2.16E-05 6.59E-03 2291.24 
Gfi1b 6.19E-06 2.79E-03 2089.07 
Cd300ld 3.71E-05 8.52E-03 1925.99 
Polq 5.23E-04 3.99E-02 1830.24 
Gprc5d 1.58E-06 1.22E-03 1774.08 
Trim67 1.48E-04 2.06E-02 1595.79 
Actbl2 4.24E-04 3.60E-02 1590.05 
Cd1d2 7.90E-05 1.41E-02 1353.41 
Npb 2.41E-05 6.95E-03 1334.04 
Gphb5 5.57E-04 4.13E-02 1297.87 
4930502E09Rik 1.53E-05 5.34E-03 1176.84 
Cyp3a41b 3.94E-05 8.88E-03 1116.74 
Spem1 3.07E-04 3.12E-02 1017.34 
Gm15350 1.16E-04 1.85E-02 929.04 
Psmb11 8.79E-05 1.52E-02 829.12 
Wnt3 1.23E-06 1.03E-03 803.99 
1700001D01Rik 2.41E-04 2.69E-02 778.85 
Platr7 1.75E-04 2.28E-02 748.43 
Cst7 5.77E-05 1.18E-02 563.79 
4930511A08Rik 3.51E-05 8.52E-03 548.58 
182 
	  
Table 2.3A (Continued)	  
Gene Symbol P-value  (Tumor vs. WT) 
FDR step up 
(Tumor vs. WT) 
Fold change 
(Tumor vs. WT) 
4930544G11Rik 3.51E-05 8.52E-03 548.58 
Rnf151 3.51E-05 8.52E-03 548.58 
Snora34 5.72E-07 8.13E-04 348.73 
Matn4 1.58E-04 2.15E-02 17.07 
A430090L17Rik 3.14E-04 3.14E-02 6.79 
Adamts16 6.32E-04 4.36E-02 6.51 
Hp 1.79E-04 2.30E-02 5.41 
Fam166a 7.59E-04 4.91E-02 3.89 
Snx29 3.98E-04 3.53E-02 3.76 
Syne1 4.88E-04 3.85E-02 3.25 
1700024P16Rik 5.07E-04 3.92E-02 3.21 
Cdon 3.21E-04 3.17E-02 2.88 
Cbx4 2.85E-04 2.95E-02 2.73 
Sp110 1.52E-04 2.08E-02 2.69 
Mycbp2 4.50E-04 3.73E-02 2.40 
Fam193b 6.46E-04 4.40E-02 2.34 
Zfp395 6.70E-04 4.50E-02 2.24 
Lemd2 4.43E-04 3.70E-02 1.82 
Ldb1 1.87E-04 2.35E-02 1.72 
Rpe 2.40E-04 2.69E-02 -1.56 
Tstd2 5.93E-04 4.23E-02 -1.57 
Cbx5 4.44E-04 3.70E-02 -1.58 
Pef1 1.45E-04 2.06E-02 -1.59 
Sumo2 4.17E-04 3.60E-02 -1.59 
Pus7l 2.23E-04 2.61E-02 -1.59 
Ndufv2 1.66E-04 2.22E-02 -1.59 
Gtf3c3 1.16E-04 1.85E-02 -1.60 
Smdt1 4.06E-04 3.56E-02 -1.63 
Cgrrf1 1.26E-04 1.90E-02 -1.64 
Ssu72 5.20E-04 3.99E-02 -1.66 
Cops3 3.78E-04 3.41E-02 -1.67 
Atp6v0e 2.64E-04 2.86E-02 -1.68 
Rps27l 2.44E-04 2.70E-02 -1.69 
Psmd7 3.61E-04 3.33E-02 -1.71 
Prelid1 5.14E-04 3.96E-02 -1.72 
Abhd12 3.32E-04 3.24E-02 -1.72 
Psmb2 6.02E-04 4.25E-02 -1.72 
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Gene Symbol P-value  (Tumor vs. WT) 
FDR step up 
(Tumor vs. WT) 
Fold change 
(Tumor vs. WT) 
Ciapin1 3.44E-04 3.31E-02 -1.75 
Ndufa12 4.54E-04 3.73E-02 -1.75 
Sike1 6.58E-04 4.45E-02 -1.77 
Rbp1 3.60E-04 3.33E-02 -1.79 
Fam63a 6.67E-04 4.50E-02 -1.80 
Psma5 3.42E-04 3.31E-02 -1.80 
Gskip 4.41E-04 3.70E-02 -1.80 
Rab4b 6.08E-04 4.25E-02 -1.80 
Rqcd1 1.81E-04 2.31E-02 -1.81 
BC031181 1.67E-04 2.22E-02 -1.84 
Msantd4 2.32E-04 2.67E-02 -1.87 
Slc2a10 7.29E-04 4.76E-02 -1.88 
Exoc3 7.31E-04 4.76E-02 -1.93 
Gpx1 7.40E-05 1.36E-02 -1.94 
Ran 2.37E-04 2.69E-02 -1.94 
Psmd8 1.72E-04 2.27E-02 -1.97 
Eif5a 7.03E-04 4.66E-02 -1.97 
Cope 4.91E-04 3.85E-02 -1.99 
Gng10 2.84E-04 2.95E-02 -2.00 
Cox5a 3.49E-04 3.33E-02 -2.02 
6030408B16Rik 1.48E-04 2.06E-02 -2.02 
Fkbp1a 5.76E-04 4.20E-02 -2.04 
Sgsm3 6.07E-04 4.25E-02 -2.07 
Wdr1 5.89E-04 4.22E-02 -2.07 
Suclg1 1.79E-04 2.30E-02 -2.08 
Ptcd2 3.84E-04 3.44E-02 -2.08 
Plp2 7.79E-04 5.00E-02 -2.08 
Cers4 2.19E-04 2.60E-02 -2.10 
Ccl7 2.42E-04 2.69E-02 -2.11 
Nelfa 2.04E-04 2.51E-02 -2.11 
Minos1 3.72E-04 3.39E-02 -2.11 
Col6a1 2.46E-04 2.70E-02 -2.12 
Prdx4 5.34E-04 4.06E-02 -2.13 
Nme1 3.56E-04 3.33E-02 -2.16 
Higd1a 4.07E-04 3.56E-02 -2.18 
Ptpn14 5.86E-04 4.21E-02 -2.19 
Alad 6.04E-04 4.25E-02 -2.25 
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Gene Symbol P-value  (Tumor vs. WT) 
FDR step up 
(Tumor vs. WT) 
Fold change 
(Tumor vs. WT) 
Rcl1 1.26E-04 1.90E-02 -2.26 
Mrpl20 6.19E-04 4.28E-02 -2.36 
Ccnd2 5.44E-04 4.11E-02 -2.45 
Actg1 1.22E-04 1.89E-02 -2.80 
B3gnt2 2.39E-04 2.69E-02 -2.86 
Tpm1 4.70E-04 3.74E-02 -2.99 
Anxa2 6.90E-04 4.60E-02 -2.99 
Bok 2.21E-04 2.60E-02 -3.35 
Synpo2 5.73E-04 4.20E-02 -3.50 
Ociad2 3.21E-04 3.17E-02 -3.74 
Ccnd1 6.72E-04 4.50E-02 -4.03 
Lgals3 2.74E-04 2.92E-02 -4.04 
Msmo1 5.86E-04 4.21E-02 -4.08 
Pwwp2b 6.96E-04 4.62E-02 -4.20 
Fdps 3.73E-05 8.52E-03 -4.26 
Ucp2 1.17E-04 1.85E-02 -4.33 
Hopx 5.60E-04 4.14E-02 -4.37 
Id1 4.58E-04 3.73E-02 -4.55 
B4galnt1 1.38E-04 2.01E-02 -5.36 
Tubb4a 4.90E-04 3.85E-02 -5.46 
S100a4 7.67E-04 4.94E-02 -5.65 
Pde9a 8.77E-05 1.52E-02 -5.85 
Nedd9 2.67E-04 2.87E-02 -6.55 
Bhlhe40 4.10E-04 3.57E-02 -6.60 
Cav1 4.18E-05 9.08E-03 -7.38 
Tes 6.55E-04 4.45E-02 -7.44 
Tmem132c 1.83E-04 2.31E-02 -7.58 
Comp 1.74E-04 2.28E-02 -7.80 
Cib2 7.19E-04 4.73E-02 -8.16 
Adrb2 2.14E-04 2.55E-02 -8.18 
Sqle 1.32E-04 1.95E-02 -8.27 
Kdr 1.51E-05 5.34E-03 -8.84 
Zdhhc14 7.04E-05 1.33E-02 -9.17 
S1pr1 3.41E-04 3.31E-02 -9.88 
Cx3cl1 5.85E-04 4.21E-02 -11.18 
Pmaip1 1.05E-04 1.77E-02 -11.48 
Perp 4.58E-04 3.73E-02 -12.97 
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Table 2.3A (Continued)	  
Gene Symbol P-value  (Tumor vs. WT) 
FDR step up 
(Tumor vs. WT) 
Fold change 
(Tumor vs. WT) 
Gpc1 3.72E-04 3.39E-02 -13.11 
Mboat2 6.02E-04 4.25E-02 -13.23 
Etv1 5.81E-04 4.21E-02 -14.89 
Efnb2 2.85E-04 2.95E-02 -19.02 
Tinagl1 4.99E-04 3.88E-02 -24.84 
Alpl 2.30E-04 2.67E-02 -28.08 
Il34 1.83E-05 5.95E-03 -31.00 
Aqp2 1.91E-04 2.38E-02 -31.06 
Sbspon 4.60E-04 3.73E-02 -31.70 
Tusc5 6.18E-04 4.28E-02 -36.97 
Dner 2.05E-04 2.51E-02 -43.14 
Rorb 4.56E-04 3.73E-02 -44.53 
Pakap 6.17E-05 1.22E-02 -56.78 
Apela 2.08E-04 2.52E-02 -82.60 
Gfra1 5.66E-04 4.17E-02 -125.15 
Ptn 7.11E-04 4.70E-02 -126.94 
2610042L04Rik 1.04E-05 4.15E-03 -579.02 
Wif1 2.21E-05 6.59E-03 -698.87 
Defb2 3.62E-04 3.33E-02 -798.56 
4933417G07Rik 6.83E-05 1.30E-02 -860.85 
Sh2d1a 1.45E-04 2.06E-02 -999.55 
Stap1 7.12E-07 8.77E-04 -1110.36 
Mirt1 2.86E-04 2.95E-02 -1149.09 
Cyyr1 3.21E-06 1.85E-03 -1221.16 
Plekhd1 4.05E-04 3.56E-02 -1566.72 
Pcdha9 7.45E-04 4.83E-02 -1706.91 
Tox2 5.49E-04 4.11E-02 -1765.30 
Vax1 8.99E-05 1.54E-02 -1800.58 
Trim80 1.23E-04 1.89E-02 -1887.39 
4930578C19Rik 5.87E-06 2.71E-03 -1896.19 
Slc25a43 1.95E-04 2.42E-02 -1900.63 
Clec4b1 1.32E-06 1.06E-03 -1959.60 
Lmtk3 8.13E-09 5.01E-05 -1986.38 
Ascl3 2.77E-04 2.94E-02 -2059.87 
Pcdha12 3.78E-04 3.41E-02 -2081.92 
Calcb 2.21E-05 6.59E-03 -2237.39 
Plch2 5.49E-04 4.11E-02 -2471.70 
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Gene Symbol P-value  (Tumor vs. WT) 
FDR step up 
(Tumor vs. WT) 
Fold change 
(Tumor vs. WT) 
Dusp5 8.27E-07 8.90E-04 -2838.85 
Col25a1 7.42E-05 1.36E-02 -2903.62 
BC055402 2.79E-04 2.95E-02 -3003.59 
Tmem54 4.68E-04 3.74E-02 -3080.46 
Clcnka 2.32E-04 2.67E-02 -3159.52 
Ecel1 4.65E-04 3.74E-02 -3443.70 
1700049E15Rik 2.23E-06 1.55E-03 -3896.23 
Serpina1c 1.21E-06 1.03E-03 -4075.91 
Gimap1 3.59E-04 3.33E-02 -4164.47 
Ms4a4c 1.19E-04 1.87E-02 -4302.21 
H2-M2 7.24E-06 3.11E-03 -4373.50 
Pcdha1 3.55E-04 3.33E-02 -4410.47 
Prss16 4.50E-06 2.31E-03 -4705.61 
Scnn1b 1.20E-05 4.51E-03 -4844.32 
Gm14851 1.62E-04 2.19E-02 -4858.30 
D030018L15Rik 4.23E-05 9.08E-03 -4876.66 
Dach1 4.90E-04 3.85E-02 -5082.17 
Tmeff1 2.47E-04 2.70E-02 -5132.64 
Adgrl3 8.02E-05 1.41E-02 -5182.67 
Drd4 2.77E-07 4.66E-04 -5661.51 
Ms4a5 2.12E-05 6.59E-03 -5678.74 
Padi2 1.36E-04 1.99E-02 -5730.72 
Dgkg 3.09E-05 8.17E-03 -5795.94 
2010107G23Rik 3.81E-06 2.07E-03 -5897.86 
Dusp13 1.26E-04 1.90E-02 -5927.36 
Pcyt1b 6.99E-06 3.07E-03 -5938.55 
Klf8 3.06E-04 3.12E-02 -6230.26 
Ptpn18 1.12E-04 1.84E-02 -6355.64 
Fcna 4.03E-06 2.13E-03 -6367.38 
Igsf21 3.27E-04 3.21E-02 -6554.08 
4931429I11Rik 3.13E-04 3.14E-02 -6594.24 
H60b 4.66E-04 3.74E-02 -6981.19 
Spink11 7.45E-08 1.97E-04 -7155.25 
Gimap8 5.47E-04 4.11E-02 -7156.39 
Tmem255b 3.40E-07 5.24E-04 -7219.94 
Galnt5 4.96E-08 1.83E-04 -7852.32 
Fbxo40 1.08E-05 4.15E-03 -8034.29 
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Gene Symbol P-value  (Tumor vs. WT) 
FDR step up 
(Tumor vs. WT) 
Fold change 
(Tumor vs. WT) 
Pcp4 4.85E-06 2.42E-03 -8040.15 
Chrm2 6.21E-05 1.22E-02 -8313.49 
Sema7a 6.09E-04 4.25E-02 -8594.00 
Scube1 1.34E-07 3.10E-04 -8835.23 
Xkr5 7.99E-05 1.41E-02 -8955.12 
6330403A02Rik 1.04E-04 1.76E-02 -9830.17 
Gdnf 4.23E-04 3.60E-02 -9878.64 
Samd5 3.02E-05 8.10E-03 -10392.51 
Pbk 2.53E-06 1.59E-03 -10466.54 
Emilin3 5.01E-05 1.04E-02 -10469.92 
Slc27a6 9.44E-07 8.90E-04 -10541.08 
Dscam 1.05E-05 4.15E-03 -10671.60 
Mmd2 4.23E-05 9.08E-03 -10741.78 
Rasd2 3.72E-05 8.52E-03 -11067.26 
Mgat5b 4.13E-05 9.08E-03 -11142.79 
Myct1 6.37E-05 1.24E-02 -11322.64 
Sox6 1.59E-05 5.44E-03 -11343.24 
Azgp1 6.58E-07 8.68E-04 -11502.03 
Pitx2 9.37E-07 8.90E-04 -12077.02 
H2-Ob 1.52E-04 2.08E-02 -12079.96 
Mt3 2.15E-05 6.59E-03 -12586.50 
Slc22a1 1.80E-05 5.94E-03 -12655.63 
Madcam1 2.26E-08 1.04E-04 -13349.08 
Vipr1 7.29E-04 4.76E-02 -13890.70 
Cd209a 1.66E-05 5.56E-03 -13958.96 
Hs3st3a1 4.18E-04 3.60E-02 -14359.28 
Mfng 2.99E-05 8.10E-03 -15733.06 
Dgkb 1.44E-05 5.23E-03 -15913.44 
Lemd1 9.64E-07 8.90E-04 -16561.37 
Egfem1 3.14E-04 3.14E-02 -16589.49 
Mdga2 3.42E-05 8.52E-03 -16715.33 
Npw 7.54E-05 1.37E-02 -16751.62 
Frem2 2.09E-04 2.52E-02 -16815.37 
Entpd3 4.94E-04 3.85E-02 -18157.82 
Tlr12 9.52E-07 8.90E-04 -18866.90 
Mall 7.62E-06 3.20E-03 -19208.91 
Klk13 1.71E-07 3.17E-04 -19227.73 
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Gene Symbol P-value  (Tumor vs. WT) 
FDR step up 
(Tumor vs. WT) 
Fold change 
(Tumor vs. WT) 
Pcp4l1 6.81E-08 1.97E-04 -21601.93 
Pdzk1ip1 2.72E-05 7.51E-03 -23010.27 
Jakmip1 2.09E-06 1.54E-03 -24978.27 
Emid1 6.45E-05 1.24E-02 -27218.54 
Klk8 2.36E-06 1.56E-03 -28606.48 
Plet1 3.47E-05 8.52E-03 -29569.98 
Pkp3 5.52E-04 4.11E-02 -29640.43 
Itga8 1.17E-04 1.85E-02 -29948.47 
Wfdc6a 1.07E-04 1.77E-02 -30001.33 
Sst 3.86E-04 3.45E-02 -30694.77 
AU021092 5.85E-06 2.71E-03 -31208.27 
Grb7 1.48E-04 2.06E-02 -32159.81 
Rnf128 1.08E-04 1.77E-02 -33329.39 
Abo 7.43E-05 1.36E-02 -33988.89 
Krt5 3.72E-05 8.52E-03 -36991.00 
Gm5615 1.28E-04 1.91E-02 -38033.02 
Plekhs1 2.58E-06 1.59E-03 -50783.54 
Ptgds 2.28E-05 6.70E-03 -77662.99 
Pdyn 2.66E-04 2.87E-02 -90302.44 
Kcnip1 3.50E-04 3.33E-02 -95679.59 
Gsdma 2.27E-06 1.55E-03 -104113.40 
Crmp1 3.80E-06 2.07E-03 -181236.20 
Gja4 1.40E-05 5.17E-03 -287440.59 
	  
	  
 
 
 
 
 
 
 
